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Abstract 
 
Therapeutic proteins are used to treat specific pathological conditions and severe 
diseases. The encapsulation into polymeric nanoparticles is a powerful strategy to 
deliver them in a sustained manner and preserve their stability. However, polymeric 
nanoparticles may get unstable in aqueous suspension, leading to their aggregation or 
fusion. The lyophilization comes to the front line as an useful approach to avoid the 
instability of nanoparticles. Nevertheless, this dehydration process may induce stresses 
to nanoparticles and encapsulated proteins. The use of excipients such as cryo- and 
lyoprotectants and the optimization of lyophilization cycle, may be useful strategies to 
avoid such stresses. Thus, the main aim of this Thesis was to undergo an optimization of 
lyophilization parameters of polymeric nanoparticles for delivery of therapeutic proteins, 
to preserve the stability of nanoparticles, and with upmost importance, better preserve 
the structural stability and bioactivity of proteins. For this purpose, poly(lactic-co-glycolic 
acid) (PLGA) as polymer and insulin as therapeutic protein were used as models. 
The formulation of nanoparticles was optimized and it was demonstrated that the 
combination of PLGA in a lactic:glycolic ratio of 50:50 and polyvinyl alcohol at 2% (w/v) 
as surfactant, resulted in nanoparticles with the best features regarding their size, zeta 
potential and association efficiency, obtaining after insulin encapsulation about 446 nm, -
24 mV and 87%, respectively. The lyophilization increased the nanoparticles porosity, 
being more evident for formulations added with cryoprotectants, namely trehalose, 
glucose, sucrose, fructose and sorbitol at 10% (w/v). The in vitro release of insulin after 
nanoparticles lyophilization, comparatively to before lyophilization showed an increased 
release of about 18% in the first 2 hours due to the porosity increase, followed by a 
sustained release up to 48 hours. The amount of insulin released from lyophilized 
nanoparticles showed some variability regarding the cryoprotectant used. 
The nanoparticles were further used to assess the influence of a standard 
lyophilization cycle, and different storage conditions over 6 months on their features. The 
addition of cryoprotectants increased nanoparticles stability upon storage. Fourier 
transform infrared spectroscopy revealed that cryoprotectants increased insulin structural 
stability close to 80%, comparatively to formulations without cryoprotectant. Formulations 
with collapsed cakes had better protein stabilization upon storage, especially that 
containing sorbitol, preserving 76, 80, and 78% of insulin structure at 4°C, 25°C/60% 
relative humidity (RH), and 40°C/75% RH, respectively. Principal component analysis 
also showed that sorbitol added formulation had the most similar insulin structural 
modifications, among the storage conditions. 
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A strategy of lyoprotectant co-encapsulation was proposed to better preserve the 
structure of the loaded protein. Insulin-loaded PLGA nanoparticles with co-encapsulated 
lyoprotectants achieved a mean particle size of 386-466 nm, and a zeta potential ranging 
between -34 and -38 mV, dependent on the lyoprotectant used. Formulations had 
association efficiencies and loading capacities of 85-91% and 10-12%, respectively. X-
ray powder diffraction studies revealed that the lyophilizates of nanoparticles with co-
encapsulated lyoprotectants were amorphous, whereas formulations with externally 
added lyoprotectants, except trehalose, showed crystallinity. The co-encapsulation of 
lyoprotectants better preserved insulin structure upon lyophilization with a spectral area 
of overlap of 82-87%, comparatively to the lyoprotectants externally added to 
nanoparticles (66-83%), and to 72% in lyoprotectant absence. Circular dichroism 
confirmed these results. 
The lyophilization cycle was optimized considering the physical-chemical 
properties of nanoparticles co-encapsulated with cryoprotectants. It was also assessed 
the influence of different freezing methods, namely freezing at -80ºC, ramped cooling at -
40ºC and freezing in liquid nitrogen in the stability and bioactivity of encapsulated insulin. 
No cake collapse was observed. The cryoprotectants were crucial to mitigate the 
different freezing stresses and better stabilize insulin structure, as the area of overlap 
was close to 90%. The structural maintenance was confirmed by circular dichroism and 
fluorescence spectroscopy. The ramped cooling at -40ºC presented the most structural 
similarity of insulin among formulations. The use of trehalose and sucrose allowed better 
protein stabilization than sorbitol in all freezing methods. The in vivo studies revealed an 
enhanced hypoglycemic effect of insulin over 24 h after administration of nanoparticles 
co-encapsulated with trehalose, comparatively to both nanoparticles without 
cryoprotectant, and with trehalose added prior lyophilization, mainly due to a superior 
insulin stabilization and bioactivity. 
An annealing step was included in the optimized lyophilization cycle of insulin-
loaded nanoparticles co-encapsulated with trehalose to decrease the duration time of 
lyophilization. The duration time of primary drying was decreased in about 38% and the 
lyophilization cycle was decreased around 26%. The lyophilizates obtained with and 
without annealing had similar residual moisture content. The nanoparticles co-
encapsulated with trehalose presented higher insulin structural maintenance, and 
formulations lyophilized with annealing presented similar insulin structural maintenance 
of those obtained without annealing. 
Overall, the optimization of lyophilization of protein-loaded nanoparticles was 
found to be crucial to preserve the stability of the lyophilizates, the nanoparticles and the 
loaded protein, in order to formulations completely fulfill their therapeutic proposes.  
 xvii 
 
Resumo 
 
 
As proteínas terapêuticas são usadas no tratamento de condições patológicas 
específicas e doenças severas. A encapsulação em nanopartículas poliméricas é uma 
estratégia poderosa para as administrar obtendo libertação prolongada, e preservar a 
sua estabilidade. Contudo, as nanopartículas poliméricas podem tornar-se instáveis em 
suspensão, levando à sua agregação ou fusão. A liofilização está na linha da frente 
como uma estratégia útil para evitar a instabilidade de nanopartículas. Não obstante, 
este processo de desidratação pode induzir stresses nas nanopartículas e nas proteínas 
encapsuladas. O uso de excipientes como crio- e lioprotetores e a otimização do ciclo 
de liofilização, são estratégias úteis para evitar tais stresses. Assim, o principal objetivo 
desta Tese é otimizar os parâmetros de liofilização de nanopartículas poliméricas para 
administração de proteínas terapêuticas, para preservar a estabilidade das 
nanopartículas, e com maior importância, preservar a estabilidade e bioactividade das 
proteínas. Para cumprir este objetivo, foram usados como modelos, o ácido poli(láctico-
co-glicólico) (PLGA) como polímero e a insulina como proteína terapêutica. 
A formulação de nanopartículas foi otimizada e verificou-se que a combinação de 
PLGA no rácio de ácido láctico:glicólico de 50:50 e álcool polivinílico a 2% (w/v) como 
surfatante, produziu as nanopartículas com as melhores características considerando o 
tamanho médio, potencial zeta e eficiência de associação, obtendo após encapsulação 
de insulina cerca de 446 nm, -24 mV e 87%, respetivamente. A liofilização aumentou a 
porosidade das nanopartículas, com maior evidência nas formulações adicionadas com 
os crioprotetores, trealose, glucose, sacarose, frutose e sorbitol a 10% (w/v). A 
libertação in vitro de insulina após liofilização das nanopartículas, comparativamente a 
antes da liofilização, aumentou cerca de 18% nas primeiras 2 horas devido ao aumento 
da porosidade, seguida de libertação prolongada até 48 horas. A quantidade de insulina 
libertada das nanopartículas liofilizadas variou de acordo com o crioprotetor usado. 
As nanopartículas foram posteriormente usadas para avaliar a influência de um 
ciclo de liofilização ‘standard’, e diferentes condições de armazenamento durante 6 
meses, nas suas características. A adição de crioprotetores melhorou a estabilidade das 
nanopartículas durante o armazenamento. Análises de infravermelho com transformada 
de Fourier revelaram que os crioprotetores preservaram melhor a estrutura da insulina 
em cerca de 80%, comparativamente às formulações sem crioprotetor. Os liofilizados 
colapsados tiveram uma melhor estabilização da proteína após armazenamento, 
especialmente com sorbitol, preservando 76, 80 e 78% da estrutura da proteína a 4°C, 
25°C/60% HR, e 40°C/75% HR, respetivamente. A análise de componente principal 
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também verificou que a formulação com sorbitol apresentou as alterações estruturais 
mais semelhantes, entre as condições de armazenamento. 
Uma estratégia de co-encapsulação de lioprotetor foi proposta para melhor 
preservar a estrutura da proteína. As nanopartículas co-encapsuladas com lioprotetores 
obtiveram um tamanho médio de 386-466 nm e um potencial zeta entre -34 e -38 mV, 
dependendo no lioprotetor usado. As formulações apresentaram eficiências de 
associação e capacidade de carga de 85-91% e 10-12%, respetivamente. Estudos de 
difração raio X de pós revelaram que os liofilizados de nanopartículas com lioprotetores 
co-encapsulados eram amorfos, enquanto quando adicionados externamente, excepto a 
trealose, revelaram cristalinidade. A co-encapsulação de lioprotetores obteve uma 
melhor preservação estrutural após liofilização com uma área de sobreposição espetral 
de 82-87%, comparada com os 66-83% dos lioprotetores adicionados externamente, e 
com 72% sem lioprotetor. O dicroísmo circular confirmou estes resultados. 
O ciclo de liofilização foi otimizado considerando as propriedades físico-químicas 
das nanopartículas co-encapsuladas com crioprotetor. Foi também avaliada a influência 
de diferentes métodos de congelação, nomeadamente congelação a -80ºC, 
arrefecimento em rampa a -40ºC e congelação em azoto líquido, na estabilidade e 
bioactividade da insulina encapsulada. Os liofilizados não colapsaram. Os crioprotetores 
foram cruciais para mitigar os stresses da congelação e preservarem melhor a estrutura 
da insulina, em cerca de 90%. A manutenção estrutural foi confirmada por dicroísmo 
circular e espetroscopia de fluorescência. O arrefecimento em rampa a -40ºC 
apresentou a maior semelhança estrutural de insulina entre as formulações. O uso de 
trealose e sacarose estabilizou melhor a proteína do que o sorbitol, nas três condições 
de congelação. Estudos in vivo durante 24 horas demonstraram um maior efeito 
hipoglicémico da insulina, após administração de nanopartículas co-encapsuladas com 
trealose, comparando às nanopartículas sem crioprotetor e adicionadas com trealose 
antes da liofilização, devido a uma superior estabilização e bioactividade da insulina. 
Foi incluída uma etapa de ‘annealing’ no ciclo de liofilização de nanopartículas 
co-encapsuladas com trehalose de forma a diminuir o tempo de duração da liofilização. 
A duração da secagem primária foi diminuída em cerca de 38%, e o ciclo de liofilização 
em cerca de 26%. Os liofilizados obtidos com e sem ‘annealing’ obtiveram um teor de 
humidade residual semelhante. As nanopartículas co-encapsuladas com trealose 
apresentaram uma manutenção estrutural de insulina superior, e as formulações 
liofilizadas com e sem annealing apresentaram uma manutenção estrutural idêntica. 
Globalmente, verificou-se que a otimização da liofilização de nanopartículas 
contendo proteínas é determinante para preservar a estabilidade dos liofilizados, 
nanopartículas e proteína, para as formulações cumprirem os objetivos terapêuticos. 
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Benefiting from the developments in the biotechnology field, the use of different 
therapeutic proteins have been growing in the last years, mainly to treat severe health 
problems such as autoimmune diseases, cancer and hormone disorders [1]. These 
drugs may be formulated into polymeric nanoparticles, both from natural and synthetic 
origin, improving the efficacy of treatment of such diseases [2]. Nanoparticles are used to 
deliver proteins by different administration routes, mainly due to their ability to preserve 
the stability of the loaded protein and to deliver in a sustained manner. They are also 
able to enhance the permeability of proteins through biological barriers such as the 
intestinal and respiratory epithelium [3, 4]. The nanoparticle polymers may be further 
functionalized, targeting the delivery to specific tissues and organs, with an increased 
accumulation of the protein in the action site, both enhancing the therapeutic effect and 
decreasing the possibility of occurrence of prejudicial side effects [5]. 
Since nanoparticles are often produced in an aqueous suspension form, they are 
physically unstable, resulting on nanoparticle aggregation and fusion upon storage. 
Furthermore, the hydrolytic action of water on the polymers may lead to drug leakage, 
hampering its sustained release or even leading to the formation of undesirable 
degradation products [6]. To avoid these issues, the nanoparticle suspension needs to 
be converted into a solid dosage form. Lyophilization or freeze-drying is an useful 
process to achieve this purpose by overcoming the instability of nanoparticle suspension, 
increasing shelf-life and facilitating its handling and storage [7, 8]. In this process, the 
removal of water occurs by sublimation of ice and desorption of unfrozen water under 
vacuum. However, freezing and desiccation stresses may occur, leading to detrimental 
effects to nanoparticle stability. Some excipients such as cryoprotectants and 
lyoprotectants may be used to minimize the freezing and desiccation stresses, 
respectively, preserving the stability of nanoparticles. The most common cryo- and 
lyoprotectants are sugars, mainly because they are easily vitrified during freezing and 
are chemically innocuous [9]. Additionally, sugars may prevent the inactivation of protein 
drugs during lyophilization and storage [10].  
Most of the research works focusing on the lyophilization of nanoparticles present 
empiric approaches on the choosing of acceptable protectants and lyophilization cycle, 
and experiments have been even performed by trial and error. It is imperative to put 
through a systematic study on the optimization of nanoparticles lyophilization, by 
evaluating the physical-chemical properties of formulations and understanding the 
engineering principles of lyophilization. Therefore, it is necessary the optimization of 
lyophilization parameters of polymeric nanoparticles for delivery of therapeutic proteins, 
to guarantee the stability of nanoparticles and upmost assure the structural stability of 
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the loaded protein. There is a lack of knowledge on the effect of lyophilization on the 
structure of proteins loaded into nanoparticles, with consequences to its bioactivity and 
the occurrence of possible toxicity problems. To bring some light to this subject, in this 
PhD Thesis, insulin was used as a model of a therapeutic protein and poly(lactic-co-
glycolic acid) (PLGA) polymer was used to produce nanoparticles and encapsulate the 
protein. In the lyophilization of nanoparticles, several sugars were used as protectants, 
namely two non-reducing sugars, trehalose and sucrose, two reducing sugars, glucose 
and fructose and one sugar alcohol, sorbitol. 
The title of the present Thesis is “Optimization of Lyophilization Parameters of 
Polymeric Nanoparticles for Delivery of Therapeutic Proteins”. This optimization focused 
not only in the lyophilization cycle, but also on the formulation and all the parameters 
involved in the lyophilization of protein-loaded polymeric nanoparticles. Considering all 
these motivations, the principal aims pursued in the present Thesis were: 
 To optimize and characterize the protein-loaded polymeric nanoparticles; 
 To assess the effect of cryoprotectants on the porosity and stability of protein-
loaded polymeric nanoparticles, after lyophilization;  
 To evaluate the stability of protein-loaded polymeric nanoparticles, upon 6 
months at different storage conditions; 
 To investigate the structural stability of the protein loaded into polymeric 
nanoparticles, upon lyophilization using cryoprotectants, and storage; 
 To propose the co-encapsulation of lyoprotectants as a strategy to better protect 
the structural stability of proteins loaded into polymeric nanoparticles; 
 To optimize the lyophilization cycle, considering the physical-chemical properties 
of protein-loaded polymeric nanoparticles; 
 To assess the effect of different freezing methods on the stability of both the 
loaded protein, and on the polymeric nanoparticles upon lyophilization using 
cryoprotectants; 
 To  evaluate the in vivo performance of protein-loaded polymeric nanoparticles; 
 To use annealing as a tool to optimize the lyophilization cycle decreasing the 
lyophilization time; 
 To evaluate the effect of annealing in lyophilization and in the stability of protein-
loaded polymeric nanoparticles using cryoprotection. 
 
This Thesis is organized in nine chapters. In Chapter 1 a brief introduction of the 
PhD project is performed and the main aims and organization of the Thesis are outlined. 
The Chapter 2 and Chapter 3 contain a state of the art overview on the Thesis subject. 
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The Chapter 2 provides a review on the polymeric nanoparticles used in the delivery of 
insulin with a special focus on the oral route, which is a potential administration route of 
nanoparticles and the most promising approach to improve the quality of life of diabetic 
patients. This chapter provides many examples of polymers used to encapsulate 
proteins, which may be subjected to lyophilization and used in other administration 
routes. In Chapter 3 it is performed a review on the lyophilization process and on its 
application in polymeric nanoparticles, with a special regard to protein-loaded polymeric 
nanoparticles. The optimization and characterization of protein-loaded nanoparticles is 
described in Chapter 4. The effect of cryoprotectants on nanoparticles porosity and 
stability upon lyophilization is also discussed in this chapter. The Chapter 5 provides a 
stability study perspective about the effect of lyophilization using cryoprotectants, on the 
structure of insulin loaded into polymeric nanoparticles. In Chapter 6 it is proposed the 
co-encapsulation of lyoprotectants as a strategy to better protect the protein loaded into 
nanoparticles. The optimization of the lyophilization cycle and the evaluation of the effect 
of the freezing step, on the stability of protein-loaded polymeric nanoparticles are 
described in Chapter 7. The in vivo performance of nanoparticle formulations is also 
assessed in this chapter. Further, the Chapter 8 describes the utility of annealing in the 
optimization of the lyophilization cycle and the evaluation of its effect on the stability of 
protein-loaded nanoparticles. Finally, the Chapter 9 provides the general conclusions of 
the Thesis and future perspectives of the work. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
          
 
 
 
 
 
 
 
Polymeric Nanoparticles for Oral 
Administration of Insulin 
 
 
 
 
 
Partially published in: 
Pedro Fonte, Francisca Araújo, Salette Reis, Bruno Sarmento, Oral insulin delivery: how 
far are we?, J Diabetes Sci Technol, 7 (2013) 520-531. 
Pedro Fonte, Francisca Araújo, Cátia Silva, Carla Pereira, Salette Reis, Hélder A. 
Santos, Bruno Sarmento, Polymer-based nanoparticles for oral insulin delivery: Revisited 
approaches, Biotechnol Adv, 33 (2015) 1342-1354. 
 
Chapter 2 
Chapter 2 I Polymeric Nanoparticles for Oral Administration of Insulin 
   
6 
 
 
1. Introduction 
 
The International Diabetic Federation reported that 366 million people were 
affected by diabetes in 2011 and estimates that by 2030 this number will raise up to 552 
million [11]. Due to its high prevalence and secondary effects, diabetes mellitus is one of 
the most lethal diseases and responsible for almost three million deaths per year 
worldwide, as reported by the World Health Organization [12]. On average, life 
expectancy is reduced by more than 20 years in people with type 1 diabetes and by up 
to 10 years in people with type 2 diabetes [13]. Type 1 and type 2 diabetes are 
characterized by a progressive decrease of β-cell function. The maintenance of blood 
glucose levels at near-normal levels reduces the risk of long term complications of 
diabetes. These complications may range from adult blindness, cardiovascular diseases 
such as heart attacks and strokes, non-traumatic amputation in adults and the possible 
necessity of renal dialysis due to the diabetic nephropathy [14]. 
In 1922, the discovery of insulin from dog pancreas was a milestone in the history 
of diabetes therapy with a Nobel Prize winning, which had a great importance in 
biomedical research [15]. Indeed, insulin is the most used and effective drug to control 
diabetes. Intensive insulin in type 1 diabetes patients is able to reduce the risks of 
nephropathy by 35% to 56%, neuropathy by 60% and retinopathy by 50% to 70% [16-
18]. From the time of this discovery, peptides and proteins have been used as 
biopharmaceuticals due to their advantages such as high activity, specificity and 
effectiveness comparatively to conventional drugs [19]. However, suitable oral 
formulations of proteins are still under development, facing countless challenges despite 
all the efforts, time and money spent on the research [19]. Hence, parenteral delivery 
remains the most common route for insulin administration [20]. 
The use of biocompatible and biodegradable nanoparticles has been described 
as a promising strategy towards oral administration of proteins and peptides [13]. In 
order to enhance the oral bioavailability of insulin, as well as to provide a stable and 
biocompatible environment to the encapsulated drug, polymeric nanoparticles have been 
claimed to be the perfect candidates for the oral delivery of insulin [21]. 
In this chapter, the benefits and drawbacks on the oral insulin delivery as well as 
the different pathways of insulin-loaded nanoparticles uptake through intestinal 
epithelium will be discussed. The different polymeric nanoparticles developed for delivery 
of insulin orally developed so far will be presented. In addition, it will be reviewed the 
efforts of the pharmaceutical industry to develop an insulin oral delivery system and the 
toxicity concerns about the use of polymer-based nanoparticles 
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2. Benefits and drawbacks on oral insulin delivery 
 
Despite all the successes achieved after insulin discovery, diabetes therapy tends 
to fail in long-lasting treatments, followed by a number of side-effects. Thus, more than a 
few improvements are urgently needed, especially regarding the administration of 
insulin. On one hand, parenteral delivery of insulin is hindered by the lack of patient 
compliance to treatment due to the uncomfortable use of injections with needles. On the 
other hand, oral administration is the most accepted delivery route due to its 
convenience, painless and easy for self-medication. Based on efficacy and toxicity, it is 
possible to tune the dosing schedule of insulin to the responses of individual patients 
[22]. Moreover, the oral route mimics the endogenous pathway of insulin after secretion, 
as it suffers the first pass to the liver instead of going to the systemic bloodstream [19, 
20]. Owing to its role in blood glucose level control, the liver is the first and foremost 
important target of pancreas-secreted insulin [23]. Indeed, only a small amount 
(approximately 20%) of subcutaneously administered insulin reaches the liver [24]. The 
reproduction as faithful as possible of the physiological mechanisms of glucose 
metabolism, allows the control and/or decrease of the side effects that are commonly 
described by patients under insulin therapy. Encountered first in the liver, insulin levels 
are reduced in systemic circulation, which minimizes the risk of hypoglycemia episodes, 
immune responses as well as insulin resistance in type 2 diabetic patients [23]. Other 
problems such as allergic reactions, lipodystrophy around the injection site and risk of 
infectious diseases transmission, can also be avoided with oral administration of insulin 
[13]. Finally, the oral route is more cost-effective since there is no need of specialized 
people for the administration, decreasing the number of visits to the hospital and 
avoiding costs in injection materials [25]. 
However, the path is not straightforward and achieving an effective oral 
formulation for delivery of insulin is still a goal to pursue. Along the gastrointestinal tract 
there are several barriers that must be overcome to increase the bioavailability of insulin. 
For instance, the harsh pH conditions in the stomach, the enzymatic activity, the 
presence of mucus and the poor permeability across the intestinal epithelium are the 
main concerns for the activity and effectiveness of the protein [13, 20, 26]. Besides the 
physiological features of the gastrointestinal tract, also a better knowledge of the 
differences between animal models and humans would guarantee a more reliable 
extrapolation of the results obtained from preclinical to clinical studies, as well as a better 
understanding of how diet, fasting states, patient-to-patient variability and disease states 
affect the protein absorption [25, 27, 28]. 
Chapter 2 I Polymeric Nanoparticles for Oral Administration of Insulin 
   
8 
 
 
3. Mechanisms of the intestinal uptake of polymeric nanoparticles 
 
Regardless of the protection of insulin by nanoparticles from the hostile 
conditions of the gastrointestinal tract, the transport across the intestinal epithelium still 
remains a barrier to overcome. As a gatekeeper, the epithelium acts by thwarting 
proteins from being absorbed, making it the major restrictive barrier to the nanoparticles 
passage from the lumen to the lamina propria [25]. The epithelial cells maintain this 
protection because of the tight junctions between adjacent cells [29]. Thus, the transport 
and the absorption mechanism may be either paracellular (between the cells) or 
transcellular (through the cells), and are mainly regulated by the characteristics of the 
mucosa and by the physicochemical properties of the nanoparticles such as size, charge 
and lipophilicity [30, 31]. The Figure 2.1 shows the pathways for insulin nanoparticle 
translocation through the intestinal epithelium. 
It is commonly accepted that due to the features of the paracellular route, which 
has a small surface area (less than 1% of the total intestine) and a limited space owing 
to the tightness of the junctions between cells (3 and 10 Å of diameter), this is not the 
most common mechanism of nanoparticles uptake [22, 23, 30]. However, it has been 
described that some natural polymers used in nanoparticles composition such as 
chitosan, may reversibly affect the tight junctions opening by mechanisms that are still 
not very well understood. For instance, some materials may act on the tight junctions 
inducing a structural reorganization of their proteins and others may modulate tight 
junctions by chelating calcium and inducing their disruption [22, 32-37]. The transcellular 
transport is thus the most probable mechanism of nanoparticles absorption [38]. This 
transport pathway may be divided into different endocytic mechanisms: phagocytosis, 
macropinocytosis, clathrin-mediated endocytosis and caveole-mediated endocytosis, 
which are adenosine triphosphate (ATP) dependents, and clathrin- and caveolae-
independent endocytosis, which are not ATP dependents. These uptake mechanisms 
occur at the apical cell membrane, where nanoparticles are taken-up, and then the 
transport occurs through cells within vesicles, releasing their contents at the basolateral 
pole [26].  
In the epithelial cells, phagocytosis is restricted to M cells, which is a receptor-
mediated process where the cellular membrane projects itself to engulf nanoparticles 
[26, 30]. M cells have several properties that favor the transport of nanoparticles such as 
lack of mucus secretion, a scant glycocalyx and reduced proteases, making the transport 
through M cells higher than the transport through enterocytes [30, 39]. However, since M 
cells are part of the immune Peyer’s patches, it may stimulate the immune responses 
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compromising further the nanoparticles administration [25]. Similar to phagocytosis, also 
macropinocytosis is an actin-dependent process capable of engulf large volumes of fluid 
containing nanoparticles; however, this is not restricted to a cellular type and it is non-
specific receptor mediated. The vesicles may have a large size (between 0.15–5 µm) 
and after formed, they fuse with the early endosomes [40]. Clathrin-mediated 
endocytosis, in turn, is a receptor-mediated uptake where the cellular membrane forms 
pits originating small vesicles coated by proteins (mainly clathrin protein), which also 
fuse with early endosomes. One strategy to enhance the nanoparticles uptake by the 
intestinal cells is to conjugate ligands to nanoparticles surface that would facilitate cell–
nanoparticle interactions and enhance the nanoparticles internalization [41]. Bacterial 
adhesins, lectins, monoclonal antibodies and specific amino acid sequences are some 
examples of ligands that can be found in more detail elsewhere [30, 42]. Finally, caveole-
mediated endocytosis is a non-specific uptake process where small caveolae-coated 
vesicles (50-80 nm) can escape from the endolysosomes and lead to direct exocytosis. 
However, the small size of the vesicles makes this a non-probable route of nanoparticles 
uptake [22, 40]. 
 
 
Figure 2.1. Pathways for insulin nanoparticle translocation through the intestinal epithelium. 
Schematic focus on phagocytosis, macro-pinocytosis, and caveolin-mediated endocytosis. 
Reprinted with permission from [26]. 
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4. Polymer-based delivery systems for oral administration of insulin  
 
In the nanotechnology field, nanoparticles may be subcategorized into 
nanospheres and nanocapsules. In nanospheres, insulin is dispersed in the 
nanoparticles matrix, whereas in nanocapsules, insulin is retained in a compartment 
surrounded by a polymer membrane [43]. Different methods and technologies may be 
used to prepare these nanoparticle types, so the best production protocol needs to be 
inferred regarding the polymer nature and also insulin stability. Indeed, the majority of 
the production protocols use heat, sonication, strong agitation and organic solvents, 
which may damage the insulin structure. 
Polymer science has increased in the last decades with better understanding of 
polymers backbones and possible modifications of their structure. In addition, also the 
drug delivery field has evolved in developing new and improved polymer-based drug 
delivery systems. Due to the amount of different existing polymeric materials, the 
physicochemical properties of nanoparticles such as charge and association efficiency 
(AE), can be modulated and nanoparticles can be tailored to retain insulin stability, 
increase its bioavailability, control the release profiles, stabilize the systems and 
modulate the biological behavior [13, 44]. Overall, polymers may be from natural or 
synthetic sources, and can be used individually or together [21].  
In this section, the focus goes to the most commonly natural and synthetic 
polymers used to produce nanoparticles for oral delivery of insulin. Thus, chitosan, 
dextran, alginate, poly(γ-glutamic acid) (γ-PGA) and hyaluronic acid as natural polymers, 
and polylactic acid (PLA), PLGA, poly(ɛ-caprolactone) (PCL), acrylic polymers and 
polyallylamine as synthetic polymers are used to encapsulate insulin for oral delivery, 
and will be briefly discussed in this section. Additionally to the properties of the different 
polymer-based nanoparticles, they may be modified to increase the interactions with the 
intestinal mucosa, for example, by modifying its surface by adsorption or grafting of 
hydrophilic molecules conferring mucoadhesion (e.g., chitosan) or hydrophilicity (e.g. 
polyethylene glycol (PEG)). The nanoparticles surface may be also modified for targeting 
purposes by grafting ligands such as peptides, glycoproteins or antibodies [27], 
carbohydrates (e.g., decanoic acid) [45], and vitamins (e.g., vitamin B12) [46, 47]. 
Formulations of nanoparticles may also contain excipients such as enzyme 
inhibitors and absorption enhancers, which may help on preserving insulin stability and 
promote its absorption through the intestinal epithelium, respectively [3]. Duck and 
chicken ovomucoid, leupeptin and sodium cholate are used as enzyme inhibitors due to 
their ability to avoid insulin degradation [48, 49]. Regarding the absorption enhancers, 
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bile salts [50], ethylenediaminetetraacetic acid [51], surfactants  and zonula occludens 
toxin [52], as well as cell-penetrating peptides such as l-penetratin [53] and octarginine 
R8 [54], have been used to promote insulin absorption through the intestinal epithelium.  
 
4.1. Chitosan nanoparticles 
 
Among the natural polymers, polysaccharides have particular interest in the oral 
delivery of insulin, because they are biocompatible, biodegradable, non-toxic and 
hydrophilic. From these polymers, chitosan is by far the most widely used for the delivery 
of insulin. Chitosan is a mucoadhesive polycationic polymer composed by N-acetyl-D-
glucosamine and D-glucosamine and it is produced by the alkaline deacetylation of chitin 
[55-57]. Together with tripolyphosphate (TPP) or even just polyelectrolyte complexation 
with insulin are the most common methods to produce chitosan nanoparticles. The 
interaction of chitosan and polyanions leads to a spontaneous formation of nanoparticles 
with high AE in an aqueous media in mild conditions, with no need for using organic 
solvents or heat, avoiding cytotoxicity concerns and threats to insulin stability, thus being 
the main advantages of these carriers [37, 58]. 
Pan et al. showed that chitosan when structured in nanoparticles is able to 
enhance the intestinal absorption of insulin comparing to chitosan in solution, with an AE 
up to 80% [59]. The release profile of insulin presented a great initial burst with pH-
sensitivity and when administered in vivo, insulin-loaded chitosan nanoparticles had a 
hypoglycemia effect for 15 h with higher bioavailability of insulin, up to 14.9%, in 
comparison with the subcutaneous administration of insulin [59]. Another study 
conducted by Mukhopadhyay et al. showed an average AE of insulin with self-assembled 
chitosan nanoparticles of approximately 85%. The nanoparticles retained insulin 
efficiently in simulated gastric conditions with significant amount of insulin released in 
simulated intestinal conditions. When administered in vivo, insulin-loaded nanoparticles 
were effective in dropping the blood glucose level [60].  
Despite promising results, other studies were performed showing that chitosan 
nanoparticles are greatly influenced by the pH of the formulations, either in the AE of 
insulin or in its release profile [61-63]. Chitosan dissolves easily in acidic conditions due 
to its basic nature (pKa ≈ 6.5), compromising the protection of insulin from the harsh 
gastric conditions [64]. In order to overcome this issue, a combination of chitosan with 
other polymers, peptides and other chitosan derivatives emerged as possible solutions to 
achieve high insulin bioavailability at the intestinal level. Makhlof et al. formulated 
chitosan nanoparticles with hydroxypropyl methylcellulose phthalate (HPMCP), a pH-
sensitive polymer, by ionic cross-linking [58]. HPMCP pKa is approximately 5.2, which 
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makes the polymer only soluble at high pH-values, thus protecting insulin from the harsh 
conditions of the stomach. As expected, chitosan/HPMCP nanoparticles revealed a 
superior acid stability with a significant control over insulin release. After oral 
administration, the hypoglycemic effect conferred by the insulin-loaded chitosan/HPMCP 
nanoparticles increased by more than 9.8 and 2.8 folds as compared to an oral insulin 
solution and insulin-loaded chitosan/TPP nanoparticles, respectively [58]. Due to the 
backbone features of chitosan with free amino and hydroxyl groups, it is also possible 
the substitution or modification with different chemicals to achieve desired properties for 
oral drug delivery [44]. 
In this context, N-trimethyl chitosan (TMC) chloride is the most used chitosan 
derivative. It is a partially quaternized derivative of chitosan, which is soluble under 
neutral and basic conditions [64]. Similar to chitosan, TMC has mucoadhesive properties 
and acts as an absorption enhancer (it has been showed a pronounced reduction in the 
transepithelial electrical resistance in Caco-2 cell monolayers) but, in contrast with 
chitosan, TMC plays an important role, especially in neutral environments where 
chitosan is ineffective as an absorption enhancer [64]. The synthesis of TMC without O-
methylation is important to obtain good enhancing permeation properties [65]. Sandri et 
al. performed a study in which it was evaluated the penetration enhancement properties 
of insulin-loaded chitosan and TMC nanoparticles. The in vitro studies using a Caco-2 
cell monolayer, evaluated the effect of nanoparticles in the enhancement of insulin 
uptake and it was verified the same enhancement effect for both chitosan and TMC 
nanoparticles, but this enhancement occurred  respectively through different 
mechanisms, opening of the tight junctions and endocytosis [66]. Furthermore, the ex 
vivo studies showed the important role of the mucus layer, where the chitosan and TMC 
nanoparticles were more efficient towards jejunum tissue (pH 66.5) due to their high 
mucoadhesive potential. As referred above, the modification of nanoparticles with 
specific ligands increases their cellular uptake. Jin et al. used TMC nanoparticles 
modified with the targeting peptide C-Src tyrosine kinase (CSK) and proved that the 
uptake of nanoparticles and the permeation of drugs across the epithelium were higher 
when they were conjugated with the peptide, which induced a significantly higher 
internalization of drugs via clathrin- and caveolae-mediated endocytosis on goblet cell-
like HT29-MTX cells [67]. Also, in co-culture models of Caco-2/HT29-MTX the CSK 
peptide modification showed higher transport for peptide conjugated nanoparticles. 
Regarding the pharmacological and pharmacokinetic studies in vivo using diabetic rats, 
the CSK-nanoparticles improved the hypoglycemic effect with a 1.5-fold higher relative 
bioavailability compared with unmodified nanoparticles [67]. 
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Besides TMC, other quaternized chitosan derivatives such as diethylmethyl 
chitosan (DEMC), triethyl chitosan (TEC) and dimethylethyl chitosan (DMEC), were 
developed aiming to the successful delivery of proteins and peptides at neutral or weakly 
alkaline pH in the small intestine [68-71]. When evaluating these three systems for the 
oral delivery of insulin, it was possible to observe that the AE of insulin was 70% for TMC 
and DEMC, and 90% for TEC and DMEC. TEC and DMEC nanoparticles presented a 5 
h sustained release with minimum burst release effect at the initial hours in phosphate 
buffered saline (PBS) without significant differences for pH 6.8 and 7.4, which was a 
higher insulin release than chitosan nanoparticles, and more sustained when compared 
to the ex vivo studies. Similar to what happened in the in vitro and ex vivo experiments; 
in the in vivo experiments the modified chitosan nanoparticles presented enhanced 
colonic absorption of insulin in comparison with an insulin solution or insulin-loaded 
chitosan nanoparticles [68-70]. 
TMC-cysteine conjugate (TMC-Cys) was synthesized in an attempt to combine 
the mucoadhesion and the permeation enhancing effects of TMC and thiolated polymers. 
TMC-Cys with several molecular weights and quaternization degrees were allowed to 
form polyelectrolyte nanoparticles with insulin through self-assembly. These 
nanoparticles presented high AE of insulin and presented a 2.1- to 4.7-fold increase in 
mucoadhesion compared to TMC nanoparticles. Moreover, compared to a insulin 
solution and TMC nanoparticles, TMC-Cys nanoparticles promoted Caco-2 cell 
internalization by 7.5–12.7 and 1.7–3.0 folds, inducing an insulin uptake increase in the 
rat intestine by 3.3–11.7 and 1.7–2.6 folds, and augmented uptake in Peyer’s patches by 
14.7–20.9 and 1.7–5.0 folds, respectively. Insulin-loaded TMC-Cys nanoparticles 
showed also significant decrease in the blood glucose levels after oral and ileal 
administration (Figure 2.2). In addition, the biocompatibility assessment revealed lack of 
toxicity of TMC-Cys nanoparticles [72]. 
A chitosan derivative with lauryl group substituted succinic anhydride via an 
amide link formation between the carboxyl group and the amine group in the chitosan, 
lauryl chitosan (LCS), was developed by Recka et al. [73]. This study showed an 
inhibitory effect by the succinyl carboxyl groups on the release kinetics of insulin at pH 
1.2 and also showed that the hydrophobic moieties of LCS were able to control the 
release of insulin at the intestinal pH. Moreover, the LCS nanoparticles were capable of 
reducing blood glucose levels in diabetic rats for 6 h. This system proved to be better not 
only in the release profiles, but also at the permeability of insulin compared to unmodified 
chitosan nanoparticles [73]. Another study carried out by Elsayed et al. showed that LCS 
nanoparticles were stable in simulated gastric fluids protecting insulin from the 
gastrointestinal tract barriers [74]. Additionally, the in vivo results clearly indicated that 
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insulin-loaded nanoparticles could effectively reduce the blood glucose levels in a 
diabetic rat model. Nevertheless, additional modifications in the insulin formulation are 
still required to improve the oral bioavailability of insulin. 
Other studies combining chitosan with arabic gum [75, 76], N,O-carboxymethyl 
chitosan [77], cationic β-cyclodextrin polymers [78, 79] have also been conducted, and 
were reviewed in more detail by Mukhopadhyay et al. [80] and Chen et al. [81]. 
 
 
Figure 2.2. Blood glucose levels in rats after oral (A) and ileal (B) administration of TMC and 
TMC-Cys nanoparticles (50 IU/kg). Mean ± standard deviation (SD) (n = 4). Significant difference 
from insulin solution: p < 0.05. NP stands for nanoparticles. Reprinted with permission from [72]. 
 
4.2. Dextran nanoparticles 
 
Dextran is a polysaccharide composed by α-D-glucose units that bind to each 
other through glycosidic bonds. Similar to chitosan, dextran is also used in biomedicine 
as a constituent of nanoparticles for insulin delivery. Chalasani et al. prepared 
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nanoparticles by an emulsion method using different dextran molecular weights. The 
nanoparticles surface was then modified and conjugated with vitamin B12, a specific 
target ligand. The AE was between 45 and 70% and from that, 65 to 83% of insulin was 
protected against gut proteases. Moreover, the in vitro release experiments showed a 
burst, followed by a controlled release step, up to 95% within 48 h. Regarding the in vivo 
tests, after 5 h of oral administration (20 IU/kg), the plasma glucose levels decreased 70 
to 75% reaching basal levels in 8-10 h and this effect was prolonged for 54 h. According 
to their results, the pharmacological availability (PA) of vitamin B12-conjugated 
nanoparticles was significantly higher than for the nanoparticles without conjugation, 
which was 29.4% higher compared to the subcutaneous injection of insulin [46, 47]. This 
insulin carrier based on vitamin B12-conjugated nanoparticles is further addressed in 
Section 5 of this chapter. 
In another study, dextran sulfate was complexed with chitosan in aqueous media 
to obtain insulin-loaded nanoparticles. This system was able to retain insulin in simulated 
gastric medium, and sustained the release of insulin up to 24 h in simulated intestinal 
medium [82]. Moreover, these nanoparticles were able to reduce the basal serum 
glucose levels in approximately 35% in diabetic rats for more than 24 h. For doses of 50 
and 100 IU/kg, the PA of insulin was 5.6 and 3.4%, respectively, which was a significant 
increase compared to the administration of oral insulin solution (1.6%) [83]. 
 
4.3. Alginate nanoparticles 
 
Alginate is an anionic polysaccharide of (1–4)-linked β-D-mannuronic acid (M) 
and a-L-guluronic acid (G); these G residues, with divalent ions, have gelling properties 
that allow the formation of nanoparticles [84]. Moreover, in contrast to chitosan, alginate 
is soluble in high pH and insoluble in low pH [44]. Sarmento et al. showed that 
alginate/chitosan polyelectrolyte complexes after optimization formed nanoparticles with 
high AE (92%) and loading degrees (14.3%), which were able to preserve the secondary 
structure of insulin, essential to its bioactivity [85, 86]. Moreover, the nanoparticles 
retained approximately 50% of the protein in gastric pH conditions for 24 h while in 
intestinal pH environment the release was more extensive, around 75% [84]. When orally 
administered, insulin-loaded nanoparticles decreased the glucose levels of serum by 
more than 40%, sustaining the hypoglycemia for more than 18 h. For doses of 50 and 
100 IU/kg, the pharmacological bioavailability of insulin was 6.8 and 3.4%, respectively. 
These values represent a significant increase of more than 1.6% when compared to 
solutions of oral insulin alone, and are over other related studies at the same dose levels 
[86].  
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Woitiski et al. produced nanoparticles formed by alginate and dextran sulfate that 
nucleated around calcium and bond to poloxamer, stabilized by chitosan, and 
subsequently coated with albumin [87, 88]. Albumin was applied to nanoparticles as the 
outermost coat, in order to protect insulin through shielding from proteolytic degradation. 
The effect of this albumin layering on insulin permeation was compared with albumin-
free nanoparticles that mimic the action of albumin being enzymatically removed during 
gastric and intestinal transport. The results showed that albumin layering was important 
toward improving insulin uptake across the intestinal membrane, possibly by stabilizing 
insulin in the intestinal conditions. Moreover, insulin permeation through different 
intestinal in vitro and ex vivo models was also studied. For the gold-standard Caco-2 cell 
monolayer, the permeation of insulin loaded into the nanoparticles was enhanced 2.1-
fold comparatively to insulin in solution, 3.7-fold for the mucus-secreting Caco-2:HT29 
co-culture and 3.9-fold for excised intestinal mucosa of Wistar rats [88]. Regarding the in 
vivo studies, insulin-loaded nanoparticles proved to reduce plasma glucose levels to 
40% of the basal values, with a sustained hypoglycemic effect over 24 h. Moreover, in an 
administered dose of 50 IU/kg, nanoencapsulated insulin had a bioavailability of 13% 
which was a 3.0-fold increase in comparison to an insulin solution. Confocal microscopy 
studies were also performed, showing internalization of nanoencapsulated insulin in the 
small intestinal mucosa [87]. The same group also studied the histopathological effects 
of nanoparticles administration, by analysing organs and tissues of diabetic rats dosed 
daily for 15 days with insulin nanoparticles. The results showed that no morphological or 
pathological alterations were observed in rat liver, spleen, pancreas, kidney or intestinal 
sections [89]. 
 
4.4. Poly(γ-glutamic acid) nanoparticles 
 
Lin et al. developed γ-PGA and chitosan nanoparticles prepared by an ionic-
gelation method. γ-PGA is a biodegradable, water-soluble anionic peptide, originated 
from the members of genus Bacillus [90]. After nanoparticles loading, the release profiles 
of insulin were significantly affected by the pH environment, being the highest amount of 
insulin released at pH 7.4. However, despite of the nanoparticles remained intact 
between pH 2.0–7.2, at lower pH they disintegrated, compromising insulin protection in 
the gastric acidic pH environment. Moreover, at pH 7.4, chitosan was deprotonated 
making the nanoparticles unstable, which lead to their disintegration. This also affected 
the ability of the formulation to open tight junctions, and thus, to increase insulin uptake. 
Nevertheless, the in vivo results clearly indicated that the administration of insulin-loaded 
nanoparticles in a dose of 15 IU/kg of insulin could effectively reduce the blood glucose 
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levels in a diabetic rat model, being this effect more pronounced when it was 
administered higher doses of insulin (30 IU/kg). The hypoglycemic effect lasted for 10 h. 
Due to the short effective time and to the pH sensitivity of the system, the same group 
improved it by lyophilizing the nanoparticles and delivering them within an enteric-coated 
capsule [91]. This process did not affect the activity of loaded insulin, which kept its 
secondary structure and its release remained pH-dependent. The enteric-coated capsule 
did not dissolve in the acidic environment of the stomach, crumbling in the high intestinal 
pH where it freed the insulin-loaded nanoparticles. As all the encapsulated nanoparticles 
reached the intestine, the intestinal absorption of insulin was enhanced and the reduction 
of blood glucose levels was prolonged, with 20% of insulin bioavailability observed [91]. 
Another study conducted by the same research group, presented a pH-responsive multi-
ion-crosslinked nanoparticles, prepared from γ-PGA and chitosan with TPP and MgSO4 
[92]. These nanoparticles showed stability in the ionically cross-linked network structure 
for 10 weeks suspended in deionized water and over a wide pH range of 1.2-7.4. When 
orally administered to diabetic rats, the nanoparticles demonstrated a hypoglycemic 
action for at least 10 h, with a bioavailability of 15.1 ± 0.9%. The toxicity studies showed 
that even at a dose 18 times higher than the one tested, the nanoparticles were well 
tolerated and not presented any toxicity [93].  
Diethylene triamine pentaacetic acid (DTPA) is known for disrupting the intestinal 
tight junctions and inhibiting the intestinal proteases by chelating divalent metal ions. Su 
and Lin conjugated DTPA with chitosan/γPGA nanoparticles (chitosan/γPGA-DTPA), a 
pH-sensitive system that disintegrated at pH above 7.0, producing a transient and 
reversible enhancement of paracellular permeability which increased the insulin uptake, 
producing a prolonged reduction of blood glucose levels [94]. When administered orally 
in an enteric-coated capsule, the system presented a maximum insulin concentration at 
4 h after treatment with a relative oral bioavailability of insulin of about 20%. 
 
4.5. Hyaluronic acid nanoparticles 
 
Hyaluronic acid is an anionic non-sulfated glycosaminoglycan natural polymer, 
used as carrier for the administration of insulin. Han and Zhao prepared insulin-loaded 
hyaluronic acid nanoparticles by the reverse-emulsion freeze-drying method [95]. The 
nanoparticles showed high insulin AE of about 95%. Due to the pH sensitivity of 
hyaluronic acid nanoparticles, the system was able to protect insulin from the low pH of 
the stomach. The results of the uptake experiments showed more than 2.0-fold increase 
in the apparent permeability coefficient comparatively to insulin in solution, and the main 
uptake mechanism of insulin was through active transport. The ex vivo experiments 
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showed that the hyaluronic acid nanoparticles significantly enhanced insulin uptake 
through the duodenum and ileum. When orally administered, hyaluronic acid 
nanoparticles also showed stronger hypoglycemic effects than insulin in solution (Figure 
2.3).  
 
 
Figure 2.3. Blood glucose levels after oral administration of insulin-loaded hyaluronic acid 
nanoparticles (50 IU/kg, squares) and insulin solution (50 IU/kg, circles); and subcutaneous 
administration of insulin solution (1 IU/kg, triangles) to diabetic rats. Statistically significant 
difference were observed for insulin-loaded hyaluronic acid nanoparticles comparatively to insulin 
solution (*p < 0.05; **p < 0.01). Mean ± SD (n = 6). HA and NPs stands for hyaluronic acid and 
nanoparticles, respectively. Reprinted with permission from [95].  
 
4.6. Polylactic acid nanoparticles 
 
PLA is an aliphatic polyester polymer considered biodegradable and 
biocompatible due to its hydrolysis into monomeric units in the body. Xiong et al. 
developed PLA-b-pluronic-b-PLA (PLA-F127-PLA) vesicles intended to deliver insulin 
orally [96]. The in vitro release study showed a biphasic release profile of insulin from the 
PLA-F127-PLA vesicles. The pluronic block copolymer showed a high permeability 
profile of insulin across the cell membrane, due to its amphiphilic properties and strong 
affinity to the small intestine caused by its polyethylene oxide (PEO) blocks. Insulin-
loaded PLA vesicles were orally administered to diabetic mice (50 IU/kg), and the blood 
glucose concentration decreased from 18.5 to 5.3 mmol/L in the first 4.5 h, reaching the 
lowest blood glucose concentration of 4.5 mmol/L after about 5 h. The same level of 
blood glucose concentration was maintained for more about 18.5 h. These results 
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showed the potential of insulin-loaded PLA-F127-PLA vesicles to be administered orally, 
due to its prolonged hypoglycemic effect. In a more recent study from the same group, 
PLA-b-pluronic-b-PLA (PLA-P85-PLA) vesicles were produced for the same purpose, 
obtaining a mean diameter of 178 nm [97]. The biocompatibility of the obtained vesicles 
was proved in cytotoxicity studies using human ovarian cancer cells OVCAR-3. In vitro 
and in vivo release studies revealed that insulin was sustainably released, and almost 
completely after 7.5 h of its administration. The oral administration of insulin-loaded PLA-
P85-PLA vesicles (200 IU/kg) in diabetic mice showed that the blood glucose levels were 
reduced, reaching its minimum (15% of the initial blood glucose level) 2.5 h after the 
administration. Upon 10.5 h, the blood glucose levels increased gradually up to 31.8% of 
the initial blood glucose concentration, keeping the same level for more 14 h. 
 
4.7. Poly(lactic-co-glycolic acid) nanoparticles 
 
PLGA an aliphatic polyester co-polymer is one of the most used synthetic 
polymers to produce nanoparticles for the oral delivery of insulin, mainly due to its 
biodegradability and biocompatibility properties as well as sustained release profiles. In 
fact, PLGA allows the production of versatile nanoparticles since it may be combined to 
other polymers or coated with different ligands, attributing to nanoparticles important 
features that may enhance the uptake of loaded drugs [98]. The ability of insulin-loaded 
PLGA nanoparticles to permeate across Caco-2 cell monolayer models, was 
demonstrated with nanoparticles produced by a double emulsion solvent evaporation 
technique, achieving an AE above 80%, and it was observed a profile of insulin 
absorption based on clathrin-mediated endocytosis in a time-dependant manner [99]. 
After intraduodenal administration to diabetic rats, the nanoparticles remained stable in 
the intestine for a period necessary to allow its uptake, and delivery of insulin into the 
bloodstream. The in vivo hypoglycemic effect was very similar to long-acting insulin. In 
another study, insulin was encapsulated into PLGA nanoparticles also using the double 
emulsion solvent evaporation technique [100], and it was found that insulin was released 
in a lower rate in pH 1.0 reaching about 90% of release in 11 days. On contrary, at pH 
7.8 the release was faster, since about 90% of the total amount of insulin was released 
in 3 days. The developed carriers were further administered orally to diabetic rats, and it 
was observed that blood glucose levels decreased while insulin levels in the blood 
increased. These results showed clearly the sustained release properties of PLGA 
nanoparticles, and its ability to protect insulin and consequently decrease the blood 
glucose levels upon oral administration. Indeed, the release profile of insulin from PLGA 
nanoparticles was characterized by a first burst release, followed by a sustained release 
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profile overtime [101]. The initial burst release may be mitigated by the combination of 
PLGA and β-cyclodextrin in nanoparticles production, which allows prolonging the effect 
of insulin for a longer period of time [102]. 
The encapsulation of hydrophilic insulin into the hydrophobic PLGA matrix may 
be challenging, thus different strategies may be used to improve the liposolubility of 
insulin as well as its loading efficiency. For instance, the complexation of insulin with 
lipophilic substances is one of these strategies. An insulin-phospholipid complex made 
by soybean phosphatidylcholine was produced to improve insulin liposolubility and 
increase its loading efficiency when encapsulated into PLGA nanoparticles [103]. The 
optimized formulation achieved an AE of about 90%, and the in vitro release study of 
insulin demonstrated an initial burst release at pH 1.2 with further slower release at pH 
6.8. Insulin complex-loaded PLGA nanoparticles (20 IU/kg) were further administered 
orally to diabetic rats and it was observed a decrease of fasting plasma glucose levels to 
about 57% in the first 8 h, which was prolonged for another more 12 h. It was also 
observed that insulin loaded into nanoparticles had 7.7% of oral bioavailability 
comparatively to the subcutaneous administration. In another study, a complex of insulin 
and sodium oleate, was loaded into PLGA nanoparticles by an emulsion solvent diffusion 
method [104]. After optimization of the formulation, it was obtained an AE of insulin of 
about 91%. Insulin:sodium oleate-loaded PLGA nanoparticles (20 IU/kg) were further 
administered orally to diabetic rats, and 12 h after the administration it was observed a 
decrease on the plasma glucose levels to about 23.9% of the initial insulin, which was 
also prolonged for 24 h. 
As stated above, one of the main issues in the oral delivery of insulin is the acid 
environment in the stomach and the action of proteolytic enzymes in the gastrointestinal 
tract. Thus, different strategies have been developed to mitigate their influence. 
Previously, it was proposed two types of nanocarriers made of a blend of PLGA and two 
polyoxyethylene derivatives, poloxamer (Pluronic F68) and poloxamine (Tetronic T904) 
for insulin oral delivery [105]. The stability of unloaded nanoparticles was assessed in 
gastric and intestinal fluids, and it was observed a strong interaction of unblended PLGA 
nanoparticles and digestive enzymes, whereas such interaction was mitigated by the 
blended formulations. In vitro results showed that insulin-loaded PLGA:Pluronic F68 
nanoparticles were able to avoid the gastrointestinal barrier. However, despite these 
positive results, in vivo studies are still needed to confirm these findings. Another 
creative strategy was to encapsulate both insulin and an antacid into PLGA 
nanoparticles [106]. Magnesium hydroxide or zinc carbonate at 2% were used as 
antacids, and the AE of insulin ranged between 81% and 85%, respectively. Using 
Fourier transform infrared spectroscopy (FTIR), circular dichroism (CD) and fluorescence 
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spectroscopy it was observed that the structural stability of insulin was maintained after 
formulation. Upon oral administration of insulin:antacid-loaded PLGA nanoparticles in 
healthy rats, the oral bioavailability of insulin increased 6-fold comparatively to an insulin 
solution. After administration to diabetic rats (120 IU/kg), the blood glucose levels 
decreased similarly to a 20 IU/kg subcutaneous administration of insulin. Despite these 
good results, the oral dose of insulin was significantly higher than the subcutaneous 
insulin in order to reach the same hypoglycemic effects, which from a cost-benefit point 
of view is less attractive.  
Another important strategy to overcome the harsh environment of the stomach is 
to use enteric coating materials. Thus, the prevention of insulin burst release in the 
stomach has been achieved by using HPMCP to produce PLGA/HPMCP nanoparticles 
to deliver insulin orally [107]. This pH-sensitive polymer was used as an enteric coating 
able to deliver insulin specifically to the small intestine. Insulin AE into the produced 
nanoparticles was about 65%, whereas insulin loaded into PLGA nanoparticles had an 
AE of about 50%. The in vitro release of insulin in simulated gastric fluid revealed that 
PLGA/HPMCP nanoparticles mitigated the initial burst release profile, characteristic of 
PLGA nanoparticles with about 20% release of insulin in the first hour, whereas PLGA 
nanoparticles released 50% of insulin in the same period. The relative bioavailability of 
insulin-loaded PLGA/HPMCP nanoparticles and insulin-loaded PLGA nanoparticles, 
comparatively to subcutaneous insulin (1 IU/kg) in diabetic rats was about 6.3% and 
3.7%, respectively. These results showed the potential of PLGA/HPMCP nanoparticles 
to deliver insulin orally. Wu et al. produced also insulin-loaded PLGA/HPMCP 
nanoparticles by a modified multiple emulsion solvent evaporation method, achieving an 
insulin AE of 94% [108]. It was also observed the release of insulin in a pH dependent 
manner at simulated gastrointestinal conditions. After oral administration to diabetic rats 
(50 IU/kg), the blood glucose levels decreased with a maximal effect between 1 and 8 h. 
Comparatively to the subcutaneous injections (5 IU/kg), the relative bioavailability was 
about 11.3%, which could be explained by the burst release of insulin in the upper 
intestine. The same research group, developed a two-stage delivery system based on a 
enteric capsule coated by the pH-sensitive HPMCP, able to selectively release insulin 
loaded into PLGA nanoparticles in the intestine [109]. Eudragit® RS was also used on 
PLGA nanoparticles production to increase the uptake of insulin across the intestinal 
mucosa, due to its enhanced mucoadhesive properties. The optimized nanoparticles 
were produced by a multiple emulsion solvent evaporation method achieving a zeta 
potential of +42 mV and an AE of about 74%, and the in vitro studies showed that the 
burst release of insulin was greatly reduced at pH 1.2. The capsule containing insulin-
loaded PLGA/Eudragit® RS nanoparticles was further administered to diabetic rats 
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inducing a prolonged reduction on blood glucose levels, and the PA of insulin was about 
9.2%.  
The modification of PLGA nanoparticles surface is also a good strategy to 
improve its properties, and its ability to enhance the uptake of insulin across the 
intestinal membrane. Indeed, the negative charge of PLGA nanoparticles may decrease 
the oral bioavailability of insulin, thus insulin-loaded PLGA nanoparticles can be coated 
with cationic chitosan to overcome this issue. In this context, Zhang et al. prepared 
chitosan-coated PLGA nanoparticles and demonstrated their higher bioadhesive 
properties when delivered orally, comparatively to uncoated PLGA nanoparticles, and 
also a higher relative pharmacological bioavailability of insulin comparatively to an insulin 
solution [110]. These results clearly showed the importance of the mucoadhesive 
properties of chitosan. In another work, nanoparticles made of PLGA and poly(fumaric-
co-sebacic anhydride) were produced and administered orally to rats, achieving a 
pharmacological bioavailability of insulin of 11% [111]. The polyanhydride compound 
was considered essential due to its bioadhesive properties. Despite of this fact, the 
nanoparticles prepared with poly(fumaric-co-sebacic anhydride) were much less efficient 
than nanoparticles prepared by the combination of poly(fumaric-co-sebacic anhydride) 
and PLGA, thus further improvements in the proposed carrier are still needed. The 
PEGylation of PLGA nanoparticles may be also used to improve the bioavailability of 
loaded insulin. Thus, a folate coupled PEGylated PLGA (FA-PEG-PLGA) nanoparticles 
were developed to improve the oral uptake of insulin [112]. The nanoparticles were 
produced by a double-emulsion solvent evaporation method, obtaining a loading of 
insulin of about 6.5% (w/w) and an AE of 87%. Insulin-loaded FA-PEG-PLGA 
nanoparticles (50 IU/kg) were further administered to diabetic rats, and it was observed a 
2-fold increase in the oral bioavailability of insulin, comparatively to subcutaneous 
administration of insulin. It was also observed the maintenance of the blood glucose 
levels for 24 h. In another approach, insulin-loaded PEGylated PLGA nanoparticles were 
functionalized with two different cell-penetrating peptides (poly[arginine]8 enantiomers, l-
R8 and d-R8) [113]. The in vitro studies in Caco-2 cell monolayers showed that 
functionalized nanoparticles significantly enhanced the permeation of insulin across the 
monolayers. Upon intestinal administration in rats, it was observed that functionalized 
nanoparticles improved the relative bioavailability of insulin in about 3.2 and 4.4-folds, 
and increased the hypoglycemic action in 2.5 and 3.7-folds, respectively for l-R8 and d-
R8 functionalized nanoparticles. This approach showed that d-R8 was better on 
promoting insulin uptake that l-R8. 
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4.8. Poly(ɛ-caprolactone) nanoparticles 
 
PCL is a biodegradable and biocompatible polyester, recognized for its good 
sustained release properties. The slower degradation profile of PCL comparatively to 
PLGA, for instance, makes it excellent for prolonged drug delivery. Damgé et al. 
developed a nanocarrier for oral insulin administration made of a mix of PCL and 
Eudragit® RS, achieving an insulin AE of about 96% [114]. Insulin-loaded nanoparticles 
(25, 50 and 100 IU/kg) were orally administered to diabetic rats, decreasing fasted 
glycemia levels with a dose dependant profile, reaching the maximal decrease at 100 
IU/kg. In addition, nanoparticles containing fluorescein isothiocyanate (FITC) labelled 
insulin adhered strongly to the intestinal mucosa, mainly due to the mucoadhesive 
properties of Eudragit® RS, allowing the uptake of insulin mainly by the Peyer’s patches. 
In another work from the same group, the same type of nanoparticles were used 
to encapsulate two different commercial insulins, Actrapid® and Novorapid®, achieving an 
AE of about 96% and 35%, respectively [115]. The in vitro release studies showed a 
burst release profile of insulin, and the in vivo studies in diabetic rats revealed that the 
Novorapid-loaded nanoparticles delivered orally decreased the glycemia, comparatively 
to empty nanoparticles. In another study, the authors used the same nanocarrier to 
encapsulate insulin aspart (short-acting insulin analogue) and obtained an AE of about 
98% [116]. The in vitro release study revealed that nanoparticles were able to release 
about 70% of insulin after 24 h. After oral administration of insulin-loaded nanoparticles 
(50 IU/kg) to diabetic rats, fasted glycemia decreased for an extended time and 
enhanced the glycemic response in a time-dependent manner, reaching a maximal effect 
at 12-24 h. Overall, it was observed that the produced nanoparticles allowed the 
suppression of postprandial peak more than 24 h comparatively to regular insulin, that 
had effect for 6-8 h only. This could be explained by the ability of insulin aspart to be 
better taken-up by the intestinal membrane than the ‘pure’ insulin. 
 
4.9. Acrylic polymers nanoparticles 
 
Acrylic polymers have been used in the oral delivery of insulin due to its ability to 
inhibit proteases activity, enhance mucoadhesion and alter the cell tight junctions 
improving the intestinal uptake. In fact, acrylic acid and its derivatives are used to 
produce nanoparticles with different properties that may improve the oral bioavailability 
of insulin. The mucoadhesive poly(acrylic acid) (PAA) was used to produce PAA-Cys 
nanoparticles to deliver insulin orally to non-diabetic rats [117]. This combination allows 
good enzymatic protection properties, and permeation enhancement due to the 
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increased mucoadhesion ability. Upon administration, it was observed a reduction of 
blood glucose levels and a significant increase of insulin concentration in serum. The 
insulin area under the curve of thiolated PAA nanoparticles was 2.3-fold higher than 
unmodified PAA nanoparticles, mainly due to the enhancement of the mucoadhesive 
properties of thiolated polymers. A similar carrier was developed in another study with 
the intention to protect loaded insulin from proteases in the intestine [118]. The in vitro 
studies showed that comparatively to insulin in solution, nanoparticles showed protection 
of respectively about 44%, 21% and 45% of the initial amount of insulin from degradation 
by trypsin, α-chymotrypsin and elastase degradation. 
Methacrylates are also useful to encapsulate insulin into nanoparticles. 
Nanospheres of crosslinked networks of methacrylic acid grafted with PEG and 
nanospheres of acrylic acid grafted with PEG, were previously developed [119]. The size 
of the copolymer gel nanospheres was dependent on the pH of the medium, as well as 
the release profile of insulin showed to be higher at pH 7.0. The in vivo studies in 
diabetic rats demonstrated that insulin-loaded copolymer nanospheres, caused a 
significant reduction of glucose level in serum, which  lasted for 6 h. Methacrylates 
demonstrated to be useful for the tight junctions opening, enhancing the intestinal 
permeation, whereas PEG conferred the protein stability and promoted mucoadhesion. 
Nanoparticles prepared by the blend of methacrylic copolymers with chitosan 
have been used to encapsulate insulin [120]. These systems enhanced the bioavailability 
of insulin due to its pH-sensitive property, which allowed insulin protection in stomach 
and promoted its interaction with the intestinal mucosa. In a different study, a complex of 
insulin and hydroxypropyl β-cyclodextrin (HPβCD) was encapsulated into 
polymethacrylic acid-chitosan-polyether PEG-polypropylene glycol copolymer) 
nanoparticles [121]. An evaluation by an enzyme linked immuno sorbent assay (ELISA) 
showed that insulin retained its biological activity after complexation and encapsulation. 
Ex vivo results using excised intestinal mucosa of rat showed good mucoadhesive 
properties of the nanoparticles. Insulin-loaded poly(isobutylcyanoacrylate) (PIBCA) 
nanoparticles produced by anionic in situ polymerization were also previously developed 
[122]. The nanoparticles were administered orally to diabetic rats, and it was observed 
positive results on oral absorption of loaded insulin.  
Eudragit® is a copolymer of ethyl acrylate, methyl methacrylate and methacrylic 
acid ester with quaternary ammonium groups, widely used as an excipient in 
pharmaceutical products. The enteric coating and controlled release properties of this 
copolymer make it helpful in the formulation of insulin-loaded nanoparticles intended to 
be administered orally. For instance, insulin-loaded thiolated Eudragit® L100 (with Cys) 
nanoparticles have been prepared by a precipitation method [123]. Thiolated and non-
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thiolated Eudragit® L100 nanoparticles containing insulin, achieved a loading efficiency of 
about 92% and 96%, respectively. The in vitro release profiles showed an insulin release 
in a pH-dependent manner, and CD measurements showed that the released insulin 
maintained its secondary structure. The in vitro mucoadhesion studies in the rat jejunum 
and ileum showed that thiolated nanoparticles had a 3.0 and 2.8-fold increase, 
respectively, comparatively to non-thiolated nanoparticles. This was attributed to the 
immobilization of the thiol groups on Eudragit® L100. The nanoparticles were further 
administered orally to rats, and the thiolated nanoparticles showed a higher and 
prolonged hypoglycemic action, with an insulin relative bioavailability of 7.33%, which 
represented a 2.8-fold increase comparatively to non-thiolated nanoparticles. In a 
different approach, nanoparticles produced by a complex coacervation method using 
Eudragit® L100-55 and chitosan polymers, were used to deliver insulin orally, achieving a 
loading efficiency of about 31%, mean particle size of about 200 nm and with a non-
spherical shape [124]. CD studies revealed that the insulin structure was not significantly 
changed after encapsulation, and its release was pH-dependent. Gelatin and Eudragit® 
L100 have been combined to produce pH-sensitive nanoparticles [125]. These 
nanoparticles were able to retain insulin, showing only about 20% of protein release 
during 90 min at pH 2.5. In contrast, at pH 7.4 the release was about 40% in the first 30 
minutes. This pH-sensitive release pattern conferred protection to insulin from the harsh 
gastric conditions along the gastrointestinal tract. Eudragit® RS, a polycationic acrylic 
polymer, was also combined with PCL achieving a relative bioavailability of insulin over 
13% [116]. The success of such carrier on insulin oral delivery is mostly attributed to the 
bioadhesive character of Eudragit® RS. 
 
4.10. Insulin-polyallylamine nanocomplexes 
 
The complexation of insulin with polymers may be a good strategy to obtain a 
different type of nanoparticles, which may be valuable in the oral delivery of insulin. 
Thompson et al. developed a nanocomplex made of polymeric self-assemblies of comb-
shaped amphiphilic polyallylamine that may be used to deliver insulin orally [126]. 
Polyallylamine was synthesized by randomly grafting palmitoyl pendant groups and 
further quaternized with methyl iodide. The obtained transmission electron microscopy 
(TEM) images showed that non-quaternized polymer complexes presented vesicular 
structures at low polymer:insulin concentrations, whereas at high concentrations they 
formed solid nanoparticles. The obtained complexation efficiency of insulin ranged 
between 78 and 93%. In vitro studies showed that the formed complex was able to 
protect insulin from degradation by pepsin and trypsin. It was also verified that 
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quaternized polymers had better protective effect against trypsin, mainly due to the 
electrostatic interaction with insulin, whereas non-quaternized polymers increased 
significantly the degradation of insulin by α-chymotrypsin. These results suggested that 
quaternized polymers could be a good option for oral delivery of insulin. 
In a different study, it was assessed the impact of the polymer architecture of 
nanocomplexes on insulin protection from degradation by trypsin, α-chymotrypsin and 
pepsin [127]. The polymer-insulin nanocomplexes were produced using quaternized 
derivatives of polyallylamine. It was verified that the polymer architecture could have 
influence on the complexes morphology, but had just a few impact on complexation 
efficiency. The polymers showed ability to reduce insulin degradation by trypsin, whereas 
it was verified that the polymer architecture played a crucial role against α-chymotrypsin 
and pepsin degradation. Thus, quaternized cetyl polymers were effective against pepsin 
degradation of insulin, whereas cholesteryl polymers significantly limited the degradation 
by α-chymotrypsin. These results indicated that to increase insulin protection against all 
the tested enzymes upon oral insulin administration, it is needed a combination of the 
used polymers. 
Further work of the same group, evaluated the effect of polymer architecture on 
the uptake of the nanocomplexes across a Caco-2 cell model [128]. It was observed that 
the nanocomplexes were able to reversibly open the tight junctions of cells increasing 
insulin uptake. Despite promising, the potential of these nanocomplexes to deliver insulin 
orally needs to be further addressed in in vivo models. 
Overall, the most relevant carriers for oral insulin delivery discussed all over the 
Section 4 of this chapter, and their features and pharmacological activity/bioavailability 
are summarized in Table 2.1. 
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Table 2.1. The most relevant polymer-based nanocarriers and their pharmacological activity/bioavailability studies developed so far. 
Polymer Mean diameter Dose 
Glucose level 
reduction 
Pharmacological 
bioavailability 
Ref. 
Chitosan 250-400 nm 21 IU/kg 58% 14.9% [59] 
200-550 nm 50 IU/kg 29% NA [60] 
100 IU/kg 33% NA 
269 nm 50 IU/kg 44.9% 4.4% [62] 
100 IU/kg 51.4% 3.2% 
339 nm 100 IU/kg 40% 3.5% 
TEC 175 nm 25 IU/kg 30% 
34% 
NA [70] 
DMEC 172 nm NA 
TMC-CSK 180-350 nm 50 IU/kg 28% 5.7% [67] 
TMC-Cys 100-200 nm 50 IU/kg 35%, 70% NA [72] 
Chitosan-γ-PGA 110-150 nm 15 IU/kg 
30 IU/kg 
25% 
50% 
NA [90] 
230-390 nm 30 IU/kg 45% 20.1% [91] 
218 nm 30 IU/kg 60% 15.1% [93] 
Chitosan-γ-PGA-DTPA 245-432 nm 30 IU/kg 50% 19.7% [94] 
LCS 270 nm 60 IU/kg 34% NA [73] 
Chitosan-dextran sulfate 500 nm 50 IU/kg 35% 5.6% [83] 
100 IU/kg  3.4% 
Chitosan-alginate 750 nm 50 IU/kg 40% 6.8% [86] 
100 IU/kg  3.4% 
 28 
 
 
         NA: Not available 
 
 
Alginate–dextran + poloxamer + chitosan + albumin 396 nm 50 IU/kg 40% 13.2% [87, 88] 
Chitosan-HPMCP 255 nm 12.5 IU/kg 35% 8.5% [58] 
Dextran + Vitamin B12 192 nm 20 IU/kg 70% 29.4% [46, 47] 
Hyaluronic acid 182 nm 50 IU/kg 40% NA [95] 
PLA-F127-PLA 56 nm 50 IU/kg 75% NA [96] 
PLA-P85-PLA 178 nm 200 IU/kg 85% NA [97] 
PLGA 247 nm 30 mg/kg 50% NA [100] 
200 nm 20 IU/kg 43% 1.7% [103] 
160 nm 20 IU/kg 76% NA [104] 
PLGA-HPMCP 169 nm 20 IU/kg 65% 6.3% [107] 
182 nm 50 IU/kg 88% 11.3% [108] 
PLGA-Eudragit® RS 285 nm 50 IU/kg 40% 9.2% [109] 
PLGA-cell penetrating peptide 190-200 nm 10 IU/kg 30%, 50% 7.5%, 11.2% [113] 
 
PCL-Eudragit® RS 
358 nm 100 IU/kg 80% 13.2% [114] 
700 nm 50 IU/kg 60% NA [116] 
PIBCA 85-182 nm 100 U/kg 75% NA [122] 
Eudragit® L100-Cys 324 nm 50 IU/kg 28% 7.33% [123] 
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5. Walkthrough on pipeline products 
 
Pharmaceutical companies are trying their best efforts on achieving a good 
formulation for oral delivery of insulin. Although the majority of the products are still in the 
development phase, some products are now in clinical trials. The main strategies focus 
on avoiding insulin degradation in the gastrointestinal tract and promoting its intestinal 
uptake. Strategies under development are concentrating efforts more on the use of 
excipients, such as protease inhibitors and absorption enhancers, together with insulin in 
conventional dosage forms like tablets or capsules, rather than the use of polymeric 
nanoparticles. Fonte el al. published a work discussing these different products to deliver 
insulin orally by pharmaceutical products recently developed [3]. This section is directed 
to describe the known delivery products based on polymer-based nanoparticles. 
Access Pharmaceuticals, Inc. (Dallas, TX, USA) developed CobOral™ 
technology, which consists in a polymer-based delivery system that takes advantage of 
vitamin B12 uptake mechanisms in the intestine to improve oral delivery of insulin. After 
oral administration, vitamin B12 attached to nanoparticles surface binds to haptocorrin in 
the stomach, and such complex migrates to the duodenum and dissociates. The intrinsic 
factor released in the stomach binds to vitamin B12 forming a complex, which binds to 
intrinsic factor receptor in the ileum. Then, the conjugated nanoparticles with vitamin B12 
reach the bloodstream by an endocytotic process. Chalasani and Russell-Jones, used a 
developed carrier to deliver insulin orally [46]. The nanoparticles produced using 
dextrans with different molecular weights and coated with vitamin B12, were loaded with 
2, 3 and 4% w/w of insulin and showed an AE of 45-70%. In vitro trials demonstrated that 
the conjugated nanoparticles were able to protect the loaded insulin from proteases 
activity in about 65-83%. The in vitro release studies revealed a first burst release 
followed by a controlled release profile, releasing 75-95% of insulin in 48 h. Insulin-
loaded nanoparticles were further administered orally to diabetic rats (20 IU/kg), leading 
to a plasma glucose reduction of 70-75% after 5 h, reaching basal levels at 8-10 h and 
obtaining a prolonged second phase until 54 h. The conjugated nanoparticles of Mw 
70,000 dextran loading insulin at 2, 3 and 4% w/w obtained a PA of 1.1, 1.9 and 2.6-fold, 
respectively, which was higher than the nanoparticles with no conjugated vitamin B12. It 
was also found that nanoparticles of Mw 70,000 dextran had a PA 1.4-fold higher than 
Mw 10,000 dextran nanoparticles. Despite of some promising results, this approach of 
insulin-loaded dextran nanoparticles coated with vitamin B12 needs further 
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investigations. Phase I clinical trials of Access Pharmaceuticals oral insulin product were 
announced, but no significant results were revealed so far [129]. 
NanoMega Medical Corporation (Lake Forest, CA, USA) developed a patented 
novel nanoparticle deliver system, made of a core of neutral γ-PGA coated with 
positively charged chitosan. This carrier is intended to facilitate the transient opening of 
tight junctions of cells promoting insulin uptake. Chitosan that is located on the outer 
surface of nanoparticles also allows the mucoadhesion of nanoparticles, and γ-PGA 
located inside the chitosan shell allows nanoparticle stabilization. The produced 
nanoparticles (30 U/kg) and an insulin solution (30 U/kg) were orally administered to 
diabetic rats, and the subcutaneously administered insulin was used as control [130]. 
The results shown in Figure 2.4 demonstrated that insulin-loaded nanoparticles were 
able to decrease blood glucose levels in a sustained manner over 8 h. The oral insulin 
solution was ineffective in decreasing the blood glucose levels and as expected, the 
subcutaneous administration of insulin decreased the blood glucose levels faster, but 
this effect was mitigated after 3 h. These results proved the ability of nanoparticles on 
increasing the intestinal uptake of insulin. No information about the current development 
stage of the developed product has been reported yet. 
 
 
Figure 2.4. Levels of glucose change after oral administration of insulin-loaded γ-PGA/chitosan 
nanoparticles. Water and insulin administered orally, and subcutaneously administered insulin 
were used as controls. Source: [130]. 
 
It is important to highlight that only a few results were revealed by the 
pharmaceutical companies regarding the oral delivery of insulin and the results 
described above are the most relevant presented so far. Despite the positive results, it 
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seems that a lot of work is still needed in the upcoming years in order to take the 
research on oral delivery of insulin to the next level. Even though, there are other 
companies trying their efforts to achieve a good polymer-based nanoparticle system for 
the oral delivery of insulin such as Aphios Corp. (Woburn, MA, USA) and NOD 
Pharmaceuticals, Inc. (San Diego, CA, USA), however the information about the used 
polymers and the products under development is too scarce. Aphios Corp. developed 
APH-0907 that is in pre-clinical development and consists in patented biodegradable 
polymer nanospheres loading insulin. NOD Pharmaceuticals, Inc., developed a 
formulation based on insulin-loaded bioadhesive nanoparticles, which are further 
formulated in unidirectional dosage forms for basal insulin supplementation. Their 
product Nodlin, which has been developed by their subsidiary Biolaxy (Shangai, China), 
uses NOD technology patented in US, EU, China and Mexico, and is currently in clinical 
phase trials I [131]. These latter companies present a lot of claims on the research of 
oral delivery of insulin, but no relevant results were reported so far. 
 
6. Toxicity concerns regarding insulin-loaded polymeric nanoparticles 
 
The toxicity assessment regarding oral administration of insulin-loaded polymer-
based nanoparticles needs to be focused both on insulin and on the carrier. 
Comparatively to the subcutaneous route, higher amounts of insulin are needed to be 
administered orally to have the same effect. However, the administration of such 
amounts in the intestine may raise toxicological problems that the majority of 
investigations usually neglect or underestimate. For instance, insulin released in a large 
amount may cause gastroparesis [132], being the effect of the prolonged administration 
of insulin on intestinal epithelium not well known so far. Regarding the carrier, the 
majority of the used polymers are recognized for being biocompatible and 
biodegradable, but the biodegraded polymeric products may accumulate inside the cells, 
which may affect unexpectedly the cellular responses [133]. Besides cytotoxicity, the 
immunological response may also be hindered. 
The excipients or adjuvants used in the formulation of nanoparticles, such as 
surfactants and absorption enhancers, may also damage the intestinal epithelium. The 
latter when continuously administered may compromise the epithelium integrity allowing 
the permeation of toxins and pathogens, which may lead to unexpectable side effects 
[134]. Other putative problems are, protease inhibitors that may interfere with proteins 
digestion leading to dietary problems and also mucoadhesive materials that may change 
the mucus turnover affecting the physiology of the intestine [135]. The developments in 
the oral insulin delivery field has focused more on improving the bioavailability of oral 
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insulin, rather than assessing the toxicity of the developed carriers, since it is assumed 
they are biocompatible. However, the toxicity in a long term of the carriers has been 
neglected. Nevertheless, some studies have been reported addressing some toxicity 
concerns. 
In vivo studies were performed upon oral administration in rats of a daily dose of 
self-assembled γ-PGA/chitosan nanoparticles during 14 days [93]. Neither significant 
difference in clinical signs nor in body weight was observed between experimental and 
control groups. No relevant pathological changes were observed in kidney, liver and 
intestine and no inflammatory reactions were also observed. The nanoparticles were well 
tolerated even at a higher dose of 18-fold than used in the 
pharmacokinetic/pharmacodynamic study. The toxicity assessments in rats, after 
administration of insulin-loaded decanoic acid grafted oligochitosan nanoparticles on the 
intestine were also performed [45]. Animals were sacrificed after a few hours and the 
histopathology studies revealed that the nanoparticles had no adverse effects on the 
intestine. Another biocompatibility assessment of TMC-Cys conjugate nanoparticles in 
Caco-2 cells after 8 h of incubation, and in rats after 2 h of administration showed no 
significant toxicity [72]. In another study, the cytotoxicity of PLGA nanoparticles and 
chitosan-coated PLGA nanoparticles was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide in Caco-2 cells and showed to be harmless to cell survival, 
since the cell viability was above 85% of the controls [110]. 
Insulin-loaded alginate–dextran complexed with chitosan–PEG–albumin 
nanoparticles were orally administered to diabetic rats for 15 days, and its toxicity effects 
were also evaluated [136]. There was no significant liver damage or biliary obstruction, 
since it was showed lower levels of alkaline phosphatase, alanine transaminase and 
aspartate aminotransaminase. In another study from the same group, the same type of 
insulin-loaded nanoparticles was administered to diabetic rats. No changes were 
observed in the liver and kidney, since some modifications on hepatic parameters and 
kidney functions were similar to normal rats and this was attributed to the chemical 
inducement of diabetes [137]. More recently, similar nanocarriers were administered to 
diabetic rats at a daily dose for 15 days, and a histopathological study was performed 
[89]. Neither pathological nor morphological modifications were observed in the intestine, 
kidney, spleen, pancreas or liver. 
 
7. Conclusion 
 
A major problem in insulin oral administration is the enzymatic degradation, as 
well as the low intestinal permeability and consequently low oral bioavailability. Thus, 
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different strategies using insulin encapsulation in polymer-based nanoparticles have 
been used to overcome these problems. The polymers used in nanoparticles production 
may be obtained from natural or synthetic sources, taking advantage of their properties 
such as the ability to preserve insulin stability, mucoadhesion, control the release and 
targeting of drugs. The combination of different polymers may accommodate all these 
properties together in the same nanocarrier.  
The research progress on finding an alternative system to deliver insulin orally 
has been concentrated more in academic research, rather than developments in the 
pharmaceutical industry. Thus, the focus has been on testing and proposing different 
carriers that have the ability to promote insulin intestinal uptake in a much larger 
extension than an oral administrated insulin solution. Positive results have been found, 
although obtained results are far from the hypoglycemic effect achievable by using 
subcutaneous insulin. In fact, the insulin amount used to formulate the oral delivery 
systems is much higher than that used for subcutaneous formulations. This is a critical 
point since the AE of the developed nanocarriers is crucial from a cost-effective point a 
view. The delivery of large amounts of insulin in the intestine also may lead to adverse 
effects. Thus, the future research developments needs to be more focused on becoming 
the developed oral insulin nanocarriers more effective and with similar biopotency of the 
subcutaneous route. Toxicity assessments of the developed nanocarriers, in a long term 
use need to be performed and their safety has to be clearly demonstrated. 
The pharmaceutical industries are trying their best efforts to develop an insulin 
oral delivery system; however, the focus on polymeric nanoparticles has been rather 
scarce, where only few industries have tried this strategy and the known results are very 
preliminary. A lot of work needs to be done still to become possible to bring to the market 
a nanoparticle-based delivery system to deliver insulin orally. Even though, the path is 
well-marked and the strategy of using polymeric nanoparticles may become in the future 
a possible answer to the search for an insulin oral delivery system. 
Overall, with the focus on the most promising administration route of insulin, the 
oral route, this chapter gave an overview about the potential polymeric nanoparticles 
used for delivery of therapeutic proteins. For therapeutic proposes, such carriers may be 
subjected to lyophilization and administered by several administration routes. 
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1. Introduction 
 
Nanoparticles are often produced in form of an aqueous suspension. However, in 
an aqueous suspension they are physically unstable, so particle aggregation and fusion 
are frequent phenomena during long storage periods. The hydrolytic action of water on 
the polymer matrix can lead to drug leakage, hamper or eliminate the sustained release 
properties or even lead to the formation of undesirable degradation products [6]. A 
nanoparticle suspension is also prone to the development and growth of microorganisms 
[138]. To overcome all these problems, the transformation of the nanoparticle 
suspension into a solid dosage form is the obvious solution. 
Lyophilization or freeze-drying is a dehydration process used to overcome the 
instability of nanoparticle suspension, increasing shelf-life and simultaneously facilitating 
its handling and storage [7, 8]. This process has three main steps, the freezing, the 
primary drying and the secondary drying. Thus, water is removed from the formulation by 
sublimation of ice and further desorption of unfrozen water under vacuum. The 
processing conditions at which formulation are subjected may generate freezing and 
desiccation stresses, with detrimental consequences to nanoparticle structure and 
stability. Different excipients such as cryoprotectants and lyoprotectants may be used to 
minimize the lyophilization stresses and preserve the physical-chemical properties of 
nanoparticles. Sugars are the preferable cryo- and lyoprotectants, mainly because they 
are chemically innocuous and may be easily vitrified during the freezing step [9]. 
Therapeutic proteins are often encapsulated into nanoparticles, and sugars are also 
important in the protection of protein drugs from inactivation, during lyophilization and 
storage [10]. Another important property of sugars is that they also affect the glass 
transition temperature (Tg and Tg’) of formulations, which have major importance on the 
optimization of the lyophilization cycle [8]. A higher cryoprotectant concentration and 
faster freezing rate lead to better nanoparticle redispersibility [139, 140]. However, there 
is some controversy, so the selection of an adequate cryo- or lyoprotectant and freezing 
rate is not straightforward, and it may depend both on the formulation properties and on 
the lyophilization cycle [7]. In most of the works focusing on lyophilization of 
nanoparticles, the choice of a good cryo- or lyoprotectant and lyophilization cycle has 
been relied in empirical approaches, and experiments have been even performed by trial 
and error. Therefore, it is crucial to perform a systematic study on the optimization of 
nanoparticles lyophilization, by assessing the physical-chemical properties of 
formulations and understanding the engineering principles inherent to lyophilization. 
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Several analytical techniques may be used to achieve this purpose, and also 
characterize the properties of both the nanoparticles and the cake upon lyophilization.  
The use of therapeutic proteins have been grown in the last years, due to their 
therapeutic benefits in severe health problems such as cancer and autoimmune 
diseases [1]. These drugs have been also loaded into polymeric nanoparticles with 
potential benefits to patients. However there is a lack of knowledge on the effect of 
lyophilization on the structure of proteins loaded into nanoparticles, and whether the 
interaction of polymers and proteins inside nanoparticles core may affect the 
conformation of proteins, in such a way that could hinders their bioactivity or even lead to 
undesirable side effects. To address such lack of knowledge, in this Thesis it was used 
as models, insulin as therapeutic protein, PLGA as nanoparticles polymer and several 
lyophilization protectants, namely trehalose, sucrose, glucose, fructose, and sorbitol.  
These compounds are briefly described below: 
 
Insulin 
Insulin is a protein hormone involved in the metabolism of carbohydrates, which 
lowers blood sugar and is used to treat both type 1 and type 2 diabetes mellitus. Insulin 
has a molecular weight of about 5.8 kDa, and is composed of two polypeptide chains, 
the A- and B- chain, with 21 and 30 amino acids, respectively, linked together by two 
disulphide bonds [141]. In Figure 3.1 is shown the organization of the primary structure 
of human insulin. This structure may slightly variate between animal species. 
Insulin is produced and stored in the body as a hexamer, but the active form is 
the monomer [142]. The hexamer is an inactive form with long-term stability, and is more 
stable than the monomer. In solution, insulin may exist as an equilibrium mixture of 
monomers, dimers, tetramers and hexamers depending on concentration, solvent 
composition, pH, metal ions and ionic strength. Upon exposure to harsh conditions, such 
as high temperatures, organic solvents, low pH and agitation, insulin can aggregate and 
even form fibrils [143]. 
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Figure 3.1. The structure of human insulin composed of A-chain with 21 amino acids, and B-
chain with 30 amino acids. Adapted from [144]. 
 
PLGA 
PLGA is a polyester and a copolymer of PLA and polyglycolic acid (PGA). PLA 
has an asymmetric α-carbon, usually stereochemically described as L or D form. Figure 
3.2 shows the chemical structure of PLGA. Different forms of PLGA may be obtained 
depending on the ratio of lactide and glycolide used for polymerization, and are identified 
regarding the molar ratio of the monomers used [145]. The chemical properties of PLGA 
depend on that ratio, and the polymer may variate from crystalline to amorphous form 
depending on both the molar ratio and block structure. The Tg is usually in the range of 
40-60ºC. 
PLGA is used to encapsulate molecules of a large size range, and it is soluble in 
chlorinated solvents, acetone, ethyl acetate and tetrahydrofuran [146]. Water may lead to 
the biodegradation of PLGA by hydrolysis of its ester linkages. The Tg, molecular weight 
and residual moisture content may variate accordingly to the hydrolysis of PLGA, and the 
modification of PLGA properties during its biodegradation influences the rate of release 
and degradation of loaded drugs [145]. PLGA is useful in drug delivery due to its 
biodegradation by hydrolysis in the body originating its monomers, lactic acid and 
glycolic acid [147]. Such monomers are by-products of different metabolic pathways, so 
its toxicity is considered negligible.  
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Figure 3.2. Chemical structure of PLGA. The x represents the number of units of lactic acid, and 
y represents the number of units of glycolic acid. 
 
Trehalose 
Trehalose is a non-reducing disaccharide formed by a linkage of two d-glucose 
molecules (Figure 3.3). The typical commercial product is trehalose in the dehydrate 
form with a molecular formula and weight of C12H26O13 and 378.33 g/mol, respectively 
[148].  
 
 
Figure 3.3. Chemical structure of trehalose. 
 
Sucrose 
Sucrose is a non-reducing disaccharide formed by a linkage of glucose and 
fructose (Figure 3.4), with a molecular formula and weight of C12H22O11 and 342.30 
g/mol, respectively [148]. 
 
 
Figure 3.4. Chemical structure of sucrose. 
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Glucose 
Glucose is a reducing monosaccharide (Figure 3.5), with a molecular formula and 
weight of C6H12O6 and 180.16 g/mol, respectively [148]. 
 
 
Figure 3.5. Chemical structure of glucose. 
 
Fructose 
Fructose is a reducing monosaccharide (Figure 3.6), with a molecular formula 
and weight of C6H12O6 and 180.16 g/mol, respectively [148]. 
 
 
Figure 3.6. Chemical structure of fructose. 
 
Sorbitol 
Sorbitol is a sugar alcohol (Figure 3.7), with a molecular formula and weight of 
C6H14O6 and 182.17 g/mol, respectively [148]. Sorbitol is an isomer of mannitol, differing 
only in the orientation of the hydroxyl group on carbon 2. 
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Figure 3.7. Chemical structure of sorbitol. 
 
The main aim of this chapter was to perform an up-to-date insight on the 
fundaments involved in the lyophilization of polymeric nanoparticles, mainly regarding 
the binomial formulation-lyophilization cycle and their storage stability. A special focus is 
given to the need of optimization of the mentioned binomial to obtain a good lyophilized 
product, discussing also the analytical methods for its characterization. Finally, the effect 
of lyophilization on the stability and structure of proteins loaded into polymeric 
nanoparticles is also scrutinized. 
 
2. Lyophilization of nanoparticles 
 
Lyophilization is commonly used to improve the long-term stability of 
nanoparticles [149]. A good lyophilizate should have some important characteristics, i.e., 
maintain the physical and chemical properties of the original product, obtain a cake with 
good aspect,  possess short reconstitution time, low residual moisture content and good 
long-term stability [150]. Furthermore, after lyophilization, the nanoparticles need to be 
easily resuspendable, presenting no modification of particle size distribution, and the 
activity of the loaded drug must be preserved. To achieve all these purposes, it is crucial 
to optimize and focus on three main aspects involved in the stability of nanoparticles, 
which are the formulation, the lyophilization process and the storage conditions.  
 
2.1. Formulation matters 
 
The thermo-physical properties of the nanoparticle suspension need to be 
properly known, and further considered to obtain a good lyophilizate. These properties 
are essentially the glass transition temperature of the frozen sample (Tg’) and the 
collapse temperature (Tc) of the formulation. The different constituents of the 
formulations such as the nanoparticles polymer, the type of surfactants, the chemical 
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groups attached on nanoparticle surface, and the nature and concentration of cryo- or 
lyoprotectant used, may influence those properties, and have important effects on the 
different stresses caused by lyophilization [7]. All these components should be regarded 
before inferring the lyophilization process, and distinguished between the components of 
the formulation with origin in the production of nanoparticles, and others added to the 
formulation prior to lyophilization, such as cryo- and lyoprotectants. Since the latter are 
specifically added to avoid the lyophilization stresses, they will be fully discussed in 
section 2.1.1 of this chapter. 
Surfactants are frequently used to stabilize the nanoparticles suspension and 
avoid their aggregation [151, 152]. Polyvinyl alcohol (PVA) is one of the most common 
surfactants used to produce nanoparticles, enabling the production of stabilized 
nanoparticles with small size and narrow distribution [151, 152]. Simultaneously, 
surfactants may also have a stabilizing effect on nanoparticles during lyophilization. It 
was reported that PCL nanoparticles formulated with 2.5% (w/v) and 5% (w/v) of PVA, 
used as surfactant, were stable with no significant aggregation upon lyophilization with 
no cryo- or lyoprotectant added [153]. Another surfactant, pluronic F68 2% (w/v), was 
also able to stabilize poly(isohexylcyanoacrylate) (PIHCA) and PIBCA nanoparticles, 
after lyophilization [154]. The PVA may remain on nanoparticles surface even after 
washing, improving the freezing resistance of nanoparticles [151, 152, 155]. Different 
studies reported that for nanoparticles without cryoprotectant the residual PVA was able 
to preserve nanoparticle structure upon lyophilization [156-159]. However, not even all 
surfactants may have a stabilization effect on nanoparticles during lyophilization. For 
instance, PLA nanoparticles stabilized with pluronic F68 were not stable upon 
lyophilization, due to the increase of this surfactant solubility in the bulk solution during 
freezing, leading to nanoparticles aggregation [160]. 
The drug present in formulation may also influence the lyophilization process, 
whether the drug is entrapped into the nanoparticles or free in the formulation. The 
presence of free drug may reduce the zeta potential of nanoparticles, leading to their 
aggregation [7]. The lyophilization process itself may lead to the leakage of the drug, or 
in the case of protein drugs, lead to the degradation of its structure. Previously, it was 
observed that the lyophilization of PCL nanoparticles resulted in desorption of 
itraconazole located at nanoparticles surface, due to the crystallization of pluronic F68 
used as stabilizer [161]. However, the modification of pluronic F68 by sodium 
deoxycholate in presence of sucrose 10% (w/v) fully stabilized the nanoparticles upon 
lyophilization. The sodium deoxycholate did not crystallize and maintained the drug-
nanoparticle association. In another work, the cyclosporine association with PCL 
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nanoparticles was enhanced upon lyophilization, in presence of pluronic due to the 
adsorption of free drug on nanoparticles surface  [162].  
 
2.1.1. Cryo- and lyoprotectants 
 
During freezing, occurs a separation of phases into ice and a cryoconcentrated 
suspension. The cryoconcentrated phase is constituted by the nanoparticles and other 
excipients like cryo- and lyoprotectants, buffers, surfactants and even unloaded drugs 
[140]. The high concentration of nanoparticles in the cryoconcentrated phase may 
motivate aggregation or even fusion of nanoparticles. Furthermore, the ice crystallization 
may induce a mechanical stress onto nanoparticles leading to their destabilization. To 
avoid these issues, some excipients may be added to the nanoparticles suspension prior 
lyophilization. Such excipients may be mainly cryoprotectants to protect from freezing 
stresses, and lyoprotectants to protect from drying stresses. The Table 3.1 summarizes 
the most used cryo- and lyoprotectants in the lyophilization of polymeric nanoparticles. 
Generally, the cryoprotectants may also act as lyoprotectants and vice-versa. 
Overall, the cryoprotectants may form a protective glassy matrix in which the 
nanoparticles are immobilized, avoiding its aggregation and protecting them from the 
mechanical stresses of ice crystals. They are known to vitrify at a specific glass Tg’, so to 
guarantee the complete solidification of the formulation, the freezing step needs to be 
performed below Tg’ of a frozen amorphous formulation or below the Teu (eutectic 
temperature) for crystalline formulations [163]. Another theory of nanoparticles 
stabilization by cryoprotectants is the particle isolation hypothesis, stating that 
cryoprotectants separate the nanoparticles in the unfrozen phase, avoiding their 
aggregation upon freezing above Tg’ [164]. 
  The most commonly used cryoprotectants are sugars, such as trehalose, 
glucose, sucrose and mannitol [7]. Other cryoprotectants such as polymers are also 
often used. Most of the works present a trial and error approach, on choosing the best 
cryoprotectant for the nanoparticle formulation. For instance, it was evaluated the 
performance of the cryoprotectants, glucose, sucrose, PVA and γ-PGA in the 
lyophilization of PCL nanoparticles [165]. It was found that glucose 1% (w/w) had the 
best stabilizing effect achieving spherical, uniform and biocompatible PCL nanoparticles 
upon lyophilization. Among the most used cryoprotectants, trehalose present some 
advantages over the other sugars mainly because of its absence of internal hydrogen 
bonds, allowing more flexible formation of hydrogen bonds with nanoparticles during 
lyophilization, less hygroscopicity, higher Tg’ and low chemical reactivity [166]. The 
stabilization effect of sugars is also directly related to their concentration. It was 
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described that PLGA and PCL nanoparticles, respectively, added with sucrose and 
glucose at a concentration of 20% (w/w), presented no macroscopic aggregation after 
reconstitution [167]. The mass ratio of nanoparticles:cryoprotectant seems to be also 
important on nanoparticles stabilization. A complete redispersion of poly(lactide acid-co-
ethylene oxide) (PLA-PEO) nanoparticles was observed after lyophilization, when 
trehalose was added at a mass ratio of 1:1 [157]. However, the exaggerated increase of 
the cryoprotectant concentration may overcome the stabilization limit, and even 
destabilize the nanoparticles. For instance, the aggregation of silica nanoparticles 
increased with higher concentration of glucose [168]. 
To infer the right type of cryoprotectant and its concentration, a freeze-thawing 
study may be performed to optimize the formulation and guarantee the stabilization of 
nanoparticles. It was performed a freeze-thawing at -20ºC, -80ºC and -196ºC on PCL-
PEG-PCL micelles testing as cryoprotectants, maltose, glucose, HPβCD and PEG of 
distinct molecular weights [169]. When not properly used, cryoprotectants may have a 
detrimental effect on nanoparticles stability. For example, the crystallization of 
cryoprotectants such as mannitol may originate a phase separation in the 
cryoconcentrated phase, without a stabilization effect on nanoparticles [7]. This is 
because in the nanoparticles enriched phase, they may interact and form aggregates. In 
addition, the ice crystals and mannitol can lead to mechanical stresses leading to 
nanoparticles fusion. Thus, to have a stabilization effect it is necessary to have mannitol 
in the amorphous phase of nanoparticles [140].  
The removal of ice and unfrozen water may also destabilize the nanoparticles, so 
lyoprotectants may be used to avoid the drying stresses. The water replacement 
hypothesis, may explain the mechanism of nanoparticles stabilization by lyoprotectants 
[170, 171]. This theory states that lyoprotectants may form hydrogen bonds, with the 
polar groups at the nanoparticles surface, at the end of the drying steps. Nanoparticles 
are stabilized because lyoprotectants act as water substitutes. The amorphous state of 
nanoparticles and lyoprotectant facilitates a maximal H-bonding between them. Thus, the 
crystallization of a lyoprotectant hampers the formation of such hydrogen bonds [140]. 
The concentration of nanoparticles may also impact the outcome of lyophilization. This 
was observed in the lyophilization of PLA-PEO copolymer nanoparticles, in which the 
concentration of nanoparticles played  an important role in the lyoprotective mechanism, 
independently of the amount of trehalose added [172]. It was observed that the highest 
lyoprotective efficiency was obtained for the highest nanoparticles concentration. 
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Table 3.1. Cryo- and lyoprotectants commonly used in the lyophilization of polymeric 
nanoparticles. 
Cryo- and lyoprotectant Polymer Drug Ref. 
Dextran PLGA Ciprofloxacin HCl [173] 
 
 Cyclosporine 
[174] 
Fructose PLGA Insulin [101, 175] 
Glucose BSA Abacavir [176] 
 PCL Cyclosporine [167] 
  Itraconazole [161] 
  - [140, 153] 
 PCL-PEG-PCL Rifampicin [169] 
 PIBCA Itraconazole [177] 
 PLA - [160] 
 PLGA Ciprofloxacin HCl [173] 
  Cyclosporine [174] 
  Insulin [101, 175] 
  - [167] 
HPβCD PCL - [140, 153] 
 PCL-PEG-PCL Rifampicin [169] 
Lactose PIBCA Itraconazole [177] 
 PLGA Testosterone [178] 
Maltose PCL-PEG-PCL Rifampicin [169] 
Mannitol Chitosan Docetaxel [179] 
    
 PLGA Ciprofloxacin HCl [173] 
  Cyclosporine [174] 
  Testosterone [178] 
PEG PCL-PEG-PCL Rifampicin [169] 
PVP PCL - [140, 153] 
PVA PCL - [153] 
 PLA - [160] 
 PLGA - [158] 
Sorbitol PCL Cyclosporine [167] 
 PLGA Insulin [101, 175] 
  - [167] 
Sucrose PCL Cyclosporine [167] 
  Itraconazole [161] 
  - [140, 153] 
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 PIBCA Itraconazole [177] 
 PLA - [160] 
 PLGA Insulin [101, 175] 
  Testosterone [178] 
  - [167] 
Trehalose PIBCA Itraconazole [177] 
 PLA - [160] 
 PLGA Ciprofloxacin HCl [173] 
  Cyclosporine [174] 
  Insulin [101, 175] 
  Testosterone [178] 
 
2.2. Lyophilization process matters 
 
After optimizing the formulation and knowing its thermo-physical properties, it is 
necessary to adequate the lyophilization parameters in order to obtain a lyophilizate with 
good quality. The lyophilization occurs in three main steps: freezing, primary drying and 
secondary drying. Thus, this dehydration process occurs in the following stages: i) 
cooling of the formulation, and conversion of water into ice. In this stage occurs the 
crystallization of crystallizable solutes and/or formation of an amorphous matrix 
containing unfrozen moisture with noncrystallizing solutes; ii) sublimation of ice using 
vacuum; iii) removal of water by evaporation from the amorphous matrix and desorption 
of residual moisture. 
The required conditions to the lyophilization process may induce some stresses 
and damage the products. That damage occurred in early stages such as during freezing 
may be drastically augmented in further stages. Although lyophilization is a robust 
technique, even trivial changes in the process such as changes in the vials type or trays, 
may be enough to transform an acceptable process into unacceptable. In Figure 3.8 it is 
shown examples of lyophilization cycles for sucrose and mannitol solutions representing 
amorphous and crystalline formulations, respectively. It is possible to observe 
differences in processing conditions, mainly regarding the shelf temperature and the 
chamber pressure. The product temperature is influenced both by the shelf temperature 
and the formulation itself, loaded into recipients with different sizes and distinct product 
volumes. Different temperatures and duration of steps are necessary to lyophilize the 
solutions. The primary drying of the amorphous formulation often requires a low 
temperature, leading to a lower sublimation rate and consequently to a required longer 
time. On its turn, in the lyophilization of the crystalline formulation it may be applied more 
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aggressive processing conditions. Thus, the sublimation rate may be quite higher, 
leading to a required shorter time for primary drying. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Lyophilization process of (A) 6 mL fill in 20 mL vial of a sucrose solution 5% w/v, and 
(B) 18 mL fill in 50 mL vial of a mannitol solution 5% w/v. Reprinted with permission from [180]. 
 
Upon freezing, the formulation constitutes a solid amorphous phase that contains 
about 15-30% of unfrozen water. After this step is complete, the temperature of the 
shelves is increased, and the ice-vapor is evacuated by the vacuum pump to promote 
the sublimation of water. After being removed, the ice crystals form a network of pores, 
that allows the exit of water vapor from the product [181]. The sublimation process 
occurs from the top to the bottom of the vial, being the primary drying the most time 
consuming step in lyophilization. After the primary drying, the shelf temperature is 
increased to remove the remainder unfrozen water and the secondary drying begins, 
normally at 20-50ºC for a few hours. Although the lyophilization purpose is to improve 
stability, some formulations may get unstable during the following events: occurrence of 
A 
B 
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a cold shock during the cooling of the formulation; formation of a cryoconcentrated 
phase, during the formation of ice; collapse of the formulation during drying; in the case 
of protein formulations, high shelf temperatures during secondary drying may lead to 
protein denaturation; presence of reactive gases such as oxygen, during drying and 
storage; Maillard reactions occurred during storage; and damage of formulation upon 
reconstitution when it is difficult to resuspend it. 
Overall, the lyophilization of nanoparticles is a complex process and demands a 
good comprehension of the process specificity. Most of the research works use the 
lyophilization of nanoparticles in a trial and error way, using different processing 
conditions and formulation excipients, and choosing the best after lyophilization and 
product characterization. Standard lyophilization cycles are frequently used, and all the 
three steps of lyophilization, mainly the secondary drying, are even unspecified in many 
papers. Therefore, the best approach is to assess the thermo-physical properties of the 
formulation, and the engineering principles of lyophilization to obtain a good lyophilizate, 
without having a trial and error approach [8]. Still, there are some research works in 
which the thermo-physical properties of formulations were assessed prior lyophilization 
[140, 182]. The evaluation of the critical properties of the nanoparticle formulation is 
crucial to infer an optimum lyophilization cycle. Those properties are mainly the Tg’ and 
the Tc of the formulation; as well as the stability of the loaded drug, the nanoparticles 
and excipients used. Usually, the Tg’ is about 2ºC lower than the Tc. In the following 
sections, all the lyophilization steps will be fully described. 
 
2.2.1. Freezing 
 
The freezing step is the first one in the lyophilization process, in which the 
formulation is cooled and ice crystals are formed. During freezing, while water freezes, 
an increase in the concentration of the remaining suspension occurs, increasing its 
viscosity and hampering further crystallization. Then, this cryoconcentrated phase 
solidifies, originating a lyophilizate with a crystalline, amorphous or a combination of both 
form [183]. The water that does not solidify during freezing is denominated bound water. 
The freezing step may be understood, by the analysis of the phase diagram of a 
water/solute system (Figure 3.9). The diagram shows that a solution increases its 
concentration during freezing until the Tg’, in which reaches the maximal concentration 
of the cryoconcentrated solution (Cg’). At this value, further cooling of the solution will not 
change its concentration. Therefore, the freezing temperature needs to be performed 
below Tg’ to obtain complete freezing. During freezing, the crystallization of a 
crystallizable solute occurs below the Teu. 
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Figure 3.9. Phase diagram for a system of water (w) / solute (s). Tm, Teu, Tg, Tg’ and Cg’ stand 
for melting temperature, eutectic temperature, glass transition temperature, glass transition 
temperature of the frozen sample and concentration of the cryoconcentrated solution, 
respectively. The crystallization of the solute occurs below Teu (gray line). There is no 
crystallization of the solute at Teu in the case of vitrification (black line), and the cryoconcentration 
follows into a glass state at Tg. Adapted from [184]. 
 
The terms cooling and freezing are usually not properly distinguished. Cooling is 
related to the decrease of the temperature of the lyophilizer shelves, the lyophilizer 
chamber and the formulation. On its turn, freezing is related with the modification of the 
physical state of the formulation from liquid to solid. During freezing the water starts to 
nucleate, and ice crystals are formed and the remainder solute phase is a mixture of 
solute concentrate and ice. When a formulation is cooled below its freezing point it 
occurs a supercooling. Thus, in an optimized lyophilization process, it is necessary to 
induce supercooling in the formulation to promote the uniform cooling and freezing [183]. 
The cooling rates may be distinctly inferred, namely in terms of, the rate that the shelf 
temperature is cooled per period of time, the rate that solution cools per period of time 
and the depth of formulation in the vial that cools per period of time. There is a difference 
between the temperature of the formulation and the shelf temperature, so the shelf-
cooling rate may not precisely define the formulation thermic behaviour. Furthermore, the 
cooling or freezing rates of the formulation may variate from vial to vial depending on 
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their position on the shelves, or even present intravial variation if the formulation is 
heterogeneous. For instance, the random freezing pattern may lead to differences in the 
ice structure from vial to vial, leading to different drying profiles, since the ice and crystal 
structure of the solute impacts the drying behaviour. At the end of sample cooling it is 
necessary a hold time, in which the temperature is maintained to assure that all vials are 
properly frozen. 
Regarding the lyophilization of nanoparticles, the freezing step is the one in which 
most of the water is removed. This is because it is in this step, that there is a formation of 
many phases and interfaces between ice and nanoparticles. However, such formation of 
phases may induce stresses to nanoparticles leading to their aggregation or fusion in the 
cryoconcentrated phase. To assure that the formulation freezes, nanoparticles need to 
be cooled below the Tg’ of the formulation if it is amorphous, or below the Teu if it is in 
the crystalline state. Thus, the shelf temperature needs to be below this critical 
temperature, and hold it for enough time to assure complete solidification of the 
suspension. Just a few papers have been reported the thermo-physical properties of 
nanoparticles before lyophilization [140, 161, 167]. To freeze the nanoparticle 
suspension it have been used different freezing methods [184]. Such methods may 
occur by placing vials onto precooled shelves, a ramped cooling on the shelves, freezing 
in an external freezer, freezing in liquid nitrogen or others. These freezing methods 
originate distinct supercooling effects, which lead to a distinct ice crystallization. 
Commonly, the freezing in liquid nitrogen result in the highest supercooling, whereas the 
freezing onto precooled shelves originates the lowest one. Thus, a larger surface area of 
ice resulting from smaller ice crystals is originated by a higher supercooling [185]. These 
smaller ice crystals may decrease the mechanical stress on nanoparticles, hampering 
their aggregation. 
There is some controversy about if a slow or fast freezing rate is better for 
nanoparticles redispersibility and prevention of irreversible aggregation. It was previously 
observed  that a faster freezing originated less aggregation of mannan-coated cationic 
nanoparticles upon thawing, comparatively to slow freezing [186]. However, when the 
formulation was added with a cryoprotectant, the freezing rate did not affect the particle 
size upon thawing. Similar results were found for PCL nanocapsules containing no 
cryoprotectant [153] In another research work, even in presence of mannitol, the freezing 
method influenced the particle size of monensin nanoparticles, and the fast freezing 
demonstrated to have a lower change of nanoparticles size, comparatively to slow 
freezing [187]. However, when trehalose was added, the freezing method showed no 
significant effect on particle size. This result may be explained by the capacity of 
mannitol to crystallize during slow freezing, and upon a fast freezing it may be produced 
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more amorphous mannitol able to protect nanoparticles. Previously, it was also reported 
that the addition of 5% (w/v) of glucose, sucrose and trehalose preserved the features of 
PCL and PLGA nanoparticles upon freeze-thawing, regardless the freezing at -70ºC or in 
liquid nitrogen [167]. Sorbitol was an effective cryoprotectant for PLGA nanoparticles 
frozen at -70ºC, and it was able to avoid the formation of macroscopic aggregates upon 
freezing of PLGA in liquid nitrogen and of PCL nanoparticles at -70ºC. 
Other studies found that a slow freezing was beneficial for the lyophilization of 
nanoparticles, mainly because it originates a more cryoconcentrated phase, in which the 
present cryoprotectant better protects the nanoparticles. For instance, it was previously 
assessed the effect of the cryoprotectant in function of the freezing rate, on the 
redispersibility of hydroxypropyl cellulose (HPC) based nanoparticles [9]. Generally, it 
was found that a fast freezing rate and high concentration of cryoprotectants produced 
better redispersibility. However, the excessive addition of cryoprotectants was prejudicial 
in many cases.  In other occasions, slower freezing rates originated a better 
redispersibility, due to the formation of a more cryoconcentrated phase. In another study, 
it was determined the effect of the molecular weight of cryoprotectants and the freezing 
rate, on nanoparticles aggregation [149]. An irreversible aggregation occurred mainly 
during drying than during freezing, but an adequate freezing rate was found to be 
essential. More homogeneous formulations originated better redispersible powders, and 
the maintenance of the local concentration of nanoparticles and cryoprotectant was 
crucial. The nanoparticles redispersibility increased, with an increase in cryoprotectants 
molecular weight. For the formulation containing PEG, the redispersibility was better in 
the case of a slow freezing. Such result was explained by the tendency of solutes to be 
excluded from growing ice crystals. Thus, the differences in the excluding behaviour of 
nanoparticles and cryoprotectants, may explain the dependence of the redispersibility 
both on the molecular weight and the freezing rate. Overall, besides the controversy 
about the best freezing rate may still exist, it is clear that the thermo-physical properties 
of the formulation have a crucial impact in the nanoparticles aggregation and 
redispersibility. 
 
2.2.2. Annealing importance in the lyophilization process 
 
The freezing step influences the morphological characteristics of the lyophilized 
cake [188]. Being the first step in lyophilization and influencing the size of ice crystals, it 
impacts the primary and secondary drying. Generally, the optimization of lyophilization 
focus on decreasing the time of the primary drying that is the longest step. Annealing is 
defined to keep formulations at a subfreezing temperature, above the Tg’ for a period of 
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time, immediately before the primary drying.  This process has a crucial influence on the 
size of ice crystals, which consequently influences the time required for the sublimation 
process, and improves the homogeneity and appearance of the cake [189]. The Figure 
3.10 shows an example of a typical lyophilization cycle containing an annealing step. It 
has been reported that annealing motivates an increase in the size of ice crystals, and 
leads to an accelerated primary drying due to the increased diameter of pores in the plug 
structure that were occupied by ice crystals [190]. Furthermore, annealing decreased 
also the heterogeneity of the drying rate between samples, achieving a more 
homogeneous cake aspect. The annealing process may also avoid the formation of the 
skin layer on the top of the cake, increasing the sublimation rate [7]. This layer may be 
formed by the deposition of nanoparticles or cryoprotectants during the ice 
crystallization, hampering the sublimation of water.  
Annealing was used in the lyophilization of PCL using as cryoprotectants 
poly(vinyl pyrrolidone) (PVP) (Tg’ of −22 °C) and sucrose (Tg’ of −31 °C), and was 
applied at different temperatures for 1 hour (20 °C, −15 °C and −10 °C)  [191]. It was 
noticed that the sublimation rate was accelerated 17% and 30% for PVP and sucrose, 
respectively, without influencing the size of nanocapsules. The proposed explanation 
was due to the increase of the size of ice crystals upon annealing and the decrease of 
mass transfer resistance by the dried layer. The impact of annealing on secondary drying 
was dependent on the used cryoprotectant, since it was observed no effect for PVP and 
a slowdown of the kinetics of secondary drying for sucrose. The use of annealing may 
also influence the long-term stability of nanoparticles. It was found that annealing and 
cryoprotectants may change the glass transition temperature (Tg) of starch nanoparticles 
in about 52-57ºC [192]. However, the residual moisture content was significantly higher 
for annealed formulations, comparatively to those lyophilized without annealing. This 
may be explained by the higher size of ice crystals in the annealed samples, leading to 
more difficult sublimation of water. Besides its benefits, further studies on the application 
of the annealing process on the lyophilization of nanoparticles are needed. 
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Figure 3.10. Example of a lyophilization cycle showing the steps: freezing, annealing, primary 
drying and secondary drying. The brown line represents the shelf temperature, and Tc stands for 
collapse temperature. 
 
2.2.3. Primary drying 
 
During the primary drying step, the water is removed by sublimation from the 
frozen formulation. To achieve this, the temperature of samples is raised under vacuum. 
Then, a porous plug is formed, which correspond to the spaces occupied by ice crystals 
[150]. Generally, the primary drying time depends on the formulation and its depth in the 
vial. The heat comes from the bottom to the top, and the sublimation front occurs from 
the top to the bottom of the vial. To avoid product collapse, the primary drying needs to 
be below the Tc of the product [193]. If product is dried above this critical temperature, it 
loses its macroscopic structure. The Figure 3.11 shows the difference between a 
collapsed and a non-collapsed cake. A collapsed cake shrinks upon lyophilization, 
whereas a non-collapsed cake is characterized by occupying the same volume of the 
initial suspension. 
The natural consequences of product collapse are long reconstitution times and 
high residual moisture content, which may negatively impact the long-term storage of 
nanoparticles. In different types of nanoparticles, it was demonstrated that the 
reconstitution of a collapsed cake was difficult, due to the absence of a porous structure 
[168, 173, 194]. Most of the research works do not assess the Tc of formulations to infer 
the lyophilization cycle, and the processing conditions of chamber pressure and shelf 
temperature are selected empirically. The cake collapse and difficulty of reconstitution 
may even influence the nanoparticles aggregation upon lyophilization. However, 
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cryoprotectants may still avoid nanoparticles aggregation in collapsed caked. It was 
observed no significant changes in the diameter of PCL nanoparticles using glucose, but 
the product collapse obtained an unacceptable aspect of the cake [153]. 
 
 
Figure 3.11. Lyophilized insulin-loaded PLGA nanoparticles. Non-collapsed cake of nanoparticles 
dried below its Tc (left vial); and collapsed cake of nanoparticles dried above its Tc (right vial). 
 
2.2.4. Secondary drying 
 
The secondary drying implicates the elimination of the adsorbed water from the 
product, that did not sublimate upon primary drying because did not previously separate 
as ice during freezing [193]. The secondary drying removes about 5-10% of the total 
moisture, and water desorption is facilitated by increasing the shelf temperature, using 
high-vacuum. However, the temperature of the product during the secondary drying 
needs to be below its Tg, otherwise it may occur product collapse. 
The unfrozen water may be located in the solute phase, both dissolved in an 
amorphous solid or as hydrate water in a crystalline hydrate, or also adsorbed on the 
surface of the crystalline product [195]. It is present in an enough amount to cause the 
rapid degradation of the product. The residual moisture content required for a product 
influences the time needed for the secondary drying, and it is desirable that for 
pharmaceutical products, the residual moisture content should be around 1% [150]. 
Many papers are quite strange, since do not distinguish the secondary drying from the 
primary drying, and do not show any evaluation of the residual moisture content of the 
product. It has been demonstrated that a high residual moisture content may destabilize 
nanoparticles upon storage, due to the crystallization of the containing cryoprotectant 
[140]. Indeed, the crystallization of amorphous sugars may occur by placing the 
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formulation at a temperature above its Tg, being also a time-dependent process. Since 
the residual moisture content may shift the Tg of the formulation to below the 
temperature of storage, it may cause the crystallization of the formulation upon storage. 
In a recent study, the drying time and shelf temperature were optimized, 
considering the residual moisture content of pharmaceutical products, by a new 
simulation program of the secondary drying [196]. Using such program, it was possible to 
predict the secondary drying conditions to obtain the desired residual moisture content, 
without a trial and error approach. 
 
2.3. Storage of nanoparticles 
 
The enhancement of the long-term stability of a product is the main purpose of 
lyophilization. Thus, it is important to assure its physical and chemical stability, and 
prevent degradation reactions such as hydrolysis. Formulations should be stored below 
its Tg, to guarantee the formulation stability [7]. Every year, different polymeric 
nanoparticle systems both in suspension and in the lyophilizate form are developed, 
however their long-term storage stability is often neglected. The long-term stability during 
storage at 25ºC and 60% of relative humidity (RH) during 12 months, or even at 
accelerated conditions at 40 ºC and 75% RH during 6 months, as recommended by the 
International Conference on Harmonization (ICH) guidelines are conditions to assess in 
stability studies [197]. Additionally to these recommendations, other stability storage 
conditions have also been used. During the stability studies, at specified time points, at 
least the drug loading, particle size and zeta potential must be evaluated to assess the 
stability of nanoparticles. Indomethacin-loaded PIBCA nanoparticles were lyophilized 
and their stability was assessed during 12 months upon storage at, -30ºC, 4ºC and room 
temperature [198]. Nanoparticles physical stability was assessed by the drug retained in 
the nanoparticles upon storage; however the particle size was not evaluated. It was 
found that upon storage at 4ºC the loss of drug content was 9.3% after 12 months. 
However, during storage at room temperature the drug loss was 8.5%, 26% and 50.5% 
upon 2, 4, 6 months, respectively.  
Regarding the lyophilizates, other properties such as the cake volume, 
reconstitution time and residual moisture content, should be also monitored during the 
stability study. Previously, doxorubicin-loaded (PEG)3–PLA nanopolymersome 
formulations were lyophilized using different lyoprotectants and stored at 2–8 ºC, 25 
ºC/65% RH and 40 ºC/75% RH [199]. The carriers showed no significant change in 
particle size, polydispersity index (PdI) and zeta potential when stored at 2-8ºC over 12 
months. No modifications were observed in terms of cake volume, reconstitution time 
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and residual moisture content, as well as in the drug content at this storage condition. 
However, when stored at 40 ºC/75% RH it was observed a significant increase in particle 
size, PdI and zeta potential. There is a clear influence of the formulation composition in 
the long-term stability of nanoparticles, since the presence of distinct cryoprotectants in a 
similar formulation may lead to different outcomes in terms of storage stability. 
Previously, it was assessed the storage stability of PLGA nanoparticles lyophilized with 
sucrose, trehalose, and mannitol at 3% (w/v) and stored at 4 ºC, 25 ºC/60% RH, and 40 
ºC/75% RH over 3 months [182]. No significant changes on nanoparticles properties 
were verified, after 3 months of storage at 4ºC in all the formulations. PLGA 
nanoparticles containing trehalose and sucrose at 3% (w/v) were also stable at 25 
ºC/60% RH upon 3 months. In the other storage conditions it was verified considerable 
changes after 3 months of storage in terms of residual moisture content and particle size 
and size distribution, which were dependent on the formulation composition.  
After lyophilization, the lyophilizate may be exposed to air and reabsorb it into the 
product. Thus, an adequate stoppering of the product is crucial, since both water and air 
may cause damages to the lyophilizate, leading to poor product stability. It is advisable 
that the stoppering of the products should be performed inside the lyophilizer chamber. 
Stoppering the product under vacuum may be also a good choice to assure product 
stability. Indeed, a high residual moisture content originated by a poor secondary drying 
or by a bad stoppering of the product, may originate the cryoprotectant crystallization, 
leading to nanoparticles destabilization [140]. Other technological methods may be used 
to estimate the shelf-life of a product. Shelf life computations revealed a shelf-life time of 
at least 18 months at -20ºC of lyophilized HI-6-loaded albumin nanoparticles containing 
trehalose 3% (w/v), with no significant degradation of the containing drug [200]. 
 
3. The lyophilization equipment 
 
The three parameters to be controlled during lyophilization are shelf temperature, 
chamber pressure and time. Thus, the lyophilizer needs to be properly designed to 
manage these processing conditions, and obtain a good lyophilizate. The lyophilization 
equipment must hold a differential pressure from vacuum to atmosphere, to operate in a 
low-pressure atmosphere, facilitating the water sublimation. This ability is important to 
obtain vacuum, however the driving force of water removal is influenced by the 
condenser. The condenser may be located inside the drying chamber, or be positioned 
in a separated place between the sample chamber and the vacuum pump. The diagram 
of a typical lyophilizer is shown in Figure 3.12. 
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Figure 3.12. Diagram of a tray style lyophilizer. Adapted from [201]. 
 
A lyophilizer is constituted by a vacuum chamber, in which vials of products are 
placed on shelves that supply cooling and heating, through a thermal fluid [163]. To the 
vacuum chamber is also associated a refrigeration unit and a vacuum pump. After 
product freezing, the chamber is evacuated by the vacuum pump, and the product 
heating and drying begins. The chamber of the lyophilizer is made of stainless steel, to 
allow an easy cleaning and thermal conductivity [180]. The door of the chamber may be 
also made of stainless steel or a clear acrylic material, with an elastomer seal to facilitate 
vacuum inside the chamber. The shelves may supply or remove thermal energy to the 
product in function of the lyophilization step. They may be also organized to serve as 
stoppering platforms, to facilitate the stoppering of vials inside the chamber avoiding the 
exposition of the product to the atmospheric air [180]. As mentioned above, it is the 
condenser, which is usually refrigerated by direct expansion of a refrigerant, that 
produces the driving force to remove water from products [180]. During the primary 
drying, the temperature of the condenser needs to be usually at least 20ºC lower than 
the temperature of the product. Therefore, it is the vacuum pump and the condenser that 
provide the conditions to the removal of water during the product drying.  
The control system manages all processing conditions and may be fully 
automatic. More recent lyophilizers may be connected to a computer, in which all the 
processing conditions are managed and recorded in real-time. This ability also allows 
defining different lyophilization cycles, suitable to lyophilize different products.  The 
temperature of the products may be also monitored real-time, by 100-ohm platinum 
resistance temperature detectors or T-type copper-constantan thermocouples. 
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4. Characterization of the lyophilized product 
 
To validate an acceptable lyophilization process, it is crucial to characterize both 
the lyophilizate and the containing nanoparticles upon lyophilization and reconstitution. In 
this section, several essential characterization methods will be described. 
 
4.1. Macroscopic aspect and reconstitution time of the lyophilizate 
 
The macroscopic appearance of the cake and the occupied volume are important 
features to assess, and infer a good lyophilization cycle. After lyophilization, the cake 
should occupy the same volume as the original frozen mass. Otherwise, cake shrinkage 
or collapse may be observed with prejudicial consequences to product appearance and 
reconstitution time. The shape, texture and colour modifications of the cake may also 
indicate detrimental changes in the physical-chemical properties of nanoparticles. 
The lyophilizate should be reconstituted in the same volume as the nanoparticle 
suspension prior to lyophilization, and the time needed to achieve complete 
reconstitution may be recorded. A good lyophilizate should rehydrates immediately, 
however in some cases such as cake collapse, the reconstitution time can be long. The 
complete reconstitution of nanoparticles may be performed immediately by water 
addition, or by swirling, shaking, vortexing or even sonication. The presence of 
excipients in formulation may be also important in the nanoparticles resuspension. It was 
previously demonstrated that cryo- and lyoprotectants facilitated the reconstitution of 
lyophilized PLA nanoparticles [139]. In another study, it was assessed the influence of 
different cryoprotectants on the reconstitution of surfactant-free PLGA nanoparticles 
[178]. No significant change of particle size and a complete reconstitution were verified 
when trehalose, sucrose and lactose at 2% (w/v) were used, however no satisfactory 
reconstitution was observed when mannitol 1% (w/v) was used. 
 
4.2. Microscopic observation of the lyophilizate 
 
The microscopic visualization may assess both the microstructure of the 
lyophilizate, and the maintenance of nanoparticles morphology and stability upon 
lyophilization. The nanoparticles may be visualized by TEM, scanning electron 
microscopy (SEM), cryogenic TEM, cryogenic SEM, environmental SEM (ESEM) and 
atomic force microscopy (AFM). The Figure 3.13 shows the SEM microphotographs of a 
lyophilizate, and insulin-loaded PLGA nanoparticles after reconstitution. Through such 
Chapter 3 I Facts and Evidences on the Lyophilization of Polymeric Nanoparticles 
  
 
 
59 
 
microscopic techniques, it is possible the visualization of both the morphology and pore 
network of the lyophilizate, and the shape and size of nanoparticles. 
The amorphous matrix of the cryoprotectant PVP, could be visualized by TEM in 
the outer surface of PCL nanoparticles after reconstitution [191]. Silica nanoparticles 
lyophilized using trehalose at 5% as cryoprotectant were observed by AFM, and it was 
found that trehalose formed a matrix embedding the nanoparticles [168]. In another 
study, lyophilized PCL nanoparticles stabilized by HPβCD were also visualized after 
reconstitution by SEM and ESEM [140]. An amorphous continuous matrix embedding the 
nanoparticles was also observed. ESEM demonstrated that PCL nanoparticles 
maintained their spherical monodisperse shape upon lyophilization. These results 
showed that the observation of nanoparticles by AFM and SEM is difficult, when the 
concentration of cryo- or lyoprotectant is higher than 5%. On its turn, TEM facilitates the 
observation of lyophilized nanoparticles after samples dilution. 
The ESEM technique allows managing the sample dehydration, by reduction of 
temperature and pressure in the sample chamber. Nanoparticles may be observed in a 
hydrated form without a complete drying, preventing the observation of individual 
nanoparticles. Furthermore, it is not required a sample preparation prior microscopic 
visualization. Overall, the ESEM is the best technique to observe lyophilized 
nanoparticles in a hydrated form, and present an advantage over SEM, since do not 
requires any conductive coating of hydrated samples. 
 
 
Figure 3.13. SEM microphotograph of the lyophilizate of insulin-loaded PLGA nanoparticles, 
containing sucrose 10% (w/v) (left microphotograph); and SEM microphotograph of insulin-loaded 
PLGA nanoparticles after reconstitution (right microphotograph). 
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4.3. Analysis of powder surface 
 
The elemental composition of the lyophilizate of nanoparticles may be assessed 
by electron spectroscopy for chemical analysis (ESCA). Such technique is based on the 
emission of electrons from materials, at a characteristic energy of atoms. It has been 
used to assess the surface of ice crystals during lyophilization [202], and the modification 
of nanoparticles surface [203]. The adsorption of proteins into an ice/liquid interface 
during freezing may lead to the loss of its native structure, resulting in its surface induced 
denaturation [204]. The surface tension of protein solutions in such interface may be 
decreased by surfactants, and this ability may be evaluated by ESCA. This kind of 
analysis may be also applied to nanoparticle formulations. ESCA assessments revealed 
the presence of PCL nanoparticles, at the powder surface of lyophilized formulation, 
containing a matrix of PVP and sucrose as cryoprotectants [140]. Thus, ESCA may be 
used to locate the presence of nanoparticles, ligands or even drugs in a lyophilizate. 
 
4.4. Thermal analysis and lyophilization microscopy 
 
The thermal analysis may be performed by differential scanning calorimetry 
(DSC). The critical temperatures of a formulation, such as Tg’ and Tg may be assessed 
by this technique, and then used to infer an adequate lyophilization cycle. As mentioned 
above, to guarantee a good quality of the lyophilizate and long-term storage stability, a 
nanoparticle formulation should be frozen below its Tg’, and both the secondary drying 
and storage should occur below its Tg. Furthermore, DSC allows evaluating the 
interaction between the nanoparticles and cryoprotectants. 
Besides being an analysis performed prior to nanoparticles lyophilization, the 
lyophilization microscopy is an important technique to guarantee the achievement of a 
product with good quality. Such technique allows the assessment of the Tc or Teu, for 
amorphous or crystalline formulations, respectively, which are crucial to define the 
temperature at which the primary drying should occur. The lyophilization microscopy 
allows the study of the lyophilization process in real-time, and the observation of the 
sublimation front. Thus, it is possible to determine the exact temperature at which the 
formulation starts to lose its structure and collapses. 
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4.5. Determination of residual moisture content 
 
The residual moisture content of a lyophilizate is mainly caused by an inefficient 
secondary drying, with a poor desorption of water from the product.  This may drastically 
influence the structure and the thermal properties of lyophilized nanoparticles. High 
residual moisture content may lead to an unexpected dissolution of the lyophilizate 
immediately after lyophilization, and to a poor long-term storage stability of 
nanoparticles. Several analytical methods such as a gravimetric technique, thermal 
gravimetric analysis or Karl Fischer titration, may be used to quantify the residual 
moisture content of the lyophilizate. For pharmaceutical products, the residual moisture 
content should be around 1% [150]. 
 
4.6. Particle size and zeta potential of nanoparticles, and drug content upon 
lyophilization 
 
The particle size after reconstitution may be assessed by photon correlation 
spectroscopy or other technique. The maintenance of the diameter of nanoparticles after 
lyophilization is a good indicator of a good lyophilization process. The ratio of 
nanoparticles size between that after and before lyophilization should be evaluated. A 
ratio around 1 indicates the maintenance of nanoparticles physical stability, whereas a 
ratio different from 1 may indicate aggregation or degradation of nanoparticles. 
Simultaneously, the PdI may be also evaluated upon lyophilization and compared with 
that obtained before lyophilization. 
The evaluation of the zeta potential may be performed by phase analysis light 
scattering, and is useful to assess if any modification of nanoparticles surface occurred 
during lyophilization. It may be also used to assess the interaction between nanoparticles 
and the excipients present in formulation. It was reported that after addition of sucrose 
10% (w/v), the zeta potential of PCL nanoparticles modified from −40.9 mV to −20.4 mV 
[161]. This could be explained by the hydrogen bonding between sucrose and 
nanoparticle surface that masks the nanoparticles surface. After lyophilization, the 
decrease in the negative charge was accentuated, due to a rearrangement of the 
surfactant at nanoparticles surface. 
The drug content of nanoparticles may be determined by a high performance 
liquid chromatography (HPLC), ultraviolet-visible (UV/Vis) spectroscopy or other 
quantification method. It is important to evaluate if occurs any leakage of the drug upon 
lyophilization. An adequate lyophilization process, that do no damages the nanoparticles 
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integrity, allows the retention of the drug entrapped into nanoparticles, which is crucial to 
the desired therapeutic effect. 
 
5. Lyophilization of protein-loaded nanoparticles 
 
Through the developments of the biotechnology field in the last decades, peptide 
and protein drugs have been developed with the aim of improving the patients quality of 
life [205]. They have been used to treat severe health problems, such as genetic and 
enzymatic disorders, autoimmune diseases and infections or even cancer [206]. 
Therapeutic proteins are mainly delivered in an invasive way, such as through 
subcutaneous injection, with a repeated administration to obtain therapeutic levels, 
mainly due to its rapid degradation and elimination [207]. Furthermore, the low 
permeation through biological barriers, such as the intestinal epithelium, turns their 
administration to be limited to the parenteral route. The encapsulation of therapeutic 
proteins into polymeric nanoparticles is a good strategy to avoid all these issues, since 
the polymeric matrices may protect proteins from in vivo hydrolytic and enzymatic 
degradation, preserving their structural stability and bioactivity, and consequently 
improve their in vivo half-life and bioavailability [2]. The ability of nanoparticles to 
enhance the permeability of proteins through epithelial barriers is important to improve 
their bioavailability [3]. Additionally, nanoparticles may be useful to deliver proteins in a 
sustained manner, reducing the required number of administration, and to target protein 
delivery to specific organs or tissues [208]. 
The lyophilization of therapeutic proteins is commonly used to improve their long-
term stability. Similar stresses suffered by nanoparticles during lyophilization, are also 
suffered by proteins, which may lead to their instability and loss of bioactivity [7].  The 
influence of lyophilization on the stability of proteins have been investigated, and it has 
been described that protein denaturation and aggregation may occur both during the 
freezing or drying steps [209, 210]. Distinct findings have been reported, showing that 
the stresses suffered have a great dependence both on the protein type and on the 
lyophilization process. For instance, it was previously described that the ice formation 
was the critical process that influenced the stability of lactate dehydrogenase (LDH) 
[211]. It was also reported that proteins can be lyophilized above Tg’ without vitrification, 
mainly because the protein unfolding occurs slowly during lyophilization, since this 
process is directly related with the system viscosity [212]. However, in another study, it 
was compared the effect of the primary drying and secondary drying stresses, and it was 
observed that the latter was the one that critically influenced the LDH stability [213]. A 
complementary study revealed that the stability of LDH was significantly influenced by 
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the duration and temperature of the secondary drying [214]. The vitrification and direct 
interaction of excipient was found to be essential on protein stabilization. Several 
excipients such as sugars and surfactants may be used to improve the stability of 
proteins [215]. It may be inferred that proteins loaded into nanoparticles are subjected to 
similar stresses suffered by protein formulations upon lyophilization. In addition, it is 
expected that both the nanoparticles and used excipients may be useful in the 
preservation of the structural stability of the loaded protein. Studies on lyophilization of 
protein-loaded nanoparticles have been focused more on the carrier stability, rather than 
in the stability of the loaded protein [216-218]. The therapeutic activity of proteins is 
directly related with their conformational structure and integrity, so this characterization is 
important to assess the influence of lyophilization in the stability of proteins loaded into 
polymeric nanoparticles. An important problem in the analysis of protein loaded into 
nanoparticles upon lyophilization is that many analytical techniques require the extraction 
of protein from nanoparticles [219]. However, there are other techniques that allow a 
non-invasive analysis of proteins in solid state, such as FTIR, ESCA, dielectric 
spectroscopy and solid-state nuclear magnetic resonance (NMR). The extraction method 
may originate artifacts, prejudicial to the protein characterization [220-222]. For example, 
the protein quantification may be difficult since it may occur a preferential extraction of 
protein molecules that are easier to diffuse out of nanoparticles. Furthermore, the 
aggregation extension may be over- or underestimated when the extraction method lead 
to aggregates formation or aggregates dissolution, respectively. The extraction media 
itself may induce irreversible conformational modifications, which is a problem when it is 
required the study of the conformation and bioactivity of the loaded protein. 
Most of the works on the lyophilization of protein-loaded nanoparticles focus more 
on the analysis of the bioactivity of proteins, rather than the characterization of their 
conformation. Previously, it was demonstrated that the combination of lyophilization and 
a cross linking treatment was important to stabilize, and increase the bioefficiency of 
insulin-loaded chitosan nanoparticles [223]. In another work, it was evaluated the ability 
of amino functionalized mesoporous silica nanoparticles to stabilize ovalbumin, a model 
antigen, at room temperature [224]. The protein was adsorbed to nanoparticles and 
lyophilized using trehalose 5% (w/v) and PEG8000 1% (w/v). Ovalbumin has a shelf-
storage stability at room temperature of just 16 hours, and using the proposed approach 
it was observed maintenance of the immunological activity of ovalbumin and the 
structure of nanoparticles after 2 months of storage.  After reconstitution, nanoparticles 
were administered to mice and they induced humoral and cell-mediated immune 
responses, demonstrating the bioactivity of ovalbumin. 
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Besides there are just a few works that evaluate the structural stability of proteins 
loaded into nanoparticles upon lyophilization, this characterization is crucial to better 
predict and understand both the activity of proteins and potential detrimental side effects 
after administration. CD assessments demonstrated that the secondary structure of 
bovine serum albumin (BSA) was preserved upon in vitro release from lyophilized 
poly(lactic-co-glycolic-co-hydroxymethylglycolic acid) nanoparticles [225]. Using the 
same technique, it was demonstrated that the structure of insulin present in a 
polyelectrolyte complex nanoparticles of amino poly(glycerol methacrylate)s, was 
preserved after lyophilization [226]. Insulin has been used as a model of therapeutic 
protein, in the study of structural stability of proteins loaded into polymeric nanoparticles 
upon lyophilization [175, 227]. It was evaluated the influence of lyophilization using 
cryoprotectants, on the structure of insulin loaded into PLGA nanoparticles upon 6 
months of storage [175]. FTIR assessments demonstrated that insulin structure was 
preserved in about 88% after encapsulation, decreasing to 71% upon lyophilization. The 
cryoprotectants used were trehalose, glucose, sucrose, fructose and sorbitol at 10% 
(w/v), and they presented different performances on the stabilization of the loaded 
protein. Interestingly, the formulations collapsed upon lyophilization, revealed better 
protein stabilization during storage. Lyophilized nanoparticle formulation containing 
sorbitol, demonstrated the most similar structural changes of insulin within the storage 
conditions, achieving an insulin structural preservation of about 76, 80, and 78% after 
stability at 4 °C, 25 °C/60% RH, and 40 °C/75% RH, respectively. In another study from 
the same authors, an interesting approach was developed by co-encapsulating 
lyoprotectants into PLGA nanoparticles together with insulin [227]. FTIR and CD 
evaluations revealed that the co-encapsulating lyoprotectants better preserved the 
structure of insulin after lyophilization in about 82-87%, comparatively to just 72% in 
absence of lyoprotectant. 
 
6. Conclusion 
 
The lyophilization process is fundamental in the improvement of the long-term 
stability of nanoparticles. The lyophilization of nanoparticles has been mostly based on 
empiric principles and trial and error approaches, without considering the main principles 
involved. Therefore, prior lyophilization, the nanoparticle formulation should be physical-
chemically characterized and the processing parameters of lyophilization need to be 
optimized regarding the formulation characteristics. The use of excipients, such as cryo- 
and lyoprotectants with the purpose of nanoparticles stabilization should also be carefully 
thought, since there is no straightforward relationship between their use and the 
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stabilization of nanoparticles. The storage conditions are also important, on the long-term 
stability of the lyophilized nanoparticles. The needed processing conditions of the 
lyophilization process, should also be inferred considering the architecture of the 
lyophilizer. The proper characterization of both the lyophilizates and nanoparticles upon 
lyophilization is fundamental to achieve a good lyophilized product, and also to 
guarantee the preservation of nanoparticles stability. Regarding the lyophilization of 
protein-loaded polymeric nanoparticles, together with the analysis of the stability of the 
carrier, it is also crucial to assess the conformation and the maintenance of protein 
structure upon lyophilization. 
This chapter may contribute to highlight all the parameters involved in the 
lyophilization of polymeric nanoparticles, in order to obtain a good lyophilizate and 
nanoparticles with long-term stability. Thus, hereafter empirical approaches on 
lyophilization of nanoparticles should be abandoned, and the focus should go on 
optimizing the lyophilization process to meet the specificity of the physical-chemical 
properties of nanoparticles. Furthermore, it is important to bring the recent developments 
on the lyophilization technology into the nanoparticles lyophilization. Such developments 
allow a more precise control and management of lyophilization processing conditions in 
real-time. In addition, the application of quality by design (QbD) and process analytical 
technology (PAT) approaches need to be more deeply applied in the nanoparticles 
lyophilization. Finally, another important concern that is one of the major challenges to 
focus in the future is the scaling up of the lyophilization of nanoparticles, assuring their 
stability, allowing polymer-based nanoparticle products to reach the market.……………. 
….……………. 
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1. Introduction 
 
The delivery of therapeutic proteins may occur under stress conditions, leading to 
their aggregation or denaturation with unpredictable side effects, such as toxicity or 
immunogenicity [228]. To mitigate these problems, proteins are often encapsulated into 
nanoparticles. These carriers are submicron sized colloidal systems prepared from 
natural or synthetic polymers, suitable to deliver both small and macro- molecules on a 
targeted or localized manner. They are able to further protect proteins from a harsh 
environment, as observed for instance in the gastrointestinal tract due to pH and 
proteolytic action of enzymes, and deliver it on a sustained manner avoiding repeated 
dose administration. PLGA is one of the most used synthetic polymers on nanoparticles 
production, mainly because of its good sustained release properties, biodegradability, 
biocompatibility, variable mechanical properties and nontoxic properties [147]. A minimal 
systemic toxicity is observed on the use of this polymer for drug delivery and biomaterial 
applications [229]. 
As delivery systems the most important characteristics of nanoparticles are the 
size, AE and release profile. Their shape and surface charge are also important features 
to control. Since nanoparticles are produced to be administered to the human body and 
interact with cells, it is imperative to produce them with a proper size, shape and surface 
charge, otherwise severe toxicity problems may occur. From an industrial and economic 
perspective, the AE is crucial especially in the case of proteins which are expensive 
products. Different techniques of production may be employed to control all these 
features, and for hydrophilic molecules such as proteins, the double emulsion solvent 
evaporation technique is one of the most used methods. This technique may be 
responsible for the formation of pores on the nanoparticles surface due to the 
evaporation of the solvent. These pores may play a role on protein release rate and on 
its stability, they may form open pathways for protein denaturation by external factors. 
The use of nanoparticles formulation has some limitations mainly due to problems 
related with the integrity of the liquid suspension [167]. To avoid some stability problems, 
surfactants are usually included in formulation to stabilize the suspension by its direct 
adsorption to nanoparticles surface. However, some aggregation may still be observed 
during storage [157, 162].  In addition, the chemical stability of the polymeric matrix of 
nanoparticles [6], and the protein must be taken into account in order to avoid the 
formation of undesired degradation products and premature release of protein. 
Lyophilization is regarded as one of the most useful methods to stabilize and 
handle colloidal systems. Otherwise, nanoparticles formulation may suffer detrimental 
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changes during storage. Proteins instability in aqueous systems is also overcome  by 
removing water by lyophilization [204]. Various stability problems affecting nanoparticles 
have been reported [168]. Regarding PLGA-based nanoparticles, the principal concern is 
the hydrolytic instability of the polymer in aqueous suspension. Hence, lyophilization is 
an important method to stabilize PLGA nanoparticles, by avoiding hydrolytic degradation 
in aqueous suspensions [182].  
As discussed above, the control of nanoparticles characteristics is crucial, so it is 
necessary to improve its stability during storage to assure that the characteristics are 
maintained during shelf-life. The lyophilization process may also result in changes of 
nanoparticles physical properties, affecting particle size and release characteristics, with 
consequent effect on the encapsulated protein release and stability. Therefore, different 
excipients like trehalose, sucrose, fructose, glucose and sorbitol may be used as 
cryoprotectant agents to increase nanoparticles physical stability during lyophilization, 
preventing their aggregation and protecting them against the mechanical stress of ice 
crystals. These sugars used as cryoprotectants are important, because they  affect the 
glass transition temperature (Tg’ and Tg), which is important to obtain a lyophilized cake 
with a stable amorphous form, a high redispersion speed, an appropriate residual 
moisture content, and a good protein protection and stabilization upon storage [8, 230]. 
How the different cryoprotectants may influence the porosity of nanoparticles, and 
therefore the protein release and stability is barely known.  
The main objective of this chapter was to develop and optimize a formulation of 
insulin-loaded PLGA nanoparticles with good physical-chemical properties and assess 
how lyophilization using a standard cycle and different cryoprotectants may influence the 
stability and porosity of nanoparticles, which is an important feature on PLGA 
nanoparticles release properties, constituting also a pathway for protein instability. 
 
2. Materials and Methods 
 
2.1. Materials 
 
For the production of nanoparticles, it were used PLGA 50:50 (Evonik Industries 
AG, Resomer® RG 503 H), PLGA 75:25 (Purac Biomaterials, Purasorb® PDLG 7502), 
PVA (Sigma-Aldrich, P1763), Pluronic® F-127 (Sigma-Aldrich, P2443), Tween® 80 
(Merck, 822187), dichloromethane (Sigma-Aldrich, 32222) and recombinant human 
insulin  (Sigma-Aldrich, 91077C). The cryoprotectants used were trehalose (Sigma-
Aldrich, 90210), sucrose (Sigma-Aldrich, 84100), fructose (Sigma-Aldrich, 47740), 
glucose (Sigma-Aldrich, 49152) and sorbitol (Sigma-Aldrich, 97336). Acetonitrile HPLC 
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Gradient Grade (Fischer Scientific, A/0627/17) and trifluoroacetic acid (Acros Organics, 
139721000) were used in the HPLC measurements and PBS (Sigma-Aldrich, P4417) 
was used in the in vitro release study. Milli-Q water was produced in-house. 
 
2.2. Preparation of PLGA nanoparticles 
 
Different formulations of nanoparticles were prepared with PLGA 50:50 and 
PLGA 75:25. Using each polymer to produce the nanoparticles, it was used different 
surfactants at two different concentrations, namely PVA, Pluronic and Tween at 1% and 
2% (w/v). The method for the nanoparticles preparation was a modified solvent 
emulsification-evaporation method, based on a w/o/w double emulsion technique [231, 
232]. Briefly, 200 mg of polymer was dissolved in 2 ml of dichloromethane. Then, 0.2 mL 
of a 20 mg/mL insulin solution in HCl 0.1 M was added to the polymeric solution, and 
homogenized using a  Bioblock vibracell 75186 sonicator (Fischer Bioblock Scientific, 
Illkirch, France), during 30 seconds with 70% of amplitude. This primary emulsion was 
poured into 25 mL of each PVA, Pluronic or Tween solution at the two different 
concentrations and then homogenized for 30 seconds using the same equipment. The 
organic solvent was then removed by evaporation, during 3 hours under magnetic 
stirring. The nanoparticles were purified three times by centrifugation using a Heraeus 
Megafuge 1.0 R centrifuge (Thermo Scientific, Asheville, NC, USA) at 4300 rpm for 50 
minutes, and redispersed in water before storage at 4ºC for further analysis. 
After optimization of the formulation, the optimal formulation was produced by the 
same methodology using PLGA 50:50 and PVA 2% as a surfactant and 0.2 mL of a 150 
mg/mL insulin solution in HCl 0.1 M. The produced nanoparticles were then purified 
three times by centrifugation at 4300 rpm for 50 minutes at 4ºC, and redispersed in water 
prior to lyophilization and storage. 
 
2.3. Lyophilization of nanoparticles 
 
The cryoprotectants used were trehalose, sucrose, fructose, glucose and sorbitol 
at a concentration of 10% (w/v). A control group of nanoparticles lyophilized with no 
cryoprotectant was also included in the study, and all this different cryoprotectant 
conditions were performed in triplicate. Samples were poured into semi-stoppered glass 
vials with slotted rubber closures and frozen at -80°C for 2h and then dried in a Modulyo 
4K lyophilizer (Edwards, Crawley, West Sussex, UK) at 0.09 mbar for 72h, being 
maintained at the condenser surface temperature of -60ºC. 
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2.4. Lyophilized samples reconstitution 
 
The lyophilizates were reconstituted by slowly adding distilled water in the inside 
wall of the vial, and then maintained during 10 minutes to ensure the proper cake 
wetting. After such period of time, samples were gently shaken in a Vortex Mixer ZX 
Classic (Velp Scientifica, Usmate, Italy) for 3 minutes to complete homogenization. After 
reconstitution, samples were physical-chemically characterized. 
 
2.5. Particle size and zeta potential analyses 
 
Samples were diluted with Milli-Q water to a suitable concentration for both 
particle size and zeta potential analyses. Particle size was analysed by dynamic light 
scattering using a 90Plus Particle Size Analyzer (Brookhaven Instruments Corporation, 
NY, USA). The zeta potential was determined by phase analysis light scattering using a 
ZetaPALS Zeta Potential Analyzer (Brookhaven Instruments Corporation, NY, USA). All 
measurements were performed in triplicate. 
 
2.6. Insulin association efficiency 
 
The AE was determined indirectly. The amount of insulin entrapped into the 
PLGA nanoparticles was calculated by the difference between the total amount used to 
prepare the nanoparticles, and the amount of insulin that remained in the supernatant 
after nanoparticles isolation by centrifugation in a Beckman Optima TL ultracentrifuge 
(Beckman Coulter, Brea, CA, USA) at 20,000 rpm for 15 min at 4ºC. The equation below 
summarizes this concept: 
 
𝐴𝐸 =
Total amount of insulin −  Free insulin in supernatant
Total amount of insulin
 x 100 
                 
The insulin concentration was determined by a HPLC-UV method previously 
developed and validated by our group [233]. Thus, the measurements were performed 
on a Merck-Hitachi LaChrom HPLC instrument (Merck, Whitehouse Station, NJ, USA) 
equipped with a XTerra RP 18 column, 5 μm particle size, 4.6 mm internal diameter × 
250 mm length (Waters, Milford, MA, USA) and a LiChrospher 100 RP-18, 5 μm particle 
size guard column (Merck, Darmstadt, Germany). All measurements were performed in 
triplicate. 
(Eq. 4.1) 
 
Chapter 4 I Optimization of Insulin-loaded PLGA Nanoparticles and Effect of Cryotectants on their 
Porosity and Stability upon Lyophilization 
  
72 
 
 
2.7. Transmission electron microscopy analysis 
 
Nanoparticles were observed by TEM, in order to characterize its morphology. 
Samples were placed on a grid, treated with uranil acetate and then observed in a JEOL 
JEM-1400 Electron Microscope (JEOL Ltd.,Tokyo, Japan). 
 
2.8. Scanning electron microscopy analysis 
 
The surface morphology of nanoparticles was observed by SEM on a FEI Quanta 
400 FEG SEM (FEI, Hillsboro, OR, USA). Nanoparticles  were resuspended and purified 
three times with distilled water by centrifugation in a Beckman Optima TL ultracentrifuge 
(Beckman Coulter, Brea, CA, USA) at 20,000 rpm for 15 min at 4ºC, to remove the 
dissolved cryoprotectant. Then, samples were mounted onto metal stubs and vacuum-
coated with a layer of gold/palladium before observation. 
 
2.9. Insulin in vitro release study 
 
Insulin-loaded PLGA nanoparticles were dispersed in 20.0 mL of pH 7.4 PBS 
solution and incubated at 37°C under magnetic stirring at 100 rpm. Aliquots were taken 
at predetermined time intervals of 0.5, 1, 2, 4, 8, 24 and 48 hours and replaced with fresh 
medium kept at the same temperature. The collected samples were centrifuged, and the 
content of insulin in the supernatant was determined by HPLC. All samples were run in 
triplicate. 
 
2.10. Statistical analysis 
 
The statistical analysis was done using the GraphPad Prism Software vs. 5.0 
(GraphPad Software Inc., La Jolla, CA, USA), and differences between the formulations 
were compared within a Tukey post hoc test, and considered to be significant at a level 
of p < 0.05. 
 
3. Results and discussion 
 
3.1. Optimization of PLGA nanoparticles formulation 
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Two different ratios of PLGA, 50:50 and 75:25, were used to produce the insulin-
loaded PLGA nanoparticles. Dichloromethane was used to dissolve PLGA in each 
formulation, and as it is removable after nanoparticles preparation, its possible toxicity is 
avoided. It was also used three different surfactants, namely PVA, Pluronic and Tween 
at two different concentrations, 1% and 2%, to increase nanoparticles stability. Thus, 
these preliminary studies aimed to produce nanoparticles both with the lower obtainable 
mean particle size and higher AE. Furthermore, the surface charge of nanoparticles must 
be negatively charged due to its polymeric matrix. These results are shown in Table 4.1. 
The optimization was performed to obtain the formulation with the best physical-chemical 
properties to be used on further experiments. 
 
Table 4.1. Physical-chemical properties of insulin-loaded PLGA nanoparticles (n = 3, mean ± SD). 
If the formulations were significantly different between them (a ≠ b; c ≠ d; e ≠ f, p < 0,05). 
 
Insulin-loaded PLGA nanoparticles were produced to take advantage of the better 
sustained release properties and protection of the encapsulated protein. A clear 
advantage of the used encapsulation technique, is the avoidance of thermal or pressure 
stresses that can damage the protein structure. This technique also allows to produce 
other kind of nanoparticles such as lipid-based nanoparticles [234]. The preliminary 
study (Table 4.1) showed that both PLGA ratios were able to produce nanoparticles, with 
the exception of PLGA 75:25 when combined with PVA. Thus, it may be concluded that 
with the used methodology, such combination was not able to produce stable 
nanoparticles. 
The results of mean particle size showed that generally, the higher 
concentrations of surfactant resulted in a reduction of the particle size, however with just 
Polymer Surfactant 
Particle Size 
(nm) 
PdI 
Zeta Potential 
(mV) 
Insulin 
AE (%) 
 
PLGA 
50:50 
 
PVA 1% 
 
437 ± 4b 
 
0.37 ± 0.03 
 
10.1 ± 2.4b,c 
 
61.1 ± 11.4a 
PVA 2% 256 ± 17c 0.20 ± 0.07 -13.2 ± 1.8d 78.9 ± 4.1c 
Pluronic 1% 1289 ± 232a 0.57 ± 0.06 10.8 ± 2.9b,e 21.7 ± 15.9b 
Pluronic 2% 426 ± 13b 0.22 ± 0.04 -9.6 ± 3.4f 31.4 ± 7.8d 
Tween 1% 455 ± 23b 0.21 ± 0.05 -8.3 ± 0.5a 0 
Tween 2% 565 ± 34d 0.35 ± 0.01 -8.3 ± 1.8 0 
PLGA 
75:25 
Pluronic 1% 419 ± 28b 0.31± 0.05 -12.3 ± 1.5a,e 12.9 ± 7.1 
Pluronic 2% 357 ± 22b 0.21± 0.03 13.4 ± 2.3c,f 8.7 ± 5.4 
Tween 1% 374 ± 61b 0.25 ± 0.15 14.7 ± 1.6b 6.6 ± 2.3 
Tween 2% 121 ± 12a 0.49 ± 0.04 -9.4 ± 2.3b,d 7.2 ± 1.1 
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a significant difference (p < 0.05) for PLGA 50:50/Pluronic formulations. This occurs 
mainly because the surfactant is able to reduce the surface tension, and promote the 
particle division during homogenization. The decrease in particle size highly increases 
the surface area, stabilizing the nanoparticles, however, when higher concentrations of 
surfactants are used, the risk of toxic side effects increases [235]. This problem was 
mitigated by removing the surfactant after nanoparticles production. Overall, it was also 
verified that when the surfactant concentration increased the PdI decreased, except for 
formulations in which Tween was used. This may be also explained by the higher 
stabilization of higher concentrations of surfactants, during nanoparticles production. 
The surface charge is an important feature, since nanoparticles are intended to 
interact with cells, the charge may play an important role on such interaction. The PLGA 
nanoparticles have negative surface charge due to its polymeric matrix [208]. This 
negative surface charge was observed in the majority of the formulations, thus being an 
indicator of a good nanoparticles production. In other formulations, the surface charge 
was positive which may be explained by an ineffective nanoparticles formation. It is also 
shown in Table 4.1, that for the PLGA 50:50/PVA, PLGA 50:50/Pluronic, and PLGA 
75:25/Tween formulations, at a surfactant concentration of 1% the surface charges of 
nanoparticles were positive and at 2% the surface charges were negative. This is 
because for those formulations, the higher concentration of surfactant better stabilized 
the nanoparticles, thus achieving the expected negative values characteristic of the 
polymeric matrix. Therefore, at a higher concentration of surfactants, the emulsification 
may have occurred more effectively and faster, forming a good emulsion and 
nanoparticles. When a lower concentration of surfactant was used, the emulsification 
process was not so effective and the surfactant remained attached to the polymer, 
becoming the surface charge of nanoparticles positively charged. 
From an industrial point of view, the AE is a crucial feature, since most of the 
therapeutic proteins encapsulated into nanoparticles are quite expensive. It was 
observed that nanoparticles produced with PLGA 75:25 obtained nanoparticles in a 
range of 100-450 nm but with low values of AE. Thus, the higher proportion of lactic acid 
of the polymer may hinder the ability of nanoparticles to encapsulate proteins. Essentially 
considering this result, the formulations containing PLGA 75:25, were not considered for 
further experiments. On one hand, formulations using PLGA 50:50/PVA, obtained 
significantly higher (p < 0.05) AE values for both surfactant concentrations, being even 
higher for the higher surfactant concentration. On the other hand, formulations using 
PLGA 50:50/Tween obtained 0% of AE for both surfactant concentrations, probably 
because the surfactant did not promote the emulsification properly, and therefore insulin 
was not encapsulated. This may be due to a possible interaction between the surfactant 
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and the polymer itself leading to an extrusion of insulin from the inner core of the forming 
particle. This may be also the explanation why it was achieved such a low AE when 
Tween 1% and 2% were used to produce PLGA 75:25 nanoparticles. 
Regarding all the results, it was selected just one formulation of PLGA 50:50 
nanoparticles for further experiments because the AE obtained for PLGA 75:25 
nanoparticles, even using different surfactants, was not satisfactory. Thus, the 
formulation produced using PLGA 50:50/PVA 2% was selected for further experiments 
regarding its lower mean particle size, higher AE and the negatively charged surface. 
The mean particle size of these nanoparticles was around 250 nm and the AE was about 
80%, which was a good achievement. In fact, the AE of hydrophilic molecules is 
improved by the double-emulsion technique, allowing the encapsulation of therapeutic 
proteins [235]. PVA is able to produce stable nanoparticles with a small size and a 
narrow PdI [151, 152]. It was also reported, that a fraction of PVA remains associated 
with the surface of nanoparticles even after nanoparticles washing. Thus, the presence 
of the PVA layer on nanoparticles surface may improve also their freezing resistance, 
which stabilizes nanoparticles during lyophilization [236]. 
 
3.2. Physical-chemical characterization of PLGA 50:50/PVA 2% nanoparticles 
 
The optimized formulation, PLGA 50:50/PVA 2%, was formulated encapsulating a 
higher amount of insulin (0.2 mL of 150 mg/mL insulin solution) to be used in further 
experiments. It was produced loaded and unloaded PLGA nanoparticles and their 
properties are shown in Table 4.2.  
 
Table 4.2. Physical-chemical properties of PLGA 50:50/PVA 2% nanoparticles after production (n 
= 3, mean ± SD). 
Formulation 
Particle Size 
(nm) 
PdI 
Zeta Potential 
(mV) 
Insulin AE 
(%) 
Insulin-loaded nanoparticles 446 ± 30 0.26 ± 0.03 -24.2 ± 3.4 87.4 ± 0.2 
Unloaded nanoparticles 247 ± 21 0.20 ± 0.06 -7.5 ± 2.3 - 
 
After insulin loading into PLGA nanoparticles, its particle size increased about 1.8 
fold comparatively to the unloaded nanoparticles. This may be explained by a higher 
encapsulation and adsorption of insulin on the particle surface increasing the particle 
size, which may also explain the increase of the negative charge on the loaded 
nanoparticles surface up to -24.2 ± 3.4 mV, since at pH 7.4 the charge of insulin is 
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negative [237]. This increase allows the increment of nanoparticles stability in the 
formulation. An AE of 87.4 ± 0.2 % was observed, which is a very good achievement. 
Therefore, even encapsulating a higher amount of insulin, the AE was even higher. This 
may be also explained by a higher amount of insulin encapsulated and of insulin that is 
associated with the nanoparticles surface and more electrostically linked, thus increasing 
insulin AE. Furthermore, comparatively to the results shown on Table 4.1 for the 
PLGA:PVA 2% formulation, after encapsulating a higher amount of insulin it was 
obtained an increase on particle size up to 446 ± 30 nm, and the surface charge became 
more negative which is once more explained by a higher adsorption of insulin on the 
particle surface. 
 
3.3. Physical-chemical characterization of PLGA 50:50/PVA 2% nanoparticles after 
lyophilization 
 
As discussed above, the major problem limiting the use of nanoparticles in a 
colloidal suspension is its physical instability by aggregation and particle fusion or/and 
the chemical instability due to hydrolysis of the polymer and the chemical reactivity 
during extended periods of storage [174]. Hence, lyophilization comes to the front line as 
an optimal method to stabilize nanoparticles. However, during lyophilization in the 
freezing step, the concentration of the nanoparticles system increases during time, which 
may induce aggregation and sometimes irreversible fusion of nanoparticles. In addition, 
the ice crystallization induces mechanical stresses, which leads to nanoparticles 
destabilization. Thus, cryoprotectants must be added to nanoparticles formulation prior 
freezing to protect and further stabilize nanoparticles. The presence of cryoprotectants in 
formulation is also important to avoid aggregation after redispersion of the lyophilizate 
[178]. Trehalose for instance showed to facilitate the resuspension of PLA-PEO 
nanoparticles after lyophilization [157]. The insulin-loaded PLGA nanoparticles were 
lyophilized with and without cryoprotectants added, and their physical-chemical 
properties were assessed after lyophilization and resuspension (Table 4.3). 
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Table 4.3. Physical-chemical properties of insulin-loaded PLGA nanoparticles after lyophilization 
with and without cryoprotectants (n = 3, mean ± SD). 
Formulation 
Particle Size 
(nm) 
PdI 
Zeta Potential 
(mV) 
 
PLGA nanoparticles 
 
422 ± 60 
 
0.37 ± 0.02 
 
-28.2 ± 5.8 
PLGA nanoparticles + 10% (w/w) Trehalose 396 ± 16 0.32 ± 0.05 -42.9 ± 1.7 
PLGA nanoparticles + 10% (w/w) Sucrose 559 ± 16 0.35 ± 0.03 -39.5 ± 2.9 
PLGA nanoparticles + 10% (w/w) Glucose 365 ± 28 0.39 ± 0.01 -36.7 ± 6.0 
PLGA nanoparticles + 10% (w/w) Fructose 712 ± 55 0.39 ± 0.01 -38.2 ± 1.7 
PLGA nanoparticles + 10% (w/w) Sorbitol 469 ± 23 0.37 ± 0.03 -36.3 ± 1.9 
 
It was observed that after lyophilization with no cryoprotectant added, the particle 
size and the zeta potential values remained in the same order of values. The negative 
surface charge even slightly increased, which showed the better colloidal stability of 
nanoparticles after lyophilization. It was also verified that further adding cryoprotectants 
prior lyophilization, the negative surface charge increased more than 1.5 fold for all the 
cryoprotectants. The trehalose-added sample showed the highest negative value of -
42.9±1.7 mV, which may be due to the adsorption of cryoprotectants on nanoparticles 
surface. These results prove that the different cryoprotectants have a more stabilizing 
effect on nanoparticles upon lyophilization. Regarding the particle size values, it was 
verified that on one hand, adding trehalose and glucose decreased the particle size after 
lyophilization respectively to 396 ± 16 nm and 365 ± 28 nm, and on the other hand 
sucrose, fructose and sorbitol increased the particle size to 559 ± 16, 712 ± 55 and 469 ± 
23, respectively. These changes on particle size may be related with the behaviour of 
each cryoprotectant during lyophilization, and its adsorption on nanoparticles surface. 
 
3.4. Transmission and scanning electron microscopy analyses 
 
The morphology of nanoparticles may be evaluated through the visualization of 
its microscopic appearance by TEM and SEM. TEM may characterize the shape of 
PLGA nanoparticles, whereas SEM may characterize the nanoparticles surface. 
However, the evaluation of nanoparticles surface by SEM with a good definition is very 
difficult, and focusing the electron beam on such a small area may also damage the 
nanoparticles. To avoid these drawbacks, during the visualization by SEM it were 
observed particles with the highest particle size that could be visualized. Therefore, it 
was possible to visualize the larger particles, and correlate its morphology and surface 
characteristics with the nanoparticles. TEM allows the observation of the lyophilized 
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nanoparticles after their suspension, however the visualization of nanoparticles by SEM 
is very difficult when the cryoprotectant concentration is more than 5 %, since a 
continuous matrix covering the nanoparticles may be observed [7]. Therefore, the 
purification of the lyophilized nanoparticles to remove the cryoprotectant was crucial, to 
allow the properly visualization of particles by SEM. 
As discussed above, the processing conditions employed in the nanoparticles 
production, influences their characteristics. The nanoparticles porosity for instance, plays 
an important role on insulin release since a large amount of pores may increase the 
release rate of the protein [238]. The porosity of nanoparticles is originated by their 
hardening during the evaporation of dichloromethane in the preparation process and by 
the rate of its evaporation, or even by the temperature of nanoparticles preparation [239]. 
Furthermore, porosity may also influence insulin structure, since pores may open a 
pathway to external factors that can lead to protein denaturation. This loss of protein 
structure may occur in different extents depending on the different nanoparticles used, 
since they may have different porosity. In addition, the influence of cryoprotectants on 
nanoparticles porosity after lyophilization, which may influence the protein release rate 
and stability, is not well established. 
 
 
Figure 4.1. TEM microphotographs of insulin-loaded PLGA nanoparticles after production (A) and 
after lyophilization with no cryoprotectant added (B) (Figure A, bar shows 200 nm; Figure B, bar 
shows 100 nm). 
 
The Figure 4.1 shows the microscopic appearance by TEM of insulin-loaded 
PLGA nanoparticles after production and lyophilization. The nanoparticles exhibited a 
spherical shape and a smooth surface, characteristic of the polymeric matrix. These 
characteristics were maintained after lyophilization with no added cryoprotectant (Figure 
4.1-B) and with added cryoprotectants (Figure 4.2). The maintenance of nanoparticles 
morphology after lyophilization showed that the lyophilization process was effective on 
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nanoparticles stabilization. The size of nanoparticles showed in Figure 4.1 and 4.2 was 
in agreement with the previous particle size evaluations. 
 
 
Figure 4.2. TEM microphotographs of insulin-loaded PLGA nanoparticles after lyophilization with: 
10% (w/v) trehalose (A); 10% (w/v) sucrose (B); 10% (w/v) glucose (C); 10% (w/v) fructose (D) 
and 10% (w/v) sorbitol (E) (Figure A-B, bar shows 100 nm; Figure C, bar shows 50 nm; Figure D-
E, bar shows 100 nm). 
 
SEM was used to assess the nanoparticles surface. The Figure 4.3-A shows the 
presence of some depressions and pores on insulin-PLGA nanoparticles surface after 
production, that were caused by the evaporation of the organic solvent. Such 
morphology was similar for nanoparticles upon lyophilization (Figure 4.3-B). 
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Figure 4.3. SEM microphotographs of insulin-loaded PLGA particles after production (A) and after 
lyophilization with no cryoprotectant added (B) (Figure A-B, bar shows 5 µm). 
 
It was also observed that lyophilization of nanoparticles added with 
cryoprotectants, significantly increased the number of pores on nanoparticles surface 
(Figure 4.4). This occurred because after solidification of all solutes and water, the ice-
vapor is evacuated and the shelf temperature increases supplying energy for 
sublimation, and thus beginning the primary drying.  The elimination of ice crystals by 
sublimation creates an open network of pores, which are pathways for water removal 
from nanoparticles [7]. This increase on nanoparticles porosity after lyophilization with 
cryoprotectants added may open a pathway for a faster insulin release from 
nanoparticles and for its degradation. The freezing step may also influence the porosity 
of nanoparticles, since this step may affect the morphological characteristics of the cake 
[184]. Therefore, the freezing step influences the size of ice crystals and subsequently 
the drying steps and thus, the surface of nanoparticles and porosity of the final cake 
strongly depends on it. The presence of such pores are necessary on a lyophilizate, 
since the absence of a porous structure such as in a collapsed cake, becomes the 
reconstitution of the lyophilizate very hard to accomplish [173, 194]. 
Both the higher release rate and insulin degradation could be mitigated by the 
adsorption of the cryoprotectant on nanoparticles surface obstructing some of the formed 
pores. This was particularly evident in Figure 4.4-A, 4.4-B and 4.4-C. 
 
 B 
D 
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Figure 4.4. SEM microphotographs of insulin-loaded PLGA particles after lyophilization with: 10% 
(w/v) trehalose (A); 10% (w/v) sucrose (B); 10% (w/v) glucose (C); 10% (w/v) fructose (D) and 
10% (w/v) sorbitol (E) (Figure A-E, bar shows 30 µm). 
 
3.5. Evaluation of insulin in vitro release from nanoparticles 
 
Several studies have been assessing the release pattern of drugs by PLGA 
nanoparticles [105, 239, 240]. However, just a few is known about the release pattern of 
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drugs from PLGA nanoparticles after lyophilization with cryoprotectants added. In 
addition, the relationship between the porosity and the surface characteristics of 
nanoparticles lyophilized with cryoprotectants, and the release pattern of insulin is not 
well established yet. 
In Figure 4.5, it is shown the cumulative release profile of insulin from 
nanoparticles in 48 hours, after formulation and after lyophilization with no cryoprotectant 
added. The release pattern for both samples was very similar, with an initial burst 
release within the first 2 hours and a sustained release pattern until the 48 hours, which 
is characteristic of the PLGA-based nanoparticles [239]. The initial burst release may be 
explained by the release of insulin which is still adsorbed on nanoparticles surface, and 
then the encapsulated insulin is released during time achieving a sustained release 
pattern. 
 
 
Figure 4.5. Cumulative release profile of insulin from PLGA nanoparticles after formulation (solid 
line) and after lyophilization with no cryoprotectant added (dotted line) (n = 3, bars represent SD). 
 
The PLGA nanoparticles after formulation released about 57% of the insulin in 
the first 2 hours, and maintained a sustained release achieving 65% of insulin released 
after 48 hours. On other hand, PLGA nanoparticles after lyophilization with no 
cryoprotectant added released about 75% of insulin in the first 2 hours, which was an 
increment of 18% of insulin released, comparatively to nanoparticles after formulation. 
Such increment of insulin release may be related to the possible increase of pores size 
of nanoparticles as could be visualized in Figure 4.3-B. Thereby, a method to precisely 
assess the diameter of nanoparticles pores is required to support this possibility. The 
lyophilized nanoparticles further released about 86% of insulin after 48 hours. 
Regarding the release patterns obtained for cryoprotectant added samples shown 
in Figure 4.6, it was possible to observe that the release pattern of insulin remained 
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similar to that with no cryoprotectant due to the polymeric matrix, with an initial burst 
release in the first 2 hours and a sustained release pattern until 48 hours. Comparatively 
to the lyophilized sample with no cryoprotectant added, the sample with trehalose added 
achieved a higher released amount of insulin while samples with the other used 
cryoprotectants added, led to a lower amount of insulin released. In fact, trehalose added 
nanoparticles released almost 91% of the insulin amount in the first 2 hours, releasing up 
to 96% of insulin after 48 hours. This could be due to the increase of the porosity of 
nanoparticles, as stated in Figure 4.4-A and to trehalose properties as cryoprotectant. In 
fact, it was reported that trehalose seems to be the best cryoprotectant for biomolecules, 
due to its many advantages comparatively with the other sugars. Such advantages are a 
higher Tg’, less hygroscopicity and the absence of internal hydrogen bonds which during 
lyophilization, allows a more flexible formation of hydrogen bonds with nanoparticles 
[166]. Due to these more flexible bonds, trehalose is removed more easily from 
nanoparticles surface and insulin is released in a higher amount. 
 
 
Figure 4.6. Cumulative release profile of insulin from PLGA nanoparticles after lyophilization with: 
no cryoprotectant (dotted line), 10% (w/v) trehalose ( ); 10% (w/v) sucrose ( ); 10% (w/v) 
glucose ( ); 10% (w/v) fructose ( ) and 10% (w/v) sorbitol ( ) added (n = 3, bars represent 
SD). 
Even increasing the porosity after lyophilization, the others cryoprotectant added 
samples showed a lower insulin released amount, mainly due to the presence of the 
sugars on the nanoparticles surface, which may obstruct the pores leading to a lower 
release. Indeed, cryoprotectants may stabilize nanoparticles during the drying steps due 
to the formation of hydrogen bonds between the cryoprotectant and the polar groups, at 
the nanoparticles surface at the end of the drying step [171]. Therefore, is harder to 
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remove these cryoprotectants from nanoparticles surface and the insulin release rate is 
lower. The glucose-added nanoparticles sample released the lowest amount of insulin 
with just almost 30% released in the first 2 hours, which was less 45% comparatively to 
the non-added cryoprotectant sample, and releasing just 44% of the total amount of 
insulin after 48 hours. 
These results showed that the porosity of nanoparticles and the presence of 
cryoprotectants on nanoparticles surface may affect the release of insulin from 
nanoparticles. This was particularly important because the increase of the porosity of 
nanoparticles after lyophilization may open a pathway for insulin release, and 
simultaneously for insulin degradation. Additionally, the cryoprotectants bonding to 
nanoparticles surface may obstruct nanoparticles pores leading to a lower insulin release 
rate. 
 
4. Conclusion 
 
The aim of this chapter was to optimize the formulation of insulin-loaded PLGA 
nanoparticles and analyze the influence of cryoprotectants on nanoparticle stability and 
porosity after lyophilization, which may influence protein release and stability. The 
formulation containing PLGA 50:50 as polymer and PVA 2% as surfactant was the one 
that presented a better combination of size, zeta potential and AE, and was chosen for 
further experiments. It was verified that the lyophilization significantly increased the 
number of pores on PLGA nanoparticles surface, being more evident when 
cryoprotectants were added. The presence of pores is important in a lyophilizate to 
facilitate its reconstitution in water, although this may have consequences to protein 
release and stability. The release profile of insulin encapsulated into PLGA nanoparticles 
showed an initial burst in the first 2 h and a sustained release up to 48 h. After 
nanoparticles lyophilization the insulin release increased due to the formation of pores, 
maintaining a sustained release during time. After lyophilization with cryoprotectants, the 
amount of insulin released was higher for trehalose and lower for sucrose, glucose, 
fructose and sorbitol comparatively to lyophilized PLGA nanoparticles with no 
cryoprotectant added. Besides the porosity, the ability of cryoprotectants to be adsorbed 
on the nanoparticles surface may also play an important role on insulin release and 
stability.
  
 
 
 
 
 
 
 
 
 
 
 
A Stability Study Perspective of the Effect of 
Lyophilization Using Cryoprotectants on the 
Structure of Insulin Loaded Into PLGA 
Nanoparticles 
 
 
 
 
Partially published in: 
Pedro Fonte, Sandra Soares, Flávia Sousa, Ana Costa, Vítor Seabra, Salette Reis, 
Bruno Sarmento, Stability study perspective of the effect of freeze-drying using 
cryoprotectants on the structure of insulin loaded into PLGA nanoparticles, 
Biomacromolecules, 15 (2014) 3753-3765.
 
Chapter 5 
Chapter 5 I A Stability Study Perspective of the Effect of Lyophilization Using Cryoprotectants on 
the Structure of Insulin Loaded Into PLGA Nanoparticles 
  
86 
 
 
1. Introduction 
 
During encapsulation, proteins may suffer structural modifications due to the 
exposure to organic solvents, hydrophobic interfaces, dehydrations, shearing stresses 
and prejudicial reactions upon storage [10]. In addition, the introduction of hydrophilic 
proteins into hydrophobic polymeric carriers is a challenge, thus complex protein-protein 
and protein-polymer interactions are expected to occur. FTIR is considered the reference 
technique to assess the secondary structure of proteins loaded into nanoparticles in a 
non-invasive way. 
The removal of water from protein-loaded nanoparticles by lyophilization may be 
fundamental to avoid the hydrolytic degradation of the nanoparticle matrix in aqueous 
suspension and to prevent loaded protein instability [182, 204]. However, this process 
also produces changes on nanoparticle properties, which may affect its robustness and 
size, with ultimately consequences to protein stability. Some sugars such as trehalose, 
glucose, sucrose, fructose and sorbitol may be used as cryoprotectants to minimize 
nanoparticles instability upon lyophilization, preventing their aggregation and protecting 
them from mechanical stress of ice crystals. Cryoprotectants may affect the Tg’ of the 
formulation, which is crucial to obtain a cake with a stable amorphous form, appropriate 
residual moisture content, good redispersibility, and, of upmost importance, good protein 
stabilization upon storage [8, 230]. Cryoprotectants are known to preserve the native 
structure of proteins after lyophilization [241, 242]. 
Comparatively to other colloidal systems, there are just a few works focusing on 
the lyophilization process of polymeric nanoparticles. Most of the investigations on 
nanoparticle lyophilization are performed by trial and error, without considering the 
scientific principles of the lyophilization process. These chemical, physical and 
engineering principles need to be regarded in order to obtain a product with good quality 
and acceptable shelf-life. Generally, researchers just use this process as a way to 
remove water without considering the physical-chemical stability of the formulation. In 
this work it is demonstrated the influence of a standard lyophilization cycle, on the 
stability of insulin-loaded PLGA nanoparticles, after lyophilization and storage. 
Thus, the aim of this chapter was to evaluate the stability of PLGA nanoparticles 
upon lyophilization and storage, and using insulin as a model of therapeutic protein, 
evaluate the maintenance of insulin secondary structure after encapsulation into PLGA 
nanoparticles. It was also evaluated the influence of lyophilization, using different 
cryoprotectants, on insulin structure. In addition, it were evaluated the modifications on 
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insulin secondary structure encapsulated into PLGA nanoparticles and on its features, 
over 6 months at different storage conditions following the ICH guidelines
 
2. Materials and methods 
 
2.1. Materials 
 
PLGA 50:50 Resomer® RG 503 H (Mw 24,000-38,000 g/mol; viscosity 0.32-0.44 
dL/g; Tg 44-48 ºC; end group: free carboxylic acid) was from Evonik Industries AG 
(Essen, Germany). PVA, dichloromethane and recombinant human insulin, trehalose 
(Mw 378.33 g/mol), glucose (Mw 180.16 g/mol), sucrose (Mw 342.30 g/mol), fructose 
(Mw 180.16 g/mol) and sorbitol (Mw 182.17 g/mol) were from Sigma-Aldrich (Steinheim, 
Germany). Acetonitrile HPLC gradient grade was from Fischer Scientific (Loughborough, 
UK) and trifluoroacetic acid from Acros Organics (Morris Plains, NJ, USA). Milli-Q water 
was produced in-house and all other reagents were of analytical grade. 
 
2.2. Preparation of PLGA nanoparticles 
 
PLGA nanoparticles were produced using a modified solvent emulsification-
evaporation method, based on a w/o/w double emulsion technique [101]. Briefly, 200 mg 
of PLGA 50:50 were dissolved in 2 mL of dichloromethane. Then, 0.2 mL of a 150 mg/mL 
insulin solution in HCl 0.1 M was added to the polymeric solution and mixed using a 
Bioblock vibracell 75186 sonicator from Fischer Bioblock Scientific (Rungis Complexe, 
France), during 30 seconds with 70% of amplitude. After this homogenization, the 
primary emulsion was poured onto 25 mL of PVA 2% (w/v) at pH 7.4 and mixed using the 
same sonication conditions. Finally, the organic solvent was completely evaporated 
under magnetic stirring. 
The nanoparticles were washed with Milli-Q water three times by centrifugation 
using a Heraeus Megafuge 1.0 R centrifuge (Thermo Scientific, Asheville, NC, USA) at 
15,000 rpm for 30 min, and redispersed in water prior lyophilization and storage. The 
same procedure was followed to produce unloaded PLGA nanoparticles. 
 
2.3. Insulin association efficiency 
 
The insulin AE was indirectly determined. The amount of insulin entrapped into 
the PLGA nanoparticles was calculated using the concept of the equation 4.1 (see 
Chapter 4). The insulin free in supernatant correspond to the amount of insulin that 
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remained in the aqueous phase after nanoparticles isolation by centrifugation using a 
Beckman Optima TL ultracentrifuge from Beckman Coulter (Brea, CA, USA) at 20,000 
rpm for 15 min at 4°C, and it was quantified by a HPLC-UV method previously validated 
[233]. Measurements were performed using a Merck-Hitachi LaChrom HPLC instrument  
from Merck (Whitehouse Station, NJ, USA) equipped with a XTerra RP 18 column, 5 μm 
particle size, 4.6 mm internal diameter × 250 mm length from Waters (Milford, MA, USA) 
and a LiChrospher 100 RP-18, 5 μm particle size guard column also from Merck 
(Whitehouse Station, NJ, USA). Samples were run in triplicate. 
 
2.4. Lyophilization of nanoparticles 
 
The PLGA nanoparticles were poured into semi-stoppered glass vials with slotted 
rubber closures at a maximal formulation height of 10 mm, and added in a set of 3 
replicates with different cryoprotectants:  trehalose, glucose, sucrose, fructose and 
sorbitol at a concentration of 10% (w/v) of the final volume in each vial.  All samples 
including those with no cryoprotectant added were then frozen at -80ºC for 6 hours and 
transferred to a Modulyo 4K lyophilizer from Edwards (Crawley, West Sussex, UK) at 
0.09 mbar for 72 h, being maintained at the condenser surface temperature of -60 ± 5 ºC. 
 
2.5. Reconstitution of lyophilized samples 
 
After lyophilization, samples were reconstituted by slowly adding distilled water in 
the inside wall of the vial and maintained during 10 minutes to ensure the proper cake 
wetting. Then, samples were shaken in a Vortex Mixer ZX Classic from Velp Scientifica 
(Usmate, Italy) during 3 minutes to obtain complete homogenization. 
 
2.6. Long-term storage study 
 
A 6 month study was performed to evaluate the long-term stability of insulin 
loaded into PLGA nanoparticles under different storage conditions, following the ICH 
guidelines [197]. Samples were stored at three different storage conditions: 4 ± 2ºC , 25 
± 2ºC / 60 ± 5% RH and 40 ± 2ºC / 75 ± 5% RH in a Climacell chamber from MMM 
Medcenter Einrichtungen GmbH (Planegg, Germany) and at all storage conditions 
samples were protected from light. Samples were analyzed in triplicate at four different 
time points, for each storage condition: after lyophilization (t0), and after 1, 3 and 6 
months of storage (t1, t3 and t6, respectively). 
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2.7. Particle size and zeta potential analyses 
 
Both formulations in suspension and after reconstitution were diluted with Milli-Q 
water to a proper concentration for both particle size and zeta potential assessments. 
The particle size and zeta potential were analyzed respectively, by dynamic light 
scattering using a 90Plus Particle Size Analyzer and by phase analysis light scattering 
using a ZetaPALS Zeta Potential Analyzer, both from Brookhaven Instruments 
Corporation (Holstville, NY, USA). All measurements were performed in triplicate. 
 
2.8. Transmission electron microscopy analysis 
 
PLGA nanoparticles morphology was characterized by TEM, by placing 
formulations in suspension and reconstituted samples on a grid, treated with uranyl 
acetate and then observed in a JEOL JEM-1400 Electron Microscope from JEOL Ltd 
(Tokyo, Japan). 
 
2.9. Scanning electron microscopy analysis 
 
The surface morphology of PLGA nanoparticles was observed by SEM on a FEI 
Quanta 400 FEG SEM from FEI (Hillsboro, OR, USA). The lyophilized nanoparticles 
containing cryoprotectants were resuspended in distilled water and washed three times 
by centrifugation at 20,000 rpm for 15 min at 4°C, to remove the dissolved 
cryoprotectant. The lyophilizates were also observed. Samples were mounted onto a 
metal stub and vacuum-coated with a layer of gold/palladium prior observation. 
 
2.10. Attenuated total reflectance-Fourier transform infrared spectroscopy analysis 
 
The secondary structure of insulin loaded into the PLGA nanoparticles upon 6 
months of storage, was assessed by FTIR. The analyses were performed in an ABB 
MB3000 FTIR spectrometer from ABB (Zurich, Switzerland) equipped with a MIRacle 
single reflection attenuated total reflectance (ATR) accessory from PIKE Technologies 
(Madison, WI, USA). 
All spectra were collected with 256 scans and a 4 cm-1 resolution in the region of 
4000-600 cm-1, and a triplicate of each formulation was analyzed. Insulin spectra were 
obtained following a double subtraction procedure [243], followed by a 15 points 
Savitsky-Golay second derivative,  and a baseline correction using 3-4 point adjustment 
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at the amide I region (1710-1590 cm-1). Finally, all spectra were area-normalized for 
further comparison. The spectral treatment was performed using the HorizonMB FTIR 
software from ABB (Zurich, Switzerland). 
 
2.10.1. Spectral similarity analysis 
 
The quantitative comparison of the similarity of FTIR spectra between the insulin 
loaded into the PLGA nanoparticles and native insulin was determined  using the area of 
overlap (AO) [244] and spectral correlation coefficient (SCC) [245] algorithms. The area 
normalized second-derivative amide I spectra were used for both methods considering 
as reference a 30 mg/mL insulin solution in HCl 0.1 M, and the results are presented as 
percentage, so the higher the percentage most similar are the spectra. This protein 
solution was used as reference, because it is generally recognized that the stability of a 
solid protein formulation increases with the increase of similarity to the FTIR spectra in 
solution [246]. 
 
2.10.2. Multivariate data analysis 
 
The principal component analysis (PCA) is a helpful method for protein structure 
characterization [247]. Therefore, it was performed a correlation of the loaded protein 
secondary structure with the influence of the lyophilization process, used cryoprotectant 
and storage condition upon 6 months of storage. A data set consisting of N objects 
(average spectra of the second-derivative spectra of insulin loaded into PLGA 
nanoparticles formulations and native insulin structure) and X variables (amide I region 
wavenumbers) was the PCA input matrix, that resulted in the scores and loadings matrix 
for each estimated principal component (PC). The PCA was performed using the Matlab 
7.9 software from MathWorks (Natick, MA, USA) with a PLS Toolbox 5.5 software from 
Eigenvector Research Inc. (Wenatchee, WA, USA). 
 
2.11. Statistical analysis 
 
The statistical analyses were performed using a one-way analysis of variance 
(ANOVA) Tukey post hoc test, with a significance level of p < 0.05 in the OriginPro 8 
software from OriginLab Corporation (Northampton, MA, USA). 
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3. Results and discussion 
 
3.1. Nanoparticles characterization 
3.1.1. Particle size, zeta potential and association efficiency 
3.1.1.1. Before lyophilization 
Insulin-loaded PLGA nanoparticles were characterized after production and 
lyophilization using different cryoprotectants, and also upon 6 months at different storage 
conditions. The nanoparticles were successfully produced by a formulation protocol 
previously optimized [101]. These carriers were used mainly by its recognized 
biocompatibility, ability to protect the loaded drug and sustained release properties. The 
production method is also widely used to encapsulate protein drugs, since it is very easy 
to reproduce and obtain nanoparticles with good properties. The Figure 5.1 shows the 
particle size, PdI and zeta potential characterization of all the formulations upon 6 
months of storage. These results are also represented in numeric values in Table 5.1. 
Insulin-loaded PLGA nanoparticles in suspension (insulin-PLGA nanoparticles) were 
obtained with a mean particle size of 446 ± 30 nm, PdI of 0.26 ± 0.03 and zeta potential 
of -24.2 ± 3.4 mV, which was a good indicator of nanoparticles stability. Insulin AE was 
87.4 ± 0.2 %, being a very good achievement regarding the hydrophilic nature of insulin, 
loaded into the hydrophobic polymeric matrix. 
 
3.1.1.2. After lyophilization 
 
Nanoparticles were lyophilized without cryoprotectant added (freeze-dried insulin-
PLGA nanoparticles) or added with trehalose (freeze-dried insulin-PLGA nanoparticles + 
trehalose), glucose (freeze-dried insulin-PLGA nanoparticles + glucose), sucrose (freeze-
dried insulin-PLGA nanoparticles + sucrose), fructose (freeze-dried insulin-PLGA 
nanoparticles + fructose) and sorbitol (freeze-dried insulin-PLGA nanoparticles + sorbitol) 
at a cryoprotectant concentration of 10% (w/v). The criteria to choose these excipients as 
cryoprotectants was to use two non–reducing sugars (trehalose and sucrose) two 
reducing sugars (glucose and fructose) and one sugar alcohol (sorbitol). Comparatively 
to mannitol, the latter is not commonly used as cryoprotectant, so its potential as a 
cryoprotectant was evaluated. The mentioned cryoprotectant concentration was used to 
obtain the highest acceptable cryoprotectant effect level. Thus, it was intention of this 
work to demonstrate how these different cryoprotectants may impact the stability of the 
carrier and the loaded protein. These cryoprotectants were expected to avoid 
aggregation and facilitate redispersion of the lyophilizate [178]. 
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Figure 5.1. Mean particle size (top bars), PdI (square symbols) and zeta potential (bottom bars) characterization of insulin-loaded PLGA nanoparticles 
formulations. Results are significantly different (p < 0.05) from insulin-PLGA nanoparticles after formulation, when marked with 1. When marked with * 
and #, results are significantly different (p < 0.05) from the corresponding formulation at t0, and from the corresponding formulation at the previous time 
point, respectively. NP stands for nanoparticles. Left, middle and right graphs are referred to 4ºC, 25ºC / 60% RH and 40ºC / 75% RH, respectively.
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After lyophilization, it was noticed that all formulations, except freeze-dried 
insulin-PLGA nanoparticles and freeze-dried insulin-PLGA nanoparticles + trehalose 
10%, were collapsed. The obtained collapsed cakes were more difficult to resuspend 
comparatively to non-collapsed cakes. Even though, all tested formulations did not 
significantly change its particle size after lyophilization, with the exception of freeze-dried 
insulin-PLGA nanoparticles + fructose 10%. The natural consequences of product 
collapse are indeed the long reconstitution time and the high residual moisture content. 
Concerning to zeta potential analyses, the overall obtained results showed that 
nanoparticles presented negative surface charge, which is characteristic of the acidic 
PLGA [147]. However, some exceptions were found indicating that nanoparticles surface 
suffered modifications. The removal of free drug from formulations supernatant prior 
lyophilization was important, since its presence in formulation may increase the zeta 
potential near to neutrality, increasing the probability of particle aggregation [7]. The zeta 
potential values decreased after lyophilization, and mainly when cryoprotectants were 
added, showing that nanoparticles became more stable. This may be explained by the 
presence of sugars that expand the location of the slipping plan during electrophoretic 
movement due to the formation of a viscous hydration layer on nanoparticles surface 
[248]. 
 
Table 5.1. Mean particle size, PdI and zeta potential characterization of insulin-loaded PLGA 
nanoparticle formulations upon 6 months of storage at the tested storage conditions (n = 3, mean 
± SD). 
Time 
point 
Formulation 
Diameter 
(nm) 
PdI 
Zeta potential 
(mV) 
 
t0 Insulin-PLGA nanoparticles 446 ± 30 0.26 ± 0.03 -24.2 ± 3.4 
Freeze-dried Insulin-PLGA nanoparticles 422 ± 60 0.37 ± 0.02 -28.2 ± 5.8 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
396 ± 16 0.32 ± 0.05 -42.9 ± 1.7 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
365 ± 28 0.39 ± 0.01 -36.7 ± 6.0 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
559 ± 16 0.35 ± 0.03 -39.5 ± 3.0 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
712 ± 55 0.39 ± 0.01 -38.2 ± 1.7 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
469 ± 23 0.37 ± 0.03 -36.3 ± 1.9 
 
4°C 
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t1 Insulin-PLGA nanoparticles 524 ± 34 0.37 ± 0.08 -39.6 ± 1.4 
Freeze-dried Insulin-PLGA nanoparticles 272 ± 10 0.38 ± 0.01 -28.2 ± 15.8 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
484 ± 37 0.40 ± 0.02 -37.6 ± 0.7 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
393 ± 10 0.39 ± 0.01 -36.7 ± 1.9 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
540 ± 21 0.40 ± 0.01 -35.1 ± 0.9 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
628 ± 4 0.35 ± 0.01 -38.2 ± 1.0 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
469 ± 16 0.37 ± 0.01 -36.3 ± 1.7 
 
t3 Insulin-PLGA nanoparticles 618 ± 203 0.39 ± 0.15 -42.0 ± 1.8 
Freeze-dried Insulin-PLGA nanoparticles 227 ± 63 0.42 ± 0.04 -29.4 ± 2.1 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
482 ± 191 0.37 ± 0.03 -56.4 ± 4.2 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
417 ± 68 0.26 ± 0.04 -20.5 ± 3.4 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
502 ± 90 0.43 ± 0.05 -52.8 ± 6.2 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
606 ± 55 0.58 ± 0.05 -8.0 ± 2.0 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
475 ± 21 0.31 ± 0.01 -34.9 ± 4.3 
 
t6 Insulin-PLGA nanoparticles 1761 ± 271 0.37 ± 0.01 -22.4 ± 1.2 
Freeze-dried Insulin-PLGA nanoparticles 1671 ± 53 0.37 ± 0.01 -15.7 ± 1.0 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
1158 ± 61 0.43 ± 0.01 -24.1 ± 1.3 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
1795 ± 88 0.42 ± 0.02 -21.2 ± 0.6 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
1205 ± 57 0.45 ± 0.05 -19.1 ± 1.5 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
1770 ± 56 0.38 ± 0.01 -20.6 ± 1.6 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
1540 ± 54 0.37 ± 0.01 -21.2 ± 0.5 
 
25°C / 60% RH 
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t1 Insulin-PLGA nanoparticles 400 ± 19 0.36 ± 0.01 -8.7 ± 4.0 
Freeze-dried Insulin-PLGA nanoparticles 451 ± 8 0.35 ± 0.01 -35.0 ± 0.6 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
408 ± 16 0.34 ± 0.01 -36.4 ± 1.1 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
378 ± 6 0.35 ± 0.01 -21.3 ± 0.5 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
643 ± 7 0.33 ± 0.02 -39.1 ± 1.8 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
702 ± 10 0.32 ± 0.01 -30.3 ± 1.1 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
470 ± 12 0.32 ± 0.01 -35.4 ± 2.2 
t3 Insulin-PLGA nanoparticles 460 ± 14 0.39 ± 0.01 10.5 ± 5.3 
Freeze-dried Insulin-PLGA nanoparticles 644 ± 10 0.33 ± 0.03 -26.9 ± 1.3 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
519 ± 165 0.36 ± 0.02 -31.7 ± 6.5 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
411 ± 11 0.38 ± 0.01 -10.1 ± 2.7 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
763 ± 21 0.36 ± 0.02 -31.7 ± 1.1 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
787 ± 21 0.36 ± 0.01 -24.4 ± 0.9 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
514 ± 17 0.38 ± 0.01 -25.8 ± 1.0 
t6 Insulin-PLGA nanoparticles 3032 ± 504 0.47 ± 0.08 -18.5 ± 7.7 
Freeze-dried Insulin-PLGA nanoparticles 1425 ± 159 0.61 ± 0.06 -22.1 ± 3.5 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
1267 ± 318 0.56 ± 0.05 -23.1 ± 3.8 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
1060 ± 47 0.55 ± 0.05 -29.0 ± 5.5 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
1107 ± 152 0.63 ± 0.08 -25.0 ± 3.0 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
1102 ± 190 0.55 ± 0.06 -31.4 ± 1.1 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
763 ± 31 0.55 ± 0.05 -24.6 ± 0.9 
 
40°C / 75% RH 
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t1 Insulin-PLGA nanoparticles 450 ± 239 0.33 ± 0.03 4.6 ± 0.6 
Freeze-dried Insulin-PLGA nanoparticles 252 ± 4 0.26 ± 0.01 -24.2 ± 2.0 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
830 ± 11 0.37 ± 0.01 -31.1 ± 1.4 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
489 ± 13 0.37 ± 0.01 -16.0 ± 0.8 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
552 ± 15 0.36 ± 0.01 -20.1 ± 1.1 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
729 ± 44 0.35 ± 0.02 -27.8 ± 0.8 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
382 ± 5 0.37 ± 0.01 -26.0 ± 1.1 
t3 Insulin-PLGA nanoparticles 657 ± 12 0.38 ± 0.01 11.4 ± 0.6 
Freeze-dried Insulin-PLGA nanoparticles 936 ± 21 0.34 ± 0.03 -14.2 ± 0.9 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
1360 ± 48 0.46 ± 0.03 -26.2 ± 1.3 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
760 ± 55 0.41 ± 0.02 -9.9 ± 1.8 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
885 ± 29 0.43 ± 0.02 -23.6 ± 1.4 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
826 ± 32 0.38 ± 0.03 -21.2 ± 1.5 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
403 ± 30 0.40 ± 0.03 -22.9 ± 1.0 
t6 Insulin-PLGA nanoparticles 619 ± 52 0.70 ± 0.01 14.5 ± 0.6 
Freeze-dried Insulin-PLGA nanoparticles 2366 ± 82 0.35 ± 0.02 -4.9 ± 1.7 
Freeze-dried Insulin-PLGA nanoparticles + 
Trehalose 10% 
1884 ± 367 0.63 ± 0.19 -20.2 ± 1.2 
Freeze-dried Insulin-PLGA nanoparticles + 
Glucose 10% 
1337 ± 27 0.42 ± 0.04 21.8 ± 1.4 
Freeze-dried Insulin-PLGA nanoparticles + 
Sucrose 10% 
1186 ± 19 0.42 ± 0.03 -21.4 ± 0.9 
Freeze-dried Insulin-PLGA nanoparticles + 
Fructose 10% 
1346 ± 47 0.41 ± 0.02 -10.2 ± 1.4 
Freeze-dried Insulin-PLGA nanoparticles + 
Sorbitol 10% 
1070 ± 37 0.45 ± 0.04 -14.0 ± 0.8 
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3.1.1.3. Upon storage 
 
The formulations were stored at different storage conditions during 6 months and 
particles were characterized at time points of 1, 3 and 6 months. Regarding the storage 
of formulations at 4ºC, during the first 3 months, particle size of nanoparticles did not 
significantly changed, except for freeze-dried insulin-PLGA nanoparticles that obtained a 
particle size of 227 ± 63 nm. This decrease was probably due to the absence of 
cryoprotectant that has the ability to form hydrogen bonds with the polymer and cover 
nanoparticles surface protecting them from hydrolytic degradation motivated by the 
residual moisture content [101]. After 6 months of storage at 4ºC (t6_4) the particle size 
significantly changed in all formulations comparatively to the corresponding formulation 
at t0, and the lyophilized formulations also significantly changed from t3 to t6. Overall, 
particle size increased more than 3-fold from t0. This fact may be explained by the 
particles aggregation upon 6 months of storage at 4ºC, which was also evident by the 
gradual difficulty to resuspend particles over time. Regarding zeta potential results, 
formulations maintained similar results upon 1 month of storage, but after 6 months the 
zeta potential of lyophilized formulations significantly increased, providing another 
indicator of nanoparticles modification. 
At 25ºC / 60% RH, after 3 months all nanoparticle formulations maintained its 
particle size except freeze-dried insulin-PLGA nanoparticles that showed a significantly 
increased particle size of 644 ± 10 nm. At t6, particle size highly increased up to 3032 ± 
504 nm which shows up also the great aggregation suffered. This particle size increase 
for all the formulations was also particularly evident by the increase of its PdI. This 
indicator shows clearly the variable size range of nanoparticles originated by the 
formation of aggregates, resulting in low homogeneity and low particle suspension 
stability. In addition, comparatively to other storage conditions the PdI values 
demonstrated that the reconstitution of the lyophilizates was more difficult at 25ºC / 60% 
RH.  Even though, after 6 months of storage, all the formulations remained colloidally 
stable since nanoparticles presented negative zeta potential values not higher than -20 
mV.  
Concerning the stability of the formulations at more extreme storage conditions, 
40ºC / 75% RH, instability was observed earlier. Although at t1 most of the formulations 
maintained its particle size, freeze-dried insulin-PLGA nanoparticles and freeze-dried 
insulin-PLGA nanoparticles + sorbitol particle size significantly changed. Freeze-dried 
insulin-PLGA nanoparticles after one month decreased its particle size down to 253 ± 4 
nm, probably due to partial surface degradation of the polymer. This degradation may be 
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particularly augmented by the increase of the number of pores on nanoparticles surface 
after lyophilization, which increases the surface area for hydrolytic processes motivated 
by residual moisture content, combined with the absence of cryoprotectants on 
nanoparticles surface [101]. Besides this decrease suffered by particle degradation, at t3 
particle size significantly increased due to particle aggregation. Indeed, the degradation 
suffered by particles led them to destabilize and have more tendency to aggregate 
overtime, increasing particle size values. At this storage condition, insulin-PLGA 
nanoparticles in suspension did not significantly changed the particle size, but it was 
clearly noticed a completely change of the formulation aspect over time, changing from a 
milky to a more aqueous aspect due to the constant degradation of particles because the 
storage temperature was close to the PLGA Tg (44-48ºC). It is recommended that the Tg 
value of a stable formulation, needs to be at least 20ºC above the storage temperature 
[249]. At t6, all the lyophilized formulations significantly increased the particle size 
comparatively to t0 and t3, which was particularly evident for freeze-dried insulin-PLGA 
nanoparticles and freeze-dried insulin-PLGA nanoparticles + trehalose. Regarding zeta 
potential, insulin-PLGA nanoparticles presented positive zeta potential values at t1, t3 
and t6 showing that the stability of nanoparticles in suspension were really compromised 
at 40ºC / 75% RH. The increased degradation suffered by PLGA nanoparticles at this 
storage condition could turned the formulation into an acidic pH, and at this condition the 
zeta potential of PLGA nanoparticles may become positive [151]. Indeed, the surface 
charge reverse may be due to a transfer of protons from the bulk solution into 
nanoparticles surface, so hydroxyl groups may be protonated at the surface.  After 6 
months of storage, the zeta potential significantly increased for all the formulations and 
freeze-dried insulin-PLGA nanoparticles + glucose increased its zeta potential into 
positive values. 
In an overall view, it may be stated that for the storage conditions except for 40ºC 
/ 75% RH, the formulations maintained similar levels of particle size upon 3 months 
comparatively to t0. The highest particle size increase was noticed from t3 to t6 at all the 
storage conditions, however it must be noticed that particles remained suitable for 
intravenous administration even after 6 months of storage. It is generally accepted that 
the particle size of intravenously administered formulations should not exceed 5 µm.  In 
addition, it was particularly evident that cryoprotectant added formulations led to a less 
particle increase upon 6 months, showing that additionally to its better performance 
during lyophilization, they were able to increase particles stability upon 6 months of 
storage. The zeta potential increased over time, however besides the mentioned 
exceptions, particles demonstrated good stability upon 6 months of storage. Regarding 
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zeta potential results, cryoprotectant added formulations showed once more to have a 
higher level of particles stabilization presenting lower negative zeta potential values.  
Most of the modifications occurred on nanoparticles stability over the 6 months of 
storage were explained by the collapse of formulations after lyophilization, which leads to 
a high residual moisture content. The inappropriate residual moisture content of 
formulations is a natural consequence of product collapse. During storage nanoparticles 
may adsorb enough moisture leading to a reduction of its Tg below the storage 
temperature, accelerating formulations instability and product collapse [250]. It is known 
that at the early stage of storage time, moisture inside the vials may increase due to 
water transfer from stoppers, and over time moisture content may increase due to its 
permeation through vials stoppers [251]. These gradual modifications over time were 
noticed by the increasing nanoparticles aggregation and resuspension difficulty over 
time. Indeed, the use of a standard lyophilization process led to this instability upon 
storage. First of all, prior lyophilization, the different formulations need to be physical and 
chemical characterized, so the critical properties of the formulations such as the Tg’ and 
the collapse temperature Tc need to be known. To prevent the collapse during 
lyophilization and storage, the product temperature must be set below the glass 
transition temperature (Tg’ and Tg, respectively) and the lyophilized product collapses 
and changes its macroscopic shape during lyophilization, when it is dried above the Tc 
[163]. Indeed, in most of the cases, lyophilization process is usually developed by trial 
and error or even in a ‘blind way’ in which samples are just dropped inside the 
lyophilizer, and attention on formulation critical properties, and the three steps of 
lyophilization are completely neglected. The intention of this chapter was to demonstrate 
what may happen to formulations stability when these procedures occur. For instance, 
when the primary drying does not begin immediately after freezing, the frozen water may 
start to liquefy which combined with an ineffective secondary drying step leads to a high 
level of residual moisture content that destabilizes formulations. 
 
3.1.2. Nanoparticles morphology 
 
The morphology of PLGA nanoparticles may be visualized by TEM and SEM, 
since these techniques provide essential information about the shape and the surface of 
nanoparticles, respectively. As previously reported [101], the visualization of 
nanoparticles surface by SEM with good definition is not easy and all the visualized 
nanoparticles surfaces may look similar, so differences between them are not possible to 
distinguish. Thus, taking advantage of formulations polydispersity, by visualizing the 
largest particles it is possible to correlate its surface and morphology with the obtained 
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nanoparticles, and then better understand the influence of storage conditions on 
nanoparticles over time. The information about nanoparticles surface is crucial to infer its 
stability, and the stability of the loaded protein. On its turn, TEM visualizations helped to 
confirm particles size and shape. 
 
3.1.2.1. Lyophilizate morphology 
 
In Figure 5.2 it is shown the microphotographs of the lyophilizates. It was noticed 
a clear difference between the lyophilizate of freeze-dried insulin-PLGA nanoparticles 
and the cryoprotectant-added formulations, since the latter presented a compact aspect. 
These structures may be advantageous since the nanoparticles inside may get more 
protected from degradation, thus the structure of the loaded protein may be also more 
protected with the addition of cryoprotectants. Considering the freeze-dried insulin-PLGA 
nanoparticles + sucrose formulation, the lyophilizate did not show clearly the particles, 
but in all the other formulations it was possible to visualize the containing particles that 
maintained its characteristic spherical shape after lyophilization. The lyophilizate of 
formulations at the different storage conditions showed that particles could be perfectly 
observed in all formulations after 1 month of storage (Figure 5.3), but structural 
modifications of the lyophilizate of some formulations started to be observed after 3 
months (Figure 5.4). For freeze-dried insulin-PLGA nanoparticles it was noticed that at 
4ºC and 25ºC / 60% RH particles maintained their shape, however at 40ºC / 75% RH 
after 3 months particles lost their stability. In the cryoprotectant-added formulations the 
compact structure of the lyophilizate obtained after lyophilization could still be observed. 
Upon 6 months, at 4ºC and 25ºC / 60% RH it was possible to notice that particles 
maintained their shape. However it was predictably at 40ºC / 75% RH that particles 
shape mostly changed and when fructose was used the shape of the cake was really 
compromised, since no particles were visualized (Figure 5.5). These results indicate that 
the other cryoprotectants offered superior stability to the lyophilizate upon 6 months of 
storage, which was mostly noticed at 40ºC / 75% RH. 
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Figure 5.2. SEM microphotographs of the lyophilizates at t0. Freeze-dried insulin-PLGA 
nanoparticles (A), freeze-dried insulin-PLGA nanoparticles + trehalose (B), freeze-dried insulin-
PLGA nanoparticles + glucose (C), freeze-dried insulin-PLGA nanoparticles + sucrose (D), 
freeze-dried insulin-PLGA nanoparticles + fructose (E) and freeze-dried insulin-PLGA 
nanoparticles + sorbitol (F). Scale bar: 20 µm (F), 100 µm (A, B, D) and 500 µm (C, E). 
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Figure 5.3. SEM microphotographs of the lyophilizates after 1 month of storage (t1) at the tested 
storage conditions. Scale bar: 100 µm. 
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Figure 5.4. SEM microphotographs of the lyophilizates after 3 months of storage (t3) at the tested 
storage conditions. Scale bar: 30 µm (all microphotographs except, no cryoprotectant 4ºC and 
40ºC / 75% RH, glucose 4ºC and 40ºC / 75% RH, sucrose 40ºC / 75% RH and fructose 40ºC / 
75% RH at 100 µm). 
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Figure 5.5. SEM microphotographs of the lyophilizates after 6 months of storage (t6) at the tested 
storage conditions. Scale bar: all microphotographs at 100 µm, except trehalose - 25ºC / 60% RH, 
glucose - 4ºC and 40ºC/75% RH; and fructose - 4ºC at 30 µm. 
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3.1.2.2. Particles morphology after lyophilizate resuspension 
 
Figure 5.6 shows the TEM microphotographs of formulations at t0, and it was 
confirmed that nanoparticles maintained its characteristic spherical shape after 
lyophilization with and without added cryoprotectants, which was also proved by SEM 
visualizations in Figure 5.7.  In Figure 5.8 and 5.9 it is shown the SEM microphotographs 
of all formulations after 6 months of storage. 
 
 
Figure 5.6. TEM microphotographs of insulin-PLGA nanoparticles after production (A) and after 
lyophilization. Freeze-dried insulin-PLGA nanoparticles (B), freeze-dried insulin-PLGA 
nanoparticles + trehalose (C), freeze-dried insulin-PLGA nanoparticles + glucose (D), freeze-dried 
insulin-PLGA nanoparticles + sucrose (E), freeze-dried insulin-PLGA nanoparticles + fructose (F) 
and freeze-dried insulin-PLGA nanoparticles + sorbitol (G). Scale bar: 200 nm. 
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Figure 5.7. SEM microphotographs of insulin-PLGA nanoparticles after production (A) and after 
lyophilization. Freeze-dried insulin-PLGA nanoparticles (B), freeze-dried insulin-PLGA 
nanoparticles + trehalose (C), freeze-dried insulin-PLGA nanoparticles + glucose (D), freeze-dried 
insulin-PLGA nanoparticles + sucrose (E), freeze-dried insulin-PLGA nanoparticles + fructose (F) 
and freeze-dried insulin-PLGA nanoparticles + sorbitol (G). Scale bar: 5 µm. 
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Figure 5.8. SEM microphotographs of insulin-PLGA nanoparticles and freeze-dried insulin-PLGA 
nanoparticles upon 6 months of storage at 4ºC and 25ºC/60% RH. Scale bar: 30 µm. NP stands 
for nanoparticles. 
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Figure 5.9. SEM microphotographs of lyophilized insulin-PLGA nanoparticles added with 
cryoprotectants upon 6 months of storage at 4ºC, 25ºC/60% RH and 40ºC/75% RH. Scale bar: all 
microphotographs at 30 µm, except trehalose 40ºC / 75% RH, glucose 40ºC / 75% RH and 
fructose 4ºC at 5 µm. 
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3.1.2.2.1. Insulin-PLGA nanoparticles 
 
The TEM and SEM microphotographs of insulin-PLGA nanoparticles at the 
storage conditions at t0, t1, t3 and t6 are shown respectively, in figures 5.10 and 5.11. 
Insulin-PLGA nanoparticles maintained its spherical shape at 4ºC and 25ºC / 60% RH 
upon 6 months, however as referred above, at 40ºC / 75% RH the formulation 
completely changed and from a milky aspect at the beginning over time became to a 
more aqueous aspect with an increasing deposit of aggregated polymer. Comparatively 
to other formulations and as expected, these results showed that lyophilization improved 
the stability of nanoparticles upon storage. At 40ºC / 75% RH insulin-PLGA nanoparticles 
macroscopic shape presented agglomerated polymer pieces in suspension, and  in SEM 
visualizations no particles were found because most of them got degraded (Figure 5.8). 
Even though, the remainder particles did not significantly changed its particle size, upon 
6 months at this storage condition (Figure 5.1). Besides of maintained their spherical 
shape at 4ºC and 25ºC / 60% RH after 6 months, insulin-PLGA nanoparticles surface 
was considerable distinct, which revealed the degradation suffered under these storage 
conditions.  In addition, the ability of particles to be more permissive relatively to external 
degradation factors, for instance through nanoparticles pores, may be different under 
these two conditions that might play a different role on the ability of the carrier to protect 
the loaded protein. 
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Figure 5.10. TEM microphotographs of insulin-PLGA nanoparticles formulations at t0, t1, t3 and 
t6, under the storage conditions. Scale bar: 100 nm (t1 25ºC / 60%RH, t6 25ºC / 60%RH); 200 nm 
(t0, t1 40ºC / 75%RH, t3 4ºC, t3 25ºC / 60% RH); 0.5 µm (t1 4ºC, t3 40ºC / 75% RH) and 1 µm (t6 
4ºC, t6 40ºC / 75% RH). 
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Figure 5.11. SEM microphotographs of insulin-PLGA nanoparticle formulations at t0, t1, t3 and t6, 
under the tested storage conditions. No particles found at 40ºC / 75% RH due to degradation 
suffered. Scale bar: 5 µm (t3 4ºC); 30 µm (t1 4ºC, t3 25ºC / 60% RH, t6 4ºC, t6 25ºC / 60% RH); 
100 µm (t1 25ºC / 60% RH) and 500 µm (t0). 
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3.1.2.2.2. Lyophilized nanoparticles 
 
Freeze-dried insulin-PLGA nanoparticles maintained its spherical shape in all 
time points and tested storage conditions except for 40ºC / 75% RH at t6. Particles 
surface was maintained after storage at 4ºC and 25ºC / 60% RH and at the latter 
condition after 6 months the surface seemed to maintain better than insulin-PLGA 
nanoparticles. At 40ºC / 75% RH particles maintained its shape upon 3 months; however 
it was not possible to visualize stable nanoparticles after 6 months storage due to 
surface degradation (Figure 5.8). The TEM and SEM microphotographs of lyophilized 
PLGA nanoparticles at the tested storage conditions at t0, t1, t3 and t6 are shown 
respectively, in figures 5.12 and 5.13. The microscopy findings for these formulations 
showed that the addition of cryoprotectants was necessary to improve nanoparticles 
stability, especially at 40ºC / 75% RH. 
SEM microphotographs of cryoprotectant added formulations, upon 6 months of 
storage are shown in Figure 5.9. Freeze-dried insulin-PLGA nanoparticles + trehalose 
maintained its spherical shape at all the tested storage conditions and time points. At 
40ºC / 75% RH after 6 months particles maintained its shape, showing that the presence 
of the cryoprotectant during lyophilization better stabilized the nanoparticles 
comparatively to lyophilized insulin-PLGA nanoparticles. Particles maintained its surface 
characteristics at all the storage conditions upon 6 months of storage except for 40ºC / 
75% RH at t6, in which particles surface completely changed due to suffered 
degradation.  
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Figure 5.12. TEM microphotographs of freeze-dried insulin-PLGA nanoparticle formulations at t0, 
t1, t3 and t6, under the tested storage conditions. Scale bar: 200 nm, all microphotographs except 
t3 40ºC / 75%RH, t6 25ºC / 60% RH at 100 nm. 
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Figure 5.13. SEM microphotographs of freeze-dried insulin-PLGA nanoparticle formulations at t0, 
t1, t3 and t6, under the tested storage conditions. NA: Not available due to particle degradation. 
Scale bar: 30 µm, all microphotographs except t3 40ºC / 75% RH at 1 µm; t0 at 5 µm; and t1 25ºC 
/ 60% RH, t6 40ºC / 75% RH at 100 µm.  
 
Chapter 5 I A Stability Study Perspective of the Effect of Lyophilization Using Cryoprotectants on 
the Structure of Insulin Loaded Into PLGA Nanoparticles 
  
 
 
115 
 
Lyophilized insulin-PLGA nanoparticles + glucose were stable and maintained 
their shape upon 6 months of storage at 4ºC and 25ºC / 60% RH, but at 40ºC / 75% RH 
after 3 months were degraded and changed into a cubical shape, which was also 
observed at t6. This showed that glucose was not effective to protect the lyophilized 
nanoparticles in such a way that could preserve its stability upon storage at 40ºC / 75% 
RH. After 6 months of storage at 4ºC, the particles surface seem to change more 
significantly than those stored at 25ºC / 60% RH, showing that freeze-dried insulin-PLGA 
nanoparticles + glucose at the latter storage condition remained more stable during that 
period of time. SEM microphotographs also showed that the shape of the particles stored 
at 40ºC / 75% RH was completely different from the particles stored at other conditions. 
Freeze-dried insulin-PLGA nanoparticles + sucrose maintained its spherical 
shape at all the tested storage conditions and time points except at 40ºC / 75% RH in 
which seems to be degraded. SEM microphotographs showed precisely this fact in 
which, comparatively to other storage conditions,  particles surface stored at 40ºC / 75% 
RH after 6 months were completely changed indicating the suffering of degradation upon 
storage (Figure 5.9). It was observed that sucrose was able to preserve particles surface 
after 3 months stored at 40ºC / 75% RH and after 6 months at the other storage 
conditions.  
Regarding freeze-dried insulin-PLGA nanoparticles + fructose, they maintained its 
shape at all the storage conditions and time points except for 4ºC at t6, and its surface 
was also maintained after 6 months at the storage conditions, however for 4ºC at t6 the 
visualized particles did not gave information about the surface. 
Freeze-dried insulin-PLGA nanoparticles + sorbitol maintained its spherical shape 
after 6 months at the storage conditions. Furthermore, the particles surface also 
maintained its characteristics upon storage which indicated that sorbitol was effective on 
protecting particles from degradation upon storage. Indeed, it was also the lyophilized 
formulation that less increased its particle size after 6 months at 25ºC / 60% RH and 
40ºC / 75% RH. The TEM and SEM microphotographs of all the cryoprotectant added 
formulations at the tested storage conditions at t0, t1, t3 and t6 are shown in figures 
5.14-5.23. The visualization of lyophilized nanoparticles by TEM after its resuspension is 
feasible, but difficult to occur by SEM whenever cryoprotectant concentration exceeds 
5%, due to a continuous amorphous matrix embedding the nanoparticles [7, 101, 168]. 
This is mainly due to the ability of cryoprotectants to form hydrogen bonds with the polar 
groups at nanoparticles surface, replacing water as it freezes [7]. This property is 
favorable for nanoparticles protection, but interferes with SEM measurements. It was 
also reported that PVA remained associated with the surface of nanoparticles even after 
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washing, acting as a cryoprotectant by improving nanoparticles freezing resistance and 
stability [236]. 
Considering the overall results it was noticed that insulin-PLGA nanoparticles 
were not stable after storage at 40ºC / 75% RH, and this was mitigated by lyophilization 
of the formulation. Even improving the stability at this condition, it was noticed that the 
addition of cryoprotectants was necessary to improve the stability of particles upon 6 
months of storage. In all the lyophilized formulations it was visualized that particles 
surface changed over time until the 6 months of storage, which is due to the degradation 
suffered upon storage and the hydrolytic action of the residual moisture content in the 
lyophilizate, which may be noticed by the ‘melted’ shape of particles surface. Indeed, 
cryoprotectants are amorphous but tend to crystallize with the increase of the residual 
water content or during heating and storage at high temperatures, becoming a source of 
instability. It was reported that high residual water content may destabilize nanoparticles 
during storage due to cryoprotectant crystallization [140]. The crystallization of 
amorphous sugars occurs when the formulation is hold above its Tg. The containing 
water may induce a shift in the Tg of the formulation to below the storage temperature, 
so a high residual water content may promote the crystallization of the formulation upon 
storage. The rate of crystallization increases with the increase of temperature and RH 
[252]. These changes on nanoparticles surface and stability may affect the stability of the 
loaded protein, since the surface modifications may lead to the open of pathways for 
loaded protein instability. Regarding, all the tested formulation it was the freeze-dried 
insulin-PLGA nanoparticles + sorbitol that seemed to be more stable at all the storage 
conditions upon 6 months of storage. 
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Figure 5.14. TEM microphotographs of freeze-dried insulin-PLGA nanoparticles + trehalose 
formulations at t0, t1, t3 and t6, under the tested storage conditions. Scale bar: 200 nm, all 
microphotographs except t1 25ºC / 60% RH, t3 25ºC / 60% RH at 100 nm; and t3 - 4ºC at 500 
nm. 
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Figure 5.15. SEM microphotographs of freeze-dried insulin-PLGA nanoparticles + trehalose 
formulations at t0, t1, t3 and t6, under the tested storage conditions. Scale bar: 30 µm, all 
microphotographs, except t0, t6 40ºC / 75% RH at 5 µm. 
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Figure 5.16. TEM microphotographs of freeze-dried insulin-PLGA nanoparticles + glucose 
formulations at t0, t1, t3 and t6, under the tested storage conditions. Scale bar: 200 nm, all 
microphotographs except t1 4ºC at 50 nm; t3 4ºC at 100 nm; and t1 25ºC / 60% RH at 0.5 µm. 
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Figure 5.17. SEM microphotographs of freeze-dried insulin-PLGA nanoparticles + glucose 
formulations at t0, t1, t3 and t6 under, the tested storage conditions. NA: Not available due to 
particle degradation. Scale bar: 30 µm, all microphotographs except t0, t3 40ºC / 75% RH, t6 
40ºC / 75% RH at 5 µm; and t1 40ºC / 75% RH at 100 µm.  
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Figure 5.18. TEM microphotographs of freeze-dried insulin-PLGA nanoparticles + sucrose 
formulations at t0, t1, t3 and t6, under the tested storage conditions. Scale bar: 200 nm, all 
microphotographs except t6 4ºC at 100 nm; and t6 40ºC / 75% RH at 1 µm. 
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Figure 5.19. SEM microphotographs of freeze-dried insulin-PLGA nanoparticles + sucrose 
formulations at t0, t1, t3 and t6, under the tested storage conditions. Scale bar: 30 µm, all 
microphotographs except t0, t1 4ºC, t3 25ºC / 60% RH, t3 40ºC / 75% RH at 5 µm. 
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Figure 5.20. TEM microphotographs of freeze-dried insulin-PLGA nanoparticles + fructose 
formulations at t0, t1, t3 and t6, under the tested storage conditions. Scale bar: 200 nm, all 
microphotographs except t3 4ºC at 100 nm; and t3 25ºC / 60% RH at 500 nm. 
 
 
 
 
 
 
Chapter 5 I A Stability Study Perspective of the Effect of Lyophilization Using Cryoprotectants on 
the Structure of Insulin Loaded Into PLGA Nanoparticles 
  
124 
 
 
 
 
Figure 5.21. SEM microphotographs of freeze-dried insulin-PLGA nanoparticles + fructose 
formulations at t0, t1, t3 and t6, under the tested storage conditions. Scale bar: 30 µm, all 
microphotographs except t0, t6 4ºC at 5 µm; and t1 40ºC / 75% RH at 100 µm. 
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Figure 5.22. TEM microphotographs of freeze-dried insulin-PLGA nanoparticles + sorbitol 
formulations at t0, t1, t3 and t6, under the tested storage conditions. Scale bar: 200 nm, all 
microphotographs except t6 4ºC, t6 25ºC / 60% RH at 100 nm; and t3 25ºC / 60% RH at 0.5 µm. 
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Figure 5.23. SEM microphotographs of freeze-dried insulin-PLGA nanoparticles + sorbitol 
formulations at t0, t1, t3 and t6, under the tested storage conditions. Scale bar: 30 µm, all 
microphotographs except t0 at 5 µm. 
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3.2. Insulin secondary structure 
 
FTIR spectroscopy is one of the most useful techniques to assess the secondary 
structure of proteins loaded into nanoparticles in a non-invasive way. The amide I region 
(1710-1590 cm-1) is the most representative region of the spectra to assess insulin 
secondary structure. The higher similarity between the second derivative spectra of 
native and loaded insulin corresponds to the lower protein structural changes. The amide 
I region of spectra can be perfectly used in the experiments because the signal of C=O 
stretching vibrations of PLGA occurs at around 1750 cm-1, so does not interfere with the 
protein IR absorption. 
 
3.2.1. Area of overlap and spectral correlation coefficient 
 
AO values represent the similarity degree of the second derivative spectra of 
native insulin and the insulin loaded into the PLGA nanoparticles. The AO and SCC 
values obtained for the formulations, at the storage conditions over 6 months are shown 
in Figure 5.24. The general average of AO values was 72.8 ± 3.4% whereas for SCC 
was 86.1 ± 4.9%, showing that SCC was in average 13.3 % higher than AO. This 
occurred because SCC values may be overestimated, disagreeing with the visual 
impression of spectral similarity [253]. However, SCC is still a good complementary 
indicator, since the higher SCC values represent minor changes on the band positions. 
Thus, AO represents the quantitative change of insulin secondary structure and SCC 
gives an important information about the changes occurred in the band positions. 
After production, insulin maintained its structure in about 88.1 ± 0.9% which 
means that insulin encapsulation process lead to a structure change of about 11.9%. 
After lyophilization (t0), the AO further significantly decreased, except for fructose added 
formulation, showing that the lyophilization process contributed to the destabilization of 
the loaded protein. Freeze-dried insulin-PLGA nanoparticles presented an AO of 71.1 ± 
0.2%, whereas cryoprotectants obtained in average 78.5 ± 3.4 %, showing that 
cryoprotectant-added formulations presented better protein stabilization after 
lyophilization. Freeze-dried insulin-PLGA nanoparticles + fructose presented the highest 
AO of 81.5 ± 3.8% after lyophilization. Overall, it was found that after lyophilization, 
loaded protein stability was not relevantly different between formulations with collapsed 
and non-collapsed cakes. Similar results were found for lyophilized protein formulations 
in a previous work [254]. 
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Figure 5.24. AO (colored bars) vs SCC (white bars) percentages of insulin-loaded PLGA 
nanoparticle formulations upon 6 months of storage at 4ºC (A), 25ºC / 60% RH (B) and 40ºC / 
75% RH (C). Results are significantly different (p < 0.05) from insulin-PLGA nanoparticles after 
formulation, when marked with 1. When marked with * and #, results are significantly different (p < 
0.05) from the corresponding formulation at t0, and from the corresponding formulation at the 
previous time point, respectively. 
 
3.2.1.1. Insulin-PLGA nanoparticles and freeze-dried insulin-PLGA nanoparticles 
 
Regarding insulin-PLGA nanoparticles it was noticed that after 1 month of storage 
at the storage conditions the AO significantly decreased, probably due to the hydrolytic 
degradation suffered by the polymer and the loaded insulin. Even though, nanoparticles 
were able to protect insulin structure upon 6 months storage, since almost the same 
level of protein structural change was maintained. The AO obtained after 6 months were 
72.2 ± 3.5%, 64.7 ± 0.4% and 71.8 ± 3.5% for 4ºC, 25ºC / 60% RH and 40ºC / 75% RH, 
respectively, which shows the great insulin degradation suffered.  The freeze-dried 
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insulin-PLGA nanoparticles at t0 had an AO of about 71.1 ± 0.2%, which showed that the 
lyophilization process contributed to an additional structural loss of about 17%. However, 
upon 6 months of storage at the storage conditions the same level of insulin structural 
change was maintained. The results obtained for lyophilized insulin-PLGA nanoparticles, 
showed that as expected, lyophilization better stabilized the loaded insulin upon storage 
comparatively to insulin-PLGA nanoparticles. 
 
3.2.1.2. Cryoprotectant added formulations 
 
As mentioned above, the overall cryoprotectant added formulations gave an extra 
protection to insulin structure, however some differences were found at the different 
storage conditions. Freeze-dried insulin-PLGA nanoparticles + trehalose maintained the 
AO level upon 3 months of storage, but it significantly decreased after 6 months to 52.5 ± 
0.7%, 51.9 ± 1.8 and 59.7 ± 14.6 at 4ºC, 25ºC / 60% RH and 40ºC / 75% RH , 
respectively. This showed that trehalose added formulation lost almost half of its native 
structure after 6 months indicating that this cryoprotectant was not effective on the 
stabilization of the formulation. Contrary to trehalose-added formulation, all the other 
cryoprotectant-added formulations that collapsed after lyophilization showed enhanced 
insulin secondary structure stabilization. This occurred because collapsed cakes may 
show increased structural relaxation times, which highly reduced the global molecular 
mobility leading to a better protein stabilization  [255]. A better protein stabilization in 
cakes collapsed after lyophilization was also reported in a previous work [256].  These 
results were in agreement with the obtained SEM microphotograps of the lyophilizates, 
since those structures may enhance the protection of the structure of loaded insulin. 
Besides some of the non-collapsed formulations collapsed upon storage, the 
formulations that collapsed after lyophilization still presented better protein stabilization.  
Freeze-dried insulin-PLGA nanoparticles + glucose presented an AO of 80.8 ± 1.2% at t0 
and did not significantly changed upon 3 months of storage, however this formulation did 
not maintained the protein stability after 6 months storage, decreasing to 65.9 ± 1.5%, 
67.1 ± 0.6 and 73.9 ± 1.1 at 4ºC, 25ºC / 60% RH and 40ºC / 75% RH, respectively. 
Freeze-dried insulin-PLGA nanoparticles + sucrose presented after lyophilization an AO 
of 72.9 ± 4.7%, and no significant changes were found after 6 months at the distinct 
storage conditions, except at 4ºC in which the AO significantly decreased down to 64.1 ± 
2.1%. As mentioned above, for freeze-dried insulin-PLGA nanoparticles + fructose it was 
obtained an AO of 81.5 ± 3.8%, and no significant changes on insulin structure were 
obtained upon 6 months of storage at all the storage conditions. Freeze-dried insulin-
PLGA nanoparticles + sorbitol presented an AO of 79.1 ± 2.5% at t0 and no significant 
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changes were found upon 6 months, being the formulation that presented the highest AO 
values after 6 months of 75.8 ± 4.0%, 80.1 ± 2.1% and 78.0 ± 0.9% at 4ºC, 25ºC/60% 
RH and 40ºC/75% RH, respectively. 
 
3.2.2. Area-normalized second-derivative amide I spectra 
 
The AO and SCC values give information about the quantitative changes of 
insulin structure, whereas the area-normalized second-derivative amide I spectra of the 
formulations shown in Figure 5.25 and 5.26 give information about the qualitative 
changes of protein secondary structure. Figure 5.25 stands for insulin-PLGA 
nanoparticles and lyophilized insulin-PLGA nanoparticles, whereas Figure 5.26 shows 
the results for all the cryoprotectant added formulations. Thus, the shown spectra allow 
the understanding of which modifications occurred in insulin secondary structure. It is 
known that the secondary structure of proteins are distinct in aqueous and lyophilized 
states [257]. Generally, lyophilization causes a decrease in α-helix and increase in β-
sheet content. The latter is due to protein-protein interactions driving to the formation of 
intermolecular β-sheets when water is removed, so β-sheet content does not reflect its 
actual intramolecular structural content. Thus, it is considered that α-helix is the best 
indicator of protein structural integrity [258]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25. Second derivative amide I FTIR spectra of insulin-PLGA nanoparticles and freeze-
dried insulin-PLGA nanoparticles stored over 6 months, at the different storage conditions. NP 
stands for nanoparticles. 
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The second-derivative FTIR spectrum of insulin shows that its secondary 
structure is dominated by α-helix (1655 cm-1), and contains also β-sheets assignments 
from high-frequency (1685 cm-1) and low-frequency (1616 cm-1) [259]. The information 
about the modifications of these bands is crucial because it represent the changes that 
insulin suffered, leading to aggregation or denaturation that besides being therapeutically 
inactive, it may induce toxicity and immunogenicity problems after administration. 
 
3.2.2.1. Insulin-PLGA nanoparticles and freeze-dried insulin-PLGA nanoparticles 
 
In Figure 5.25 it is shown that for insulin-PLGA nanoparticles at t0, the insulin 
structure changed from a α-helix content decrease to a high-frequency β-sheet increase 
and over time at the different storage conditions, the α-helix of insulin shifted into a 
random coil between 1650-1630 cm-1, and this shift was particularly evident at 25ºC / 
60% RH and 40ºC / 75% RH. This showed that insulin loaded into PLGA nanoparticles in 
the suspension form was not stable during storage. For freeze-dried insulin-PLGA 
nanoparticles, the α-helix of insulin shifted into 1660 cm-1 after lyophilization, and besides 
some decrease of content of the α-helix band of the formulation upon storage, at the 
storage conditions it oscillated in the range of 1660-1655 cm-1 which is the characteristic 
α-helix band of insulin. A clear difference was observed at t6 for 40ºC / 75% RH with a 
loss of α-helix content and a random coil band formation at 1630 cm-1. Regarding the 
information given by figure 5.25 it was possible to conclude that as expected, 
lyophilization improved the stability of insulin upon storage since the α-helix band of 
insulin was mainly located in its characteristic region. 
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Figure 5.26. Second-derivative amide I FTIR spectra of freeze-dried insulin-PLGA nanoparticles 
added with cryoprotectants stored over 6 months, at the different storage conditions. 
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3.2.2.2. Cryoprotectant added formulations 
 
In Figure 5.26 it is possible to visualize which kind of structural modifications 
occurred, when insulin-PLGA nanoparticles were lyophilized with the added 
cryoprotectants. It was observed a clear α-helix content loss after lyophilization for 
trehalose, glucose, sucrose and fructose added formulations. For freeze-dried insulin-
PLGA nanoparticles + trehalose, it was noticed that insulin structure changed over time 
and for all the storage conditions at t6, the α-helix content drastically decreased and a 
large β-sheet band was formed at 1688 cm-1, showing that insulin got denatured upon 
storage. In fact, trehalose added formulation it was the one in which insulin structure 
most changed. Trehalose is considered the preferable cryoprotectant due to its absence 
of internal hydrogen bonds allowing more flexible bonds formation with nanoparticles 
during lyophilization, low chemical reactivity and hygroscopicity and higher glass Tg’. 
However, our findings show up that trehalose used in a standard lyophilization cycle was 
not the best cryoprotectant on preserving the stability of insulin.  For freeze-dried insulin-
PLGA nanoparticles + glucose, it was observed that the α-helix band of insulin oscillated 
between 1660-1650 cm-1 and at t6 for 4ºC, a clear random coil band at 1638 cm-1 
occurred. Freeze-dried insulin-PLGA nanoparticles + sucrose was the formulation in 
which α-helix content decreased the most after lyophilization (t0). Even though, the α-
helix band of insulin upon storage, at the different conditions remained at the acceptable 
region of 1660-1650 cm-1. For freeze-dried insulin-PLGA nanoparticles + fructose it was 
noticed a clear modification of insulin structure, over the 6 months at the storage 
conditions, with a loss of α-helix content and a formation of a random coil band at 1639 
cm-1. Regarding the overall results shown in Figure 5.26, it seems that for lyophilized 
insulin-PLGA nanoparticles + sorbitol, insulin secondary structure seemed to not change 
as much as other cryoprotectants. However differences in the α-helix content were still 
noticed. These results indicated that for a standard lyophilization process, sorbitol may 
be considered a good choice, since allowed a better maintenance of insulin structure 
comparatively to the other cryoprotectants over 6 months of storage. It was reported that 
the stereochemical conformation of polyalcohols may be responsible for a modified 
interaction with the frozen mass [167]. Sorbitol was the only cryoprotectant used that 
have tendency to form a different crystal morphology during lyophilization and storage, 
and this fact could benefit the stability of the loaded insulin. 
Besides the effects of the lyophilization process, during storage the acidification 
of the environment around nanoparticles due to the polymer degradation products, lactic 
acid and glycolic acid, and the presence of PLGA carboxylic acid end groups may 
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expose proteins to an acidic environment and induce its degradation and instability or 
even block its release due to the interaction with the positive charges of the remaining 
encapsulated protein [219]. In addition, the use of reducing sugars such as glucose and 
fructose may present a problem as excipients because they are reactive with proteins, 
which may also be an additional problem for protein stability [260]. Even sucrose may be 
hydrolyzed forming glucose and fructose upon lyophilization and storage [256], so the 
use of these kind of cryoprotectants needs to be properly regarded. 
 
3.2.3. Principal component analysis 
 
All the changes in insulin structure after formulation, lyophilization and storage 
may be more intuitively compared by PCA. This technique allows a spatial distribution of 
formulations considering the type of insulin structural changes, and the differences in the 
secondary structure of insulin from obtained FTIR spectra may be more intuitively 
compared by the PCA represented in Figure 5.27.  Considering the PCA shown in Figure 
5.27-A, formulations could be grouped in 3 PCs with 95.55% of the captured total 
variance. The first PC was based on the native-like structure of insulin, which 
represented 84.08% of the dataset variance (Figure 5.27-B). Figure 5.27-A shows that 
the majority of the changes on insulin structure in the formulations and conditions over 6 
months were close to the native like structure. It was for insulin-PLGA nanoparticles at all 
the storage conditions that the overall structural changes most deviated from insulin 
native structure, showing that lyophilization was crucial to preserve insulin structure. In 
addition, freeze-dried insulin-PLGA nanoparticles + trehalose at t6 for all the storage 
conditions was the formulation in which insulin structure mostly changed, showing up 
that this cryoprotectant was not as effective as others to preserve insulin structure upon 
6 months of storage. A significant change on protein structure was also noticed for 
freeze-dried insulin-PLGA nanoparticles + sucrose at t1 and t6 for 25ºC / 60% RH. In 
addition, the changes of insulin structure in freeze-dried insulin-PLGA nanoparticles + 
sorbitol formulations at all the storage conditions seemed to be the closest ones, 
showing up that using this sugar as cryoprotectant helped to mitigate insulin structure 
modifications over storage time. 
To further debrief smaller spectral modifications among formulations, all data set 
was mean-centered and the obtained new PCA shown in Figure 5.27-C explained 
88.35% of the total variance in three PCs, with 47.87% in PC1, 24.52% in PC2 and 
15.96% in PC3. Figure 5.27-D showed that the PCA-loadings were distributed by 
different secondary structure motifs. The overall results showed clearly the modifications 
occurred in insulin structure in all the formulations, showing different small variabilities 
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between samples and even among the same group of formulations. The highest noticed 
structural deviations occurred again for freeze-dried insulin-PLGA nanoparticles + 
trehalose at t6 for all the storage conditions and at t3 for 25ºC / 60% RH. Freeze-dried 
insulin-PLGA NP + fructose at t1 and t3 for 40ºC / 75% RH also presented some 
considerable insulin structural changes. 
 
 
Figure 5.27. PCA from second-derivative amide I spectra of the formulations in three PCs (A), 
and the loadings plot on the first PC (B). PCA scores from mean-centered second-derivative 
amide I spectra (C), and the corresponding loadings plot (D). NP stands for nanoparticles. 
 
4. Conclusion 
 
The instability of insulin-PLGA nanoparticles upon storage was mitigated by 
lyophilization. The further addition of cryoprotectants prior lyophilization improved the 
stability of particles. The morphology of nanoparticles surface changed over time, but 
sorbitol provided better morphological stability at the storage conditions. Indeed, this was 
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the lyophilized formulation that presented less particle size increase supposing less 
aggregation. The lyophilization process contributed to the instability of insulin structure, 
which was attenuated by the addition of cryoprotectants. The formulations that collapsed 
after lyophilization showed enhanced protein stability, and presented the same level of 
insulin structural protection over 6 months. Among the cryoprotectants, sorbitol showed 
the highest insulin structure maintenance after 6 months of storage, and more similar 
structural modifications among all the storage conditions, revealing sorbitol as a versatile 
cryoprotectant.  
In conclusion, it was noticed that the use of a non-optimized lyophilization 
process led to the collapse of some formulations with negative consequences to cake 
resuspension and nanoparticles aggregation over time. However, collapsed formulations 
presented better protein stabilization upon storage. Indeed, cryoprotectants enhanced 
particles stability upon lyophilization, but they presented different performances on the 
stabilization of the loaded protein. Therefore, it is highly recommendable to optimize the 
lyophilization process in order to make an optimal balance between obtaining a good 
cake that is easily resuspendable and avoiding nanoparticles aggregation upon storage, 
and to choose a proper cryoprotectant to achieve the highest stabilization of the protein 
loaded into PLGA nanoparticles.  
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1. Introduction 
 
Despite the benefits of lyophilization, the process itself may affect nanoparticle 
properties, and negatively impact the stability of the loaded protein. Lyoprotectants are 
often used to mitigate nanoparticle instability upon lyophilization, protecting the particles 
from mechanical stress of ice crystals and reduce aggregation by the formation of a 
glassy matrix. Lyoprotectants have been shown to prevent nanoparticle aggregation and 
assure their redispersion after freeze-thawing [261], and also to maintain protein native 
structure upon lyophilization [241, 242]. Two main theories have been suggested to justify 
the positive impact of lyoprotectants as protein formulation stabilizers. The water 
replacement theory states that lyoprotectants may form hydrogen bonds on the surface of 
proteins, and after removal of water during drying, sugars substitute the water molecules 
[170, 171]. The other theory states that proteins are stabilized due to their immobilization 
in a rigid and inert glass matrix formed by lyoprotectants [262, 263]. These principles may 
also be applied to nanoparticle formulations, and it is probably the combination of these 
two mechanisms that impacts the quality of the dried product. Commonly, a significant 
amount of lyoprotectant, often higher than the drug content, is used to preserve the 
structure of the lyophilizate and it is generally accepted that a faster freezing and higher 
lyoprotectant concentration lead to better nanoparticle redispersion properties [139, 140, 
264]. However, the crystallization of lyoprotectants may induce irreversible aggregation 
[265]. 
During the encapsulation process, proteins may change their structure, which is 
potentially detrimental to their bioactivity. This may be caused by exposure to organic 
solvents, dehydration, shearing stress and interaction with hydrophobic interfaces [219]. 
Furthermore, the encapsulation of such hydrophilic molecules into hydrophobic polymeric 
carriers may result into unwanted protein-polymer and protein-protein interactions. Since 
lyoprotectants are usually added to nanoparticles prior to lyophilization, the influence of 
the loading of lyoprotectants together with proteins into nanoparticles may be a strategy to 
explore in order to improve the maintenance of the protein structure and nanoparticle 
characteristics upon lyophilization. 
Thus, the aim of the present study was to assess the influence of the co-
encapsulation of lyoprotectants and a therapeutic protein model, insulin, into PLGA 
nanoparticles, on the protein structural stability upon lyophilization. The effect of both 
reducing and non-reducing sugars was determined. In addition, the nanoparticle 
formulations and their lyophilizates were fully characterized, and their performance as 
drug delivery systems was evaluated in vitro. 
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2. Materials and Methods 
 
2.1. Materials 
 
For the nanoparticle production, PLGA 50:50 Resomer® RG 503 H (Mw 24,000-
38,000; Tg 44-48 ºC) from Evonik Industries AG (Essen, Germany) was used. 
Recombinant human insulin, dichloromethane and PVA were obtained from Sigma-
Aldrich (Steinheim, Germany). Trehalose, glucose, sucrose, fructose and sorbitol were 
also from Sigma-Aldrich (Steinheim, Germany). Trifluoroacetic acid from Acros Organics 
(Morris Plains, NJ, USA) and acetonitrile HPLC Gradient Grade from Fischer Scientific 
(Loughborough, UK) were used for the HPLC analysis. Chloroform from VWR (Soborg, 
Denmark) was used for protein extraction from nanoparticles prior to the CD analysis. 
Milli-Q water was produced in-house and other reagents were of analytical grade. 
 
2.2. Preparation of PLGA nanoparticles 
 
PLGA nanoparticles were produced following a previously developed protocol, 
based on a modified solvent emulsification-evaporation, w/o/w double emulsion technique 
[175]. Briefly, 200 mg of PLGA 50:50 were dissolved in 2 mL of dichloromethane, 0.2 mL 
of a 150 mg/mL insulin solution in HCl 0.1 M was added and then sonicated during 30 
seconds at 70% of amplitude using a Bioblock vibracell 75186 sonicator from Fischer 
Bioblock Scientific (Rungis Complexe, France). This primary emulsion was poured into 25 
mL of PVA 2% (w/v) at pH 7.4 and sonicated using the same previous conditions. Finally, 
the dichloromethane was removed under magnetic stirring for 3 hours. A similar 
encapsulation protocol was used to produce co-encapsulated lyoprotectant formulations, 
by dissolving insulin in a lyoprotectant HCL 0.1 M solution of trehalose, glucose, sucrose, 
fructose and sorbitol at 10 % (w/v). Unloaded nanoparticles were also produced. 
 
2.3. Insulin association efficiency and loading capacity 
 
The AE was calculated using the equation 4.1 (see Chapter 4), and loading 
capacity (LC) was calculated using the following equation: 
             (Eq. 6.1) 
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The insulin present in the supernatant was obtained by centrifugation of formulations, 
using a Beckman Optima TL ultracentrifuge from Beckman Coulter (Brea, CA, U.S.A.) for 
30 minutes at 40,000 x g and 4ºC. The dry mass was obtained after lyophilization of 
hydrated nanoparticles obtained by centrifugation. Insulin in the supernatant was 
quantified by a validated HPLC-UV method [233],  and using a described protocol [175]. 
 
2.4. Freeze-thaw experiments 
 
Freeze-thaw studies were performed in the chamber of a VirTis Advantage Plus 
Benchtop lyophilizer (SP Scientific, Warminster, PA, USA) with the vacuum pump 
switched off, to assess the effect of controlled freezing on the behavior of trehalose, 
glucose, sucrose, fructose and sorbitol at 10% (w/v) as lyoprotectants. Nanoparticles 
without lyoprotectant were used as control sample. The freezing step was performed by 
first cooling 1 mL of each sample from room temperature to 5ºC at a cooling rate of 
5ºC/minute, followed by isothermal incubation for 15 minutes. Then, nanoparticles were 
frozen to -55ºC at a cooling rate of 1ºC/minute and held at this temperature for at least 60 
minutes. In the thawing step, formulations were heated to 5ºC at 1ºC/minute. A set of 
triplicates of each formulation was used in the experiments. 
 
2.5. Lyophilization of PLGA nanoparticles 
 
Nanoparticles were washed three times with Milli-Q water, and the nanoparticles 
were collected after each washing step by centrifugation using a Heraeus Megafuge 1.0 R 
centrifuge (Thermo Scientific, Asheville, NC, USA) for 30 minutes at 23,000 x g. The 
particles were redispersed in water prior to lyophilization. Nanoparticle formulations 
intended to have external lyoprotectant were redispersed in water containing trehalose, 
glucose, sucrose, fructose and sorbitol at a concentration of 10% (w/v). The nanoparticles 
were poured into semi-stoppered glass vials with slotted rubber closures at a maximal 
height of 10 mm. All formulations were lyophilized in a VirTis Advantage Plus Benchtop 
lyophilizer (SP Scientific, Warminster, PA, USA), by freezing at -55ºC for 5 hours, followed 
by a first drying step at -45ºC and pressure of 400 mTorr during 40 hours, followed by a 
secondary drying step at 20ºC and pressure of 200 mTorr during 8 h. 
 
2.6. Residual moisture content 
 
The residual moisture content of the lyophilizates was determined by Karl Fischer 
titration using an 870 KF Titrino plus (Metrohm AG, Herisau, Switzerland). The same 
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amount of powder of each nanoparticle formulation was analyzed after lyophilization. A 
set of triplicates of each formulation were used in the experiment. 
 
2.7. Reconstitution of lyophilizates 
 
After lyophilization, samples were reconstituted by addition of distilled water in the 
inside wall of the vial and maintained during 10 minutes to ensure the cake wetting. 
Samples were then hand swirled to obtain complete homogenization.  
 
2.8. Particle size and zeta potential analyses 
 
Prior to particle size and zeta potential analyses, formulations in suspension and 
after reconstitution were diluted with Milli-Q water to obtain a suitable concentration. The 
mean particle size and zeta potential were analyzed following a described methodology 
[175]. The freeze-thawing ratio was calculated dividing the measured mean particle size 
of nanoparticles after with that before freeze-thawing. The lyophilization ratio was 
determined by dividing the measured mean particle size of nanoparticles after with that 
before lyophilization. A set of triplicates of each formulation was used in the experiments. 
 
2.9. Scanning electron microscopy analysis 
 
The morphology of PLGA nanoparticles was observed by SEM on a Quanta 400 
FEG SEM from FEI (Hillsboro, OR, USA.). Formulations with lyoprotectants were 
resuspended in water and washed by centrifugation for 15 minutes at 23,000 x g and 4 ºC 
to remove the lyoprotectant. Prior to microscopic observation, all samples were mounted 
onto metal stubs and vacuum-coated with a layer of gold/palladium for 60 s using a 15 
mA current. 
 
2.10. X-Ray powder diffraction experiments 
 
The diffractograms were collected using a X-ray powder diffractometer 
PANanalytical X’pert PRO with a PIXcel detector (PANanalytical B.V., Almelo, the 
Netherlands). XRPD patterns were obtained with a Cu Kα radiation (45 kV, 40 mA, λ = 
1.54187 Å), and with a 96-well plate stage in transmission mode from 2-40º2θ with a scan 
speed of 0.067º/s. 
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2.11. Attenuated total reflectance-Fourier transform infrared spectroscopy analysis 
 
The secondary structure of insulin loaded into PLGA nanoparticles was determined 
by ATR-FTIR. The insulin spectra were obtained following a previously described protocol 
[175]. All samples were analyzed and treated in triplicate. 
 
2.11.1. Analysis of spectral similarity 
 
The similarity of the area normalized second-derivative amide I spectra between the 
insulin loaded into PLGA nanoparticles and native insulin (dissolved in 0.1 M HCl), was 
quantitatively determined using the AO algorithm [244]. A 30 mg/mL insulin solution in 
HCl 0.1 M was used as reference, to obtain the spectral similarity to the native protein. 
The latter was used as reference, since it is generally recognized that the stability of a 
solid protein formulation increases with the increase of similarity to the FTIR spectra in 
solution [246]. Insulin lyophilized with and without lyoprotectants was also used as control 
sample in selected cases. 
 
2.12. Circular dichroism analysis 
 
To assess the structure of insulin loaded into the PLGA nanoparticles, insulin was 
extracted prior to CD analysis. Thus, chloroform was used to dissolve the nanoparticles 
polymer and the loaded insulin was redissolved in HCl 0.01 M. The measurements were 
obtained in an Olis DSM-10 CD Spectrophotometer (Olis Inc., Bogart, GA, USA). The CD 
spectra were determined from 250 to 190 nm using a 0.1 cm cell, a step size of 0.5 nm a 
bandwith of 1.5 nm, and an averaging time of 5 seconds. The lamp housing was purged 
with nitrogen and an average of 5 scans was obtained. All spectra were corrected by 
subtraction of the respective reference. The molar ellipticity of insulin was calculated as 
CD signal x MRW (mean residual weight of each insulin residue, 116 Da)[insulin 
concentration (mg/mL x cell pathlength (0.1 cm)]. The concentration of insulin was 
determined by UV absorption at 280 nm in a NanoDrop 2000c UV-Vis spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA), using a molar extinction coefficient of 6200 M-
1cm-1 for 1.0 mg/mL. A set of triplicates of each formulation was used in the experiments. 
An insulin solution at 0.2 mg/mL was used as reference, and samples of reconstituted 
lyophilized insulin containing lyoprotectants were also used as controls. 
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2.13. Insulin in vitro release study 
 
The insulin in vitro release study was performed by dispersion of the lyophilizates 
into 10 mL of pH 7.4 PBS solution, and incubation at 37ºC under magnetic stirring at 100 
rpm. Aliquots were collected at predetermined times of 0.5, 1, 2, 4, 8, 12, 24 and 48 
hours, and replaced with similar volume of fresh medium. The collected samples were 
centrifuged for 30 minutes at 40,000 rpm and 4ºC, and insulin present in the supernatant 
was quantified using the HPLC method described above. A set of triplicates of each 
formulation was used in the experiments. 
 
2.14. Statistical analysis  
 
The statistical analysis was performed using a one-way ANOVA Tukey post hoc test, 
with a significance level of p < 0.05 in the OriginPro 8 software from OriginLab 
Corporation (Northampton, MA, USA). 
 
3. Results and discussion 
 
Insulin was used as a therapeutic protein model, and loaded into PLGA 
nanoparticles following a protocol previously optimized [101] in order to study the stability 
of the protein upon nanoparticle lyophilization. The criteria to choose the used 
lyoprotectants was to have two nonreducing sugars (trehalose and sucrose), two reducing 
sugars (glucose and fructose), and one sugar alcohol (sorbitol). Three different 
approaches were used, namely insulin-loaded PLGA nanoparticles with co-encapsulated 
lyoprotectant, with externally added lyoprotectant, and both with co-encapsulation and 
external addition of lyoprotectant. Therefore, insulin-loaded PLGA nanoparticles were co-
encapsulated with trehalose (insulin-trehalose 10%-PLGA nanoparticles), glucose 
(insulin-glucose 10%-PLGA nanoparticles), sucrose (insulin-sucrose 10%-PLGA 
nanoparticles), fructose (insulin-fructose 10%-PLGA nanoparticles) and sorbitol (insulin-
sorbitol 10%-PLGA nanoparticles) at 10% (w/v), as a function of the final volume of insulin 
solution. The externally added lyoprotectant was also added at 10% (w/v), but as a 
function of the final volume of the formulation. The concentration used in all lyoprotectant 
containing formulations was 10% (w/v) to obtain the highest acceptable lyoprotectant 
effect, since usually the level of lyoprotectant stabilization depends on its concentration 
[7]. To make a direct comparison, the same lyophilization process was used to lyophilize 
all samples. 
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Since in protein formulations, nonreducing sugars are preferable to avoid potential 
Maillard reaction, it was assessed the performance of the different lyoprotectants on the 
protection of the loaded protein, whether they are co-encapsulated or not. To determine 
the feasibility of co-encapsulating lyoprotectants, it was imperative to properly 
characterize the nanoparticles, the obtained lyophilizates, and the structural integrity of 
the loaded protein. 
 
3.1. Particle size, zeta potential, association efficiency and loading capacity 
 
The physical-chemical properties of insulin-loaded PLGA nanoparticles prior to 
lyophilization are depicted in Table 6.1. PLGA nanoparticles loading insulin without co-
encapsulation of lyoprotectant (Insulin-PLGA nanoparticles) presented a mean particle 
size of 333 ± 19 nm and zeta potential of -26.3 ± 0.5 mV. The insulin-loaded PLGA 
nanoparticles with co-encapsulated lyoprotectants, with the exception of glucose, resulted 
in higher particle size (p < 0.05) than insulin-PLGA nanoparticles. Still, mean particle size 
for different formulations was lower than 500 nm. The PdI values were around 0.30. 
 
Table 6.1. Physical-chemical properties and characterization of insulin AE and LC of insulin-loaded 
PLGA nanoparticles with or without co-encapsulated lyoprotectant (n = 3, mean ± SD). Results are 
significantly different (p < 0.05) from insulin-PLGA nanoparticles, when marked with *. 
 
The zeta potential analysis, showed that all nanoparticles presented a negative 
surface charge, which is characteristic of the acidic PLGA polymer [147]. The PLGA 
nanoparticles co-encapsulating lyoprotectants presented even lower zeta potential values, 
around, -35 mV. The zeta potential was significantly lower (p < 0.05) than PLGA 
Formulation 
Diameter 
(nm) 
PdI 
Zeta potential 
(mV) 
AE (%) LC (%) 
Insulin-PLGA nanoparticles 333 ± 19 0.24 ± 0.18 -26.3 ± 0.5 88.2 ± 1.4 12.2 ± 0.1 
Insulin-trehalose 10%-PLGA 
nanoparticles 
418 ± 26* 0.31 ± 0.03 -36.0 ± 0.7* 89.0 ± 1.7 11.2 ± 0.1 
Insulin-glucose 10%-PLGA 
nanoparticles 
386 ± 16 0.33 ± 0.01 -38.2 ± 2.4* 91.1 ± 0.6 11.5 ± 0.1 
Insulin-sucrose 10%-PLGA 
nanoparticles 
424 ± 45* 0.33 ± 0.01 -36.3 ± 1.1* 91.0 ± 2.0 11.1 ± 1.0 
Insulin-fructose 10%-PLGA 
nanoparticles 
466 ± 15* 0.30 ± 0.02 -34.1 ± 1.6* 84.5 ± 2.2 10.1 ± 0.3 
Insulin-sorbitol 10%-PLGA 
nanoparticles 
433 ± 40* 0.31 ± 0.02 -35.2 ± 2.1* 89.8 ± 2.4 10.6 ± 0.2 
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nanoparticles without co-encapsulated lyoprotectant, apparently because of the 
lyoprotectant contained in the nanoparticles. This may be explained by the presence of 
sugars that expand the location of the slipping plane during electrophoretic movement 
due to the formation of a viscous hydration layer on nanoparticles surface [248]. The 
same effect has been observed previously [175]. Thus, the co-encapsulation of 
lyoprotectants may increase the colloidal stability of PLGA nanoparticles, as the more 
negative zeta potential is expected to result in greater particle-particle repulsion. 
The PLGA nanoparticles were also characterized in terms of insulin AE and LC to 
determine their ability to encapsulate the protein (Table 6.1). Insulin-PLGA nanoparticles 
obtained an AE of 88.2 ± 1.4 % and a LC of 12.2 ± 0.1, which are very good 
achievements considering the hydrophobic nature of the polymer and hydrophilic nature 
of insulin. All the other formulations with co-encapsulated lyoprotectants presented similar 
values of AE and a slightly lower LC of insulin, due to the presence of lyoprotectants 
loaded into the nanoparticles. This achievement demonstrates the robustness of the 
production protocol and the ability to co-encapsulate lyoprotectants, without negatively 
affecting insulin AE and LC. 
 
3.2. Freeze-thaw study 
 
The ability of lyoprotectants to avoid the aggregation of PLGA nanoparticles during 
lyophilization, at different lyoprotection levels: co-encapsulated (in), externally added (out) 
or both (in + out); was determined by a freeze-thaw experiment. The freeze-thawing ratio 
was obtained by dividing the mean particle size of nanoparticles after with that before 
freeze-thawing (Table 6.2). Thus, values around 1 represent that the mean particle size of 
nanoparticles was maintained upon freeze-thawing. The freeze-thawing ratio for insulin-
PLGA nanoparticles was 0.87 ± 0.08, and for the PLGA nanoparticles with co-
encapsulated lyoprotectants except fructose (1.28 ± 0.11), the freeze-thawing ratio did not 
show significant (p < 0.05) nanoparticle aggregation, indicating that the nanoparticle 
stability was not significantly affected by freeze-thawing.  
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Table 6.2. Characterization of freeze-thawing ratio, lyophilization ratio and residual moisture 
content of PLGA nanoparticles with different lyoprotection levels (n = 3, mean ± SD). The freeze-
thawing results are significantly different (p < 0.05) from formulation containing no lyoprotectant, 
when marked with *. 
Lyoprotectant 
level (w/v) 
Freeze-thawing 
ratio 
Lyophilization ratio 
Residual 
moisture (%) 
 
No lyoprotectant 
 
0.87 ± 0.08 
 
1.91 ± 0.15 
 
0.98 ± 0.12 
In    
Trehalose 10% 0.94 ± 0.03 0.50 ± 0.07 1.31 ± 0.49 
Glucose 10% 1.19 ± 0.12 0.94 ± 0.09 0.91 ± 0.14 
Sucrose 10% 1.06 ± 0.15 1.26 ± 0.11 1.82 ± 0.61 
Fructose 10% 1.28 ± 0.11* 0.83 ± 0.18 1.74 ± 0.83 
Sorbitol 10% 1.18 ± 0.18 0.36 ± 0.02 1.24 ± 0.59 
Out    
Trehalose 10% 1.07 ± 0.11 0.51 ± 0.07 0.71 ± 0.11 
Glucose 10% 0.95 ± 0.11 1.15 ± 0.13 0.84 ± 0.08 
Sucrose 10% 1.11 ± 0.07 0.66 ± 0.09 0.87 ± 0.23 
Fructose 10% 0.99 ± 0.05 1.29 ± 0.16 1.61 ± 0.47 
Sorbitol 10% 0.91 ± 0.11 1.92 ± 0.22 1.59 ± 0.69 
In + Out    
Trehalose 10% 0.85 ± 0.15 0.43 ± 0.02 0.70 ± 0.15 
Glucose 10% 0.97 ± 0.04 0.72 ± 0.08 0.74 ± 0.10 
Sucrose 10% 1.08 ± 0.03 0.75 ± 0.06 0.88 ± 0.16 
Fructose 10% 1.06 ± 0.09 0.77 ± 0.04 0.80 ± 0.17 
Sorbitol 10% 1.09 ± 0.24 0.56 ± 0.06 1.49 ± 0.29 
 
3.3. Lyophilizate visual inspection and reconstitution 
 
All the lyophilizates were visually inspected. It was expected that the 
lyoprotectants were able to facilitate the reconstitution of the lyophilizate and avoid 
nanoparticle aggregation [178]. The lyophilizates of PLGA nanoparticles with co-
encapsulated lyoprotectants were white with cotton-like texture. For insulin-PLGA 
nanoparticles and all other formulations a slight shrinkage of the cake was observed upon 
lyophilization. Significant collapse of the lyophilizates was not observed, which was a 
good achievement since their collapse may negatively affect the nanoparticle 
redispersion. All the cakes were easy and fast to completely reconstitute obtaining good 
suspensions with no visual aggregates. 
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3.4. Particle size and zeta potential upon lyophilization 
 
Prior to lyophilization, PLGA nanoparticles were centrifuged and washed with Milli-
Q water to remove the surfactant PVA. Additionally, the removal of free drug by 
centrifugation and washing was important since its presence on nanoparticle surface may 
increase the zeta potential near to neutrality, increasing the probability of nanoparticle 
aggregation [7].  
The lyophilization ratio was obtained by dividing the mean particle size of 
nanoparticles after with that before lyophilization. Thus, values around 1 represent that 
the mean particle size of nanoparticles was maintained after lyophilization. Figure 6.1 
shows the characterization of all the PLGA nanoparticles in terms of mean particle size 
and zeta potential after lyophilization. Insulin-PLGA nanoparticles showed an increase 
mean particle size (637 ± 77 nm), resulting in a lyophilization ratio of 1.91 ± 0.15 (Table 
6.2), which shows the high nanoparticle aggregation that may occur upon lyophilization. 
The addition of external lyoprotectants to PLGA nanoparticles resulted in 
nanoparticle stabilization since no significant aggregation was noticed. The exception was 
the addition of external sorbitol that showed not to prevent nanoparticle aggregation, 
presenting a lyophilization ratio of 1.92 ± 0.22. The lyophilization of PLGA nanoparticles 
with co-encapsulated lyoprotectants presented different behaviors. Nanoparticles with 
glucose and fructose presented similar mean particle sizes after lyophilization whereas, 
lyophilization with sucrose showed a slight aggregation with a lyophilization ratio of 1.26 ± 
0.11, and with trehalose and sorbitol a decreased particle size, resulting in a lyophilization 
ratio below 1, 0.50 ± 0.07 and 0.36 ± 0.02, respectively. The formulations containing 
trehalose showed the most similar particle size, obtaining a mean particle size of 206 ± 16 
nm, 169 ± 26 nm and 179 ± 14 nm for co-encapsulated, added and both co-encapsulated 
and added lyoprotectant, respectively. In general, only few samples showed any 
significant aggregation, as determined by the lyophilization ratio, with only the insulin-
PLGA nanoparticles and the formulation with externally added sorbitol showing a ratio 
above 1.3. The formulations with the smallest change in particle size after lyophilization 
were PLGA nanoparticles co-encapsulated or externally added with glucose, obtaining a 
lyophilization ratio of 0.94 ± 0.09 and 1.15 ± 0.13, respectively. With the exception of 
PLGA nanoparticles with the external fructose and sorbitol, the PdI values were below 0.4 
(Table 6.3).  
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Figure 6.1. Mean particle size (top bars) and zeta potential (bottom bars) characterization of 
insulin-loaded PLGA nanoparticles lyophilized with different lyoprotection levels: no lyoprotectant 
(none), co-encapsulated lyoprotectant (In), added lyoprotectant (Out) and both co-encapsulated 
and added lyoprotectant (In + Out) (n = 3). Results are significantly different (p < 0.05) from insulin-
PLGA nanoparticles after production, when marked with *; and significantly different (p < 0.05) 
from lyophilized insulin-PLGA nanoparticles, when marked with #. 
 
After lyophilization and redispersion, the nanoparticles retained its characteristic 
negative surface charge. Insulin-PLGA nanoparticles showed a decreased zeta potential 
of -36.2 ± 2.1 mV. Similar behavior was also observed in previous works using a different 
lyophilization protocol [101, 175], although the cause of the decreased zeta potential 
remains elusive. The PLGA nanoparticles with co-encapsulated lyoprotectants showed 
the most similarity with PLGA nanoparticles containing no lyoprotectant, with -37.9 ± 0.5 
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mV, -42.3 ± 2.5 mV, -37.5 ± 4.6 mV, -38.5 ± 2.7 mV and -39.0 ± 5.5 mV, for trehalose, 
glucose, sucrose, fructose and sorbitol, respectively.  
 
Table 6.3. PdI of insulin-loaded PLGA nanoparticles after lyophilization with different lyoprotection 
levels (n = 3, mean ± SD). 
 
 
 
 
 
 
 
 
 
 
 
 
3.5. Residual moisture content 
 
The residual moisture content was determined for all the lyophilizates, since it is 
an important parameter to assure the long-term stability of PLGA nanoparticles, and the 
maintenance of the structure of the loaded protein [175]. Generally, lyoprotectants are 
amorphous but have a tendency to crystallize with increased residual moisture content, 
which in turn may be a source of nanoparticle instability [140]. Furthermore, the 
adsorption of moisture by lyophilized formulations during storage may decrease their Tg, 
promoting nanoparticle instability and lyophilizate collapse [250]. Generally it is accepted 
that the desired residual moisture content of lyophilizates should be around 1% or even 
less [7]. The residual moisture content of all the formulations is shown in Table 6.2, and 
were observed to be around 1%, indicating that the lyophilization process and particularly 
the secondary drying step was effective in removing water. The low water content is also 
crucial to avoid the hydrolysis of the PLGA matrix, improving the shelf-life of PLGA 
nanoparticles. 
Formulation PdI 
 
No lyoprotectant 
 
0.36 ± 0.03 
In  
Trehalose 10% 0.23 ± 0.09 
Glucose 10% 0.38 ± 0.01 
Sucrose 10% 0.35 ± 0.01 
Fructose 10% 0.39 ± 0.01 
Sorbitol 10% 0.17 ± 0.09 
Out  
Trehalose 10% 0.27 ± 0.08 
Glucose 10% 0.38 ± 0.02 
Sucrose 10% 0.32 ± 0.04 
Fructose 10% 0.73 ± 0.24 
Sorbitol 10% 0.47 ± 0.01 
In + Out  
Trehalose 10% 0.28 ± 0.05 
Glucose 10% 0.37 ± 0.01 
Sucrose 10% 0.36 ± 0.01 
Fructose 10% 0.38 ± 0.01 
Sorbitol 10% 0.35 ± 0.02 
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3.6. Nanoparticle morphology 
 
3.6.1. Before lyophilization 
 
All the samples were visualized by SEM (Figure 6.2). Along with nanoparticles, 
some non-particle shaped material could also be observed. The microphotograph of 
insulin-PLGA nanoparticles shows that nanoparticles presented spherical shape and 
smooth surface, characteristic of the encapsulation methodology. The same nanoparticle 
characteristics were verified when insulin was co-encapsulated with the different 
lyoprotectants. This indicated that the developed production protocol was capable of 
loading lyoprotectants inside nanoparticles without negatively affect their formation. The 
nanoparticle size range shown in all microphotographs was in agreement with the mean 
particle size characterization (section 3.1 of this chapter). 
 
 
Figure 6.2. SEM microphotographs of insulin-loaded PLGA nanoparticles. Scale bar: all 
microphotographs at 3 µm. Np stands for nanoparticles. 
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3.6.2. After lyophilization 
 
After resuspension of the lyophilizates all samples were observed by SEM (Figure 
6.3). The microphotographs showed that insulin-PLGA nanoparticles maintained their 
spherical shape after lyophilization. However, an increased roughness of the nanoparticle 
surface was observed. This was probably due to the removal of water from the 
nanoparticles during the lyophilization process. This surface modification may increase 
the burst release of the loaded drug, which usually is undesirable. The ability of 
lyoprotectants to form hydrogen bonds with polar groups on the nanoparticle surface, 
replacing water as it freezes, may help mitigate nanoparticle roughness [101]. Thus, the 
effect of lyoprotectants on surface features was also tested.  
The PLGA nanoparticles containing external lyoprotectants were washed with 
water before lyophilization, otherwise their visualization by SEM would be difficult when 
the concentration of lyoprotectants exceeds 5%, because of the formation of a continuous 
amorphous matrix embedding the nanoparticles [7, 101]. All the PLGA nanoparticles 
containing lyoprotectants, whether co-encapsulated and/or externally added, generally 
maintained the spherical shape and smooth surface of nanoparticles, showing that 
lyoprotectants and the lyophilization process preserved nanoparticle morphology and 
mitigated nanoparticles roughness. In addition, the particle size visualized in the 
microphotographs of all formulations was in agreement with the results of mean particle 
size (section 3.4 of this chapter). 
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Figure 6. 3. SEM microphotographs of insulin-loaded PLGA nanoparticles, after lyophilization with different lyoprotection levels. Scale bar: all microphotographs 
at 1 µm; except In – trehalose 10%, In - glucose 10%, Out – trehalose 10%, glucose 10%, sucrose 10%, fructose 10% at 3 µm; and no lyoprotectant,  
In – sucrose 10%, fructose 10%, sorbitol 10%, at 5 µm.
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3.7. X-ray powder diffraction analysis 
 
XRPD is a very useful technique to study the crystalline state, and for 
characterization of polymorphs of solid materials such as lyophilizates. It has previously 
been stated that the crystallization of lyoprotectants during freezing, drying or storage 
may destabilize nanoparticles [140]. Nanoparticles and lyoprotectants in the amorphous 
state allow better hydrogen-bonding, which is one of the proposed stabilizing 
mechanisms of lyoprotectants, and thus the crystallization of lyoprotectants may have a 
negative effect on their performance as stabilizers. Therefore, all lyophilizates and 
control samples were analyzed by XRPD, to search for clear peaks in the XRPD 
diffractograms that indicate crystallinity. If no peaks were observed it means that 
formulations remained in the amorphous state. The obtained XRPD patterns are shown 
in Figure 6.4. As control samples, it were used the PLGA polymer and insulin bulk 
materials, lyophilized insulin, and lyophilized insulin added with lyoprotectants (Figure 
6.4-A), and all those controls presented an amorphous state. Patterns indicative of 
amorphous state were also noticed for insulin-PLGA nanoparticles (Figure 6.4-C), and 
the PLGA nanoparticles with co-encapsulated lyoprotectants (Figure 6.4-B). Regarding 
the PLGA nanoparticles with added lyoprotectants prior lyophilization (Figure 6.4-C), the 
formulation with added trehalose remained in the amorphous state, and a few sharp 
peaks were found for the glucose, sucrose and fructose formulations.  In contrast, clear 
evidence of crystallinity was noticed for the PLGA nanoparticles with added sorbitol. 
Considering the nanoparticle formulations with both co-encapsulated and added 
lyoprotectants, those containing trehalose and fructose were in the amorphous state and 
just a few peaks were observed for the sucrose formulation (Figure 6.4-D). A clear 
pattern of crystallinity was found for formulations containing glucose and sorbitol. 
The overall XRPD diffractograms demonstrated that all PLGA nanoparticles with 
co-encapsulated lyoprotectants, yielded amorphous lyophilizates. These results showed 
that the co-encapsulation of lyoprotectants avoided crystallization upon lyophilization. 
The same amorphous state was verified for all the formulations containing trehalose, 
showing its versatility and good performance as lyoprotectant, as reported earlier [166]. 
A clear evidence of lyoprotectant crystallization upon lyophilization was observed for 
PLGA nanoparticles with sorbitol added and for formulations with both co-encapsulated 
and added glucose and sorbitol. The crystallization of sorbitol, is likely related to its 
higher intrinsic propensity to crystallize compared to lyoprotectants such as sucrose or 
fructose. 
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Figure 6.4. XRPD pattern of control samples, namely PLGA and insulin bulk materials, lyophilized 
insulin and lyophilized insulin added with lyoprotectants (A) and insulin-loaded PLGA 
nanoparticles lyophilized with different lyoprotection levels: in (B), out (C) and in and out (D). 
 
3.8. Insulin secondary structure 
 
3.8.1. Fourier transform infrared spectroscopy analysis 
 
FTIR spectroscopy is a very useful technique to noninvasively assess the 
secondary structure of proteins loaded into nanoparticles [85]. To perform this analysis, 
the amide I region (1710-1590 cm-1) is generally used, and the higher the similarity 
between the second derivative spectra of loaded insulin and native insulin, the better the 
maintenance of its secondary structure.  
 
3.8.1.1. Area of overlap 
 
The AO represents the degree of similarity between the area-normalized second-
derivative spectra of native insulin and the insulin loaded into the different formulations. It 
was reported that proteins may lose their stability upon lyophilization potentially because 
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of their adsorption to the liquid/ice interface during the freezing step, which may lead to 
the loss of native conformation due to surface-induced denaturation [204]. The native 
structure of insulin was determined by the analysis of an insulin solution 30 mg/ml, and 
the AO values obtained for all the lyophilized PLGA nanoparticles are shown in Figure 
6.5. The controls of lyophilized insulin and insulin with lyoprotectants at 10% (w/v), 
showed a similar AO around 85%. 
 
 
Figure 6.5. AO percentages of insulin loaded into PLGA nanoparticle formulations after 
lyophilization with different lyoprotection levels (n = 3). Formulations of insulin lyophilized with and 
without lyoprotectants were used as controls. Results are significantly different (p < 0.05) from 
formulation with no lyoprotectant, when marked with *, and from corresponding control formulation 
when marked with #. 
 
Insulin-PLGA nanoparticles (no lyoprotectant, none) obtained an AO of 72.2 ± 
7.5%, and this significant reduction in AO may be caused both by the encapsulation 
process and the lyophilization process. This result clearly indicates the need to use of 
stabilizers to better stabilize insulin structure. Compared to this formulation, all PLGA 
nanoparticles with co-encapsulated lyoprotectants significantly (p < 0.05)  improved the 
stability of the loaded insulin, with AOs of 83.3 ± 0.3%, 85.3 ± 1.0%, 82.4 ± 1.5%, 86.5 ± 
0.8% and 85.3 ± 1.6% for formulations with co-encapsulated trehalose, glucose, 
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sucrose, fructose and sorbitol, respectively. The insulin-loaded PLGA nanoparticles with 
added fructose and sorbitol also showed a significantly better insulin stabilization, 
whereas the other tested formulations showed no statistical improvement of insulin 
stability. The overall results showed that the co-encapsulation of lyoprotectants was a 
useful strategy to better preserve insulin structure.  
Comparing the AO of insulin from all PLGA nanoparticles with the respective 
formulation with added lyoprotectant, which is the most common method to use sugars 
as lyoprotectants, it was observed that formulations co-encapsulated with the tested 
lyoprotectants, except sorbitol, showed an increase of insulin stabilization upon 
lyophilization, since the former showed an AO of 78.3 ± 2.4%, 72.2 ± 3.0%, 65.6 ± 1.8%, 
83.3 ± 1.2% and 83.4 ± 1.8% for trehalose, glucose, sucrose, fructose and sorbitol, 
respectively. The strategy of co-encapsulating lyoprotectants into nanoparticles together 
with the protein also yielded the most similar AO values. These results clearly showed 
that the co-encapsulation of lyoprotectants, offered better insulin stabilization upon 
lyophilization over the conventional method of lyoprotectant addition prior lyophilization. 
This was also evidenced by the similar AO values of PLGA nanoparticles with co-
encapsulated lyoprotectants and the controls of lyophilized insulin, which were about 
84.2 ± 0.2%, 80.7 ± 0.8%, 86.4 ± 0.1%, 83.5 ± 0.1%, 81.7 ± 0.1% and 83.8 ± 0.7% for 
respectively no lyoprotectant, trehalose, glucose, sucrose, fructose and sorbitol 
containing formulations. The AO values obtained by comparing the spectra of the 
lyophilized formulations at the different lyoprotection levels with the respective lyophilized 
insulin controls (with lyoprotectants) (Figure 6.6), showed that PLGA nanoparticles with 
co-encapsulated lyoprotectant were most similar to the insulin controls. Surprisingly, the 
expected superior lyoprotection level by placing the lyoprotectant both inside and outside 
the nanoparticles did not offer higher insulin stability, comparatively to formulations with 
co-encapsulated lyoprotectants. 
Depending on the lyoprotection level, lyoprotectants presented different 
performances; however, formulations containing fructose and sorbitol showed similar 
performances on insulin stabilization for all lyoprotection levels. However, it is likely ill-
advised to use reducing sugars as lyoprotectants in close contact with a protein, as 
these may react with the protein over time forming a covalent sugar adduct (Maillard 
reaction) [260].  
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Figure 6.6. AO percentages of insulin loaded into PLGA nanoparticles formulations after 
lyophilization with different lyoprotection levels (n = 3), comparatively to respective lyophilized 
controls of insulin with and without lyoprotectant.………………………………………………… 
 
3.8.1.2. Visual comparison of area-normalized second-derivative amide I spectra 
 
The AO values represent the quantitative maintenance of the native structure of 
insulin, whereas the visual comparison of the area-normalized second-derivative amide I 
spectra (Figure 6.7), gives information about the qualitative changes of insulin secondary 
structure. It has been described that the secondary structure of proteins is different in 
aqueous and lyophilized state [257]. Usually, the lyophilization process results in an 
increase in the β-sheet content, and a concomitant decrease in α-helix. The increase of 
β-sheet content is mainly due to protein-protein interactions, which drives to the 
formation of intermolecular β-sheets upon water removal, thus the β-sheet content does 
not properly represent protein intramolecular structural content. Therefore, it is accepted 
that the α-helix content is a better indicator of the protein structural integrity [258]. The 
area-normalized second-derivative FTIR spectrum of native insulin (Figure 6.7, insulin 
solution 30 mg/ml) fit well with the known secondary structure that is dominated by α-
helix (1655 cm-1), but also contain β-sheets (bands at 1638 and 1685 cm-1) [259]. 
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Figure 6.7. Area-normalized second-derivative amide I FTIR spectra of insulin loaded into lyophilized PLGA nanoparticles containing no lyoprotectant (A), 
trehalose 10% (B), glucose 10% (C), sucrose 10% (D), fructose 10% (E) and sorbitol 10% (F) at different lyoprotection levels. 
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The changes of these bands upon lyophilization represent the change of insulin 
structure. These changes may ultimately lead to aggregation or denaturation, which 
negatively impacts insulin bioactivity and may potentially cause adverse events upon 
administration.  
It is shown in figure 6.7-A that insulin loaded into insulin-PLGA nanoparticles 
changed its structure upon lyophilization, verified by the decrease and slight shift of α-
helix to 1653 cm-1 and increase of the β-sheet bands, in particular the potential 
intermolecular β-sheet bands at 1700 cm-1 and 1616 cm-1.  These structural changes 
show the necessity to use lyoprotectants to stabilize the protein upon lyophilization. 
Figures 6.7-B to 6.7-F, represent the area-normalized second-derivative spectra of the 
formulations at the different lyoprotection levels. Overall, when compared to the insulin 
solution 30 mg/ml, the controls of insulin lyophilized together with lyoprotectants, with 
exception of sorbitol, showed an increase in α-helix content, with also a band shift for 
formulations containing reducing sugars and sorbitol, showing the proposed stabilizing 
effect of lyoprotectants. Compared to the other trehalose containing formulations, the 
PLGA nanoparticles with co-encapsulated trehalose preserved the insulin structure best, 
with just a slight decrease and shift of α-helix to 1658 cm-1. The other formulations 
containing trehalose showed a decrease and shift of α-helix into 1650 cm-1. Regarding 
the β-sheet content, the formulation with added trehalose just slightly increased its high-
frequency β-sheet, whereas the trehalose- in + out formulation surprisingly showed a 
significant increase in low- and high-frequency β-sheet and a possible intermolecular β-
sheet band formation at 1618/1700 cm-1.  
The FTIR spectra of PLGA nanoparticles containing glucose (Figure 6.7-C) 
showed a similar insulin structure in glucose-in and glucose-in + out formulations with a 
slight decrease in the α-helix and shift to 1658 cm-1. Insulin loaded into glucose-out 
PLGA nanoparticles suffered a higher structural modification with also a decrease and 
shift of α-helix to 1650 cm-1, and an increase of low- and high- frequency β-sheet as well 
as possible intermolecular β-sheet band formation at about 1620/1700 cm-1. The insulin 
loaded into all sucrose containing formulations showed a similar pattern of structure 
modifications, with the characteristic decrease in α-helix content and increase of low- 
and high-frequency β-sheet, and possible intermolecular β-sheet band formation at 
1620/1700 cm-1. However the insulin in sucrose-out and –in + out PLGA nanoparticles 
showed a similar and higher loss of α-helix content, than the sucrose-in formulation. The 
PLGA nanoparticles containing fructose showed most similarity among the different 
lyoprotection levels, which was mostly characterized by a slight decrease of α-helix. 
Finally, insulin loaded into PLGA nanoparticles containing sorbitol also showed a close 
similarity, with the exception of sorbitol-in + out which in addition to the slight decrease of 
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the α-helix content also increased its high-frequency β-sheet and intermoleculat β-sheet 
at 1620/1700 cm-1. 
Thus, the results showed that PLGA nanoparticles with co-encapsulated 
lyoprotectants demonstrated a higher protein structural stabilization than the other 
strategies. No apparent insulin aggregation was found in these formulations, as derived 
from the absence of intermolecular β-sheets bands, whereas in the PLGA nanoparticles 
containing trehalose (in + out), glucose (out), sucrose (out, in + out) and sorbitol (in + 
out) did show such bands. Surprisingly, the combination of lyoprotectant co-
encapsulation and external addition performed worse than the co-encapsulation alone. 
 
3.8.2. Circular dichroism experiments 
 
All samples were analyzed by CD spectroscopy to also assess insulin secondary 
structure and confirm the results obtained by FTIR spectroscopy. In contrast to FTIR, to 
perform CD experiments it was necessary to extract insulin from nanoparticles to avoid 
spectral artifacts due to light scattering, and the obtained results are shown in Figure 6.8. 
The CD spectrum of 0.2 mg/ml insulin solution in HCl 0.01 was used as reference of 
insulin native structure and showed two minima at about 210 nm and 222 nm, which are 
characteristic of a predominant α-helix structure of the protein [266]. 
The insulin CD spectra of the lyophilized PLGA nanoparticles, showed a 
reduction of the α-helix structure of insulin. This was evident by the decrease in the 
intensity and the shift of insulin band from 192 nm to ca. 200 nm, and decrease of the 
bands at 210 nm and 222 nm. The results are then in agreement with the results 
obtained by FTIR, with an overall modification of insulin structure from α-helix, likely into 
β-sheet. The controls of lyophilized insulin containing lyoprotectants also showed 
reductions in α-helix content, as also observed by FTIR. More importantly, CD 
measurements showed that all the PLGA nanoparticles with co-encapsulated 
lyoprotectants better preserved the structure of insulin upon lyophilization, compared to 
the other formulations containing the same lyoprotectant. This was evident by the higher 
similarity CD spectra of those spectra, in particular the CD signals at 210 nm and 222 
nm, with the spectrum of native insulin. Therefore, these results also show that the 
strategy of co-encapsulation of lyoprotectants together with insulin offered superior 
stability of insulin structure upon lyophilization, over the conventional method of 
lyoprotectant addition prior to lyophilization.  
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Figure 6.8. Far-UV CD spectra of insulin loaded into lyophilized PLGA nanoparticles containing no lyoprotectant (A), trehalose (B), glucose (C), sucrose (D), 
fructose (E) and sorbitol (F) at different lyoprotection levels.………………………………………………………………………………………………………….……..
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Such strategy may also be successfully applied in the encapsulation of therapeutic 
proteins into other polymer-based or even lipid-based nanoparticles, such as PLA 
nanoparticles, PCL nanoparticles and solid lipid nanoparticles (SLN), with clear benefits 
to the stabilization of the loaded protein and consequent preservation of its bioactivity 
upon lyophilization.  
 
3.9. In vitro release study 
 
Just a few studies are known about the release profile of drugs by PLGA 
nanoparticles after lyophilization using lyoprotectants [101, 178]. To verify the potential of 
carriers to deliver the loaded drug, it is essential to assess the release profile of insulin 
under simulated in vitro conditions, from the developed PLGA nanoparticle formulations. 
The release patterns of insulin are shown in Figure 6.9. These results were slightly 
different from those obtained in a previous work [101], which could be explained by the 
use of a different lyophilization process that impacts the quality of the final product, and 
consequently the performance of PLGA nanoparticles as delivery systems. 
The insulin-PLGA nanoparticles (no lyoprotectant) showed a release of insulin of 
58.6 ± 4.7% in the first 2 hours, increasing the release up to 76.7 ± 2.7% until 48 h. The 
increase of nanoparticle porosity upon lyophilization is likely responsible for the release 
of more than 50% of insulin in the first 2 h. The formulations with co-encapsulated 
lyoprotectants showed a similar profile, achieving more than 60% of insulin release after 
48 hours (Figure 6.9-A). Trehalose, glucose, sucrose, fructose and sorbitol formulations, 
achieved an insulin release after 48 hours of 82.5 ± 3.47%, 68.6 ± 4.2%, 69.7 ± 4.2%, 
70.5 ± 3.5% and 73.5 ± 2.7%, respectively. The PLGA nanoparticles with added 
lyoprotectants showed a lower release of insulin (ca. 60%) after 48 hours (Figure 6.9-B) 
compared to the insulin-PLGA nanoparticles. This was particularly evident in the lower 
burst release of insulin in the first 2 hours, of 47.0 ± 4.0%, 36.6 ± 2.3%, 34.6 ± 4.4%, 
43.1 ± 3.6% and 48.2 ± 4.0% for those added trehalose, glucose, sucrose, fructose and 
sorbitol, respectively. A similar behavior was also observed for formulations both with co-
encapsulated and added lyoprotectants (Figure 6.9-C). 
The overall formulations revealed a sustained release pattern of insulin, which is 
characteristic of PLGA nanoparticles [145, 147]. This consisted of an initial burst release 
in the first 2 hours followed by a sustained release until 48 h. This initial burst release 
may be explained by the increase of the porosity of the lyophilizates and nanoparticles. 
Indeed, the increase of nanoparticle porosity upon lyophilization facilitates the release of 
insulin, which leads to a higher release rate of insulin upon lyophilization of PLGA 
nanoparticles compared to the same carriers directly after production [101]. Then, after 
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this initial burst release, the erosion of the nanoparticle polymer overtime is responsible 
by the sustained release of insulin until 48 h. 
 
 
Figure 6.9. Cumulative release profile of insulin loaded into PLGA nanoparticles lyophilized with 
different lyoprotection levels: A: in, B: out and C: in + out. (n = 3, vertical lines represent SD). 
 
The possible explanation, for the lower release of insulin from PLGA nanoparticle 
formulations containing lyoprotectants may be due to the presence of sugars that 
increase the osmotic pressure in the aqueous medium, decreasing significantly the burst 
release of insulin. This behavior has been previously described [267]. The increase of 
the osmotic pressure avoids the influx of water from the aqueous medium into the PLGA 
nanoparticles, reducing the formation of water channels which are responsible by the 
initial burst release [268]. Overall, besides the increase in porosity of nanoparticles upon 
lyophilization, the release of insulin could be mitigated by the presence of lyoprotectants 
on nanoparticle formulations. 
 
4. Conclusion 
 
Insulin-loaded PLGA nanoparticles with co-encapsulated lyoprotectants were 
successfully produced, and likely would have an improved colloidal stability. No 
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significant aggregation of PLGA nanoparticles was observed, indicating the suitability of 
the lyophilization process. The formulations with co-encapsulated lyoprotectants 
obtained a good lyophilizate with white cotton-like texture, whereas in the remainder 
formulations the lyophilizate slightly shrunk.  The lyophilizate of PLGA nanoparticles with 
co-encapsulated lyoprotectants were amorphous, whereas formulations at the other 
tested lyoprotection levels presented some crystallinity. Those containing trehalose 
were, however, amorphous, revealing its versatility compared to the other lyoprotectants.  
Regarding the stability of the loaded insulin, it was demonstrated that the co-
encapsulation of lyoprotectants offered superior insulin stability compared to the 
conventional lyoprotectant addition method. In addition, these formulations showed the 
most similar structure maintenance among the lyoprotection levels. The simultaneous 
co-encapsulation and addition of lyoprotectant to the external phase could even be 
detrimental to insulin stabilization. Furthermore, the reducing sugars did not show an 
adverse effect on insulin stability, when they were co-encapsulated. The PLGA 
nanoparticles with added lyoprotectants showed a lower in vitro release of insulin, 
compared to formulations co-encapsulated with the same lyoprotectants. 
In summary, the co-encapsulation of lyoprotectants together with insulin is a 
promising approach to better stabilize the protein upon lyophilization. At the same time 
this strategy uses much lower amount of lyoprotectant in formulations and improves the 
overall stability of insulin-loaded PLGA nanoparticles. Therefore, the findings achieved in 
this chapter may represent an impulse in the development of a new paradigm in the 
lyophilization of protein-loaded nanoparticles. 
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1. Introduction 
 
The freezing step is considered the most determinant for product quality, since it 
impacts the type and size of ice crystals, influencing the water vapor flow during the 
drying steps, with obvious consequences to the final lyophilized product. The exact 
mechanism behind freezing during lyophilization is not well understood yet.  Apparently, 
during freezing, ice crystals grow and nucleate, excluding the solutes in formulation into 
a cryoconcentrated phase in which a phase separation or even crystallization may occur 
[184]. The freezing step is also the most aggressive stage of the lyophilization process, 
leading to possible aggregation or even fusion of nanoparticles. Therefore, 
cryoprotectants are frequently added to formulations to protect nanoparticles from 
lyophilization stresses. 
Different freezing methods may be used to obtain different freezing rates, as the 
shelf-ramped freezing [269] and the quench freezing using liquid nitrogen [184, 270]. 
Regardless the freezing method, the freezing step needs to occur at a temperature 
below the Tg’ to guarantee the total solidification and, consequently, an acceptable 
lyophilized product. On its turn, the primary drying needs to occur below the Tc of the 
formulation, otherwise the obtained cake can collapse, which may lead to an inefficient 
water removal causing high residual moisture content and difficulty on redispersion of the 
lyophilizate [168, 204]. The optimization of the lyophilization cycle considering these 
critical temperatures is often neglected, and lyophilization is even used to dehydrate 
nanoparticle suspensions in a standard, empiric or even trial and error manner [7]. 
Previously, it was evaluated  the influence of a standard lyophilization cycle using 
different cryoprotectants on the structure of a protein loaded into PLGA nanoparticles, 
and its stability upon 6 months of storage [175]. More recently, it was verified that the co-
encapsulation of cryoprotectants improved the stability of protein-loaded PLGA 
nanoparticles after lyophilization [227]. In the present chapter, these approaches were 
taken further by assessing the influence of the freezing step, which is the most important 
one in lyophilization, on the structural stability of protein loaded into PLGA nanoparticles 
co-encapsulated with cryoprotectants, upon lyophilization using an optimized cycle. 
Thus, the purpose of this chapter was to develop an optimized lyophilization cycle 
regarding the physical-chemical properties of the nanoparticles containing, insulin as a 
model therapeutic protein, and assess the effect of the freezing step in the structural 
stability of the encapsulated protein. In addition, it was determined the performance of 
several cryoprotectants in the preservation of insulin structure using different freezing 
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methods. Ultimately, the structural stability of the protein and consequent performance in 
vivo was also evaluated. 
 
2.  Materials and Methods 
 
2.1. Materials 
 
For the nanoparticles production it was used PLGA 50:50 Resomer® RG 503 H 
(Mw 24,000-38,000; Tg 44-48 ºC) from Evonik Industries AG (Essen, Germany). PVA, 
dichloromethane, recombinant human insulin, trehalose, sucrose, sorbitol and thioflavin 
T were from Sigma-Aldrich (Steinheim, Germany). For the HPLC analysis, it was used 
acetonitrile HPLC Gradient Grade from Fischer Scientific (Loughborough, UK) and 
trifluoroacetic acid from Acros Organics (Morris Plains, NJ, USA). Chloroform from 
Sigma-Aldrich (Steinheim, Germany) was used for protein extraction from nanoparticles. 
Streptozotocin used in the in vivo experiments was also from Sigma-Aldrich (Steinheim, 
Germany) and sodium citrate was from Merck KGaA (Darmstadt, Germany). The Milli-Q 
water was produced in-house and other reagents were of analytical grade. 
 
2.2. Preparation of PLGA nanoparticles 
 
The PLGA nanoparticles were produced by a modified solvent emulsification-
evaporation, w/o/w double emulsion technique, which protocol was previously developed 
and optimized to co-encapsulate insulin and cryoprotectants into PLGA nanoparticles 
[227].  Briefly, 2 mL of dichloromethane were used to dissolve 200 mg of PLGA 50:50, 
and then added with 0.2 mL of a 150 mg/mL insulin solution in HCl 0.1 M containing also 
the different cryoprotectants used (trehalose, sucrose or sorbitol) at a concentration of 
10% (w/v). This mixture was sonicated at 70% of amplitude for 30 seconds using a 
Bioblock vibracell 75186 sonicator from Fischer Bioblock Scientific (Rungis Complexe, 
France), forming the primary emulsion. The latter was then poured into 25 mL of PVA 
2% (w/v) at pH 7.4, and again sonicated using the same previous conditions. Then, the 
organic solvent was removed by evaporation under magnetic stirring for 3 h. The same 
production method was also used to formulate both insulin loaded and unloaded PLGA 
nanoparticles to be used as controls. After production, nanoparticles were washed three 
times with Milli-Q water, and collected after each washing step by centrifugation for 30 
minutes at 23,000 x g using a Heraeus Megafuge 1.0 R centrifuge (Thermo Scientific, 
Asheville, NC, USA). Finally, nanoparticles were redispersed in water. 
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2.3. Insulin association efficiency, loading capacity and retention efficiency 
 
The AE was calculated using the equation 4.1 (see Chapter 4) and LC of insulin 
was calculated using equation 6.1 (see Chapter 6). The free insulin in supernatant was 
obtained by centrifugation of nanoparticles suspension at 40,000 x g at 4ºC for 30 min, in 
a Beckman Optima TL ultracentrifuge from Beckman Coulter (Brea, CA, U.S.A.). The dry 
mass of nanoparticles was obtained by lyophilization of nanoparticles after 
centrifugation. The insulin retention efficiency was determined by the amount of insulin 
which remained loaded after lyophilization, and was determined after reconstitution of 
nanoparticles and quantification of insulin present in supernatant after nanoparticle 
centrifugation. Insulin was quantified using a HPLC-UV method previously validated 
[233], in a Merck-Hitachi LaChrom HPLC instrument equipped with a LiChrospher 100 
RP-18 guard column, 5 μm particle size from Merck (Whitehouse Station, NJ, U.S.A.) 
and also a XTerra RP 18 column, 5 μm particle size, 4.6 mm internal diameter x 250 mm 
length from Waters (Milford, MA, U.S.A.). All the obtained samples were run in triplicate. 
 
2.4. Particle size and zeta potential analyses 
 
The insulin-loaded PLGA nanoparticles in suspension and reconstituted after 
lyophilization were diluted with Milli-Q water to obtain a proper concentration, prior to the 
analysis of particle size and zeta potential. These analysis were respectively, performed 
by dynamic light scattering using a 90Plus Particle Size Analyser, and by phase analysis 
light scattering using a ZetaPALS Zeta Potential Analyser, both from Brookhaven 
Instruments Corporation (Holstville, NY, USA). The lyophilization ratio was calculated as 
the mean particle size after lyophilization, divided by the mean particle size before 
lyophilization.  
 
2.5. Differential scanning calorimetry analysis 
 
The thermal behavior of insulin-loaded PLGA nanoparticles during freezing was 
assessed using a Setaram DSC 131 from SETARAM instrumentation (Caluire, France) 
device equipped with a liquid nitrogen cooling system. 40 µL of each sample were placed 
into aluminum pans and frozen until -90ºC at a freezing rate of 5ºC/min.  Then, samples 
were heated up at a rate of 1ºC/min and Tg’ was obtained by the onset of the transition. 
An empty aluminum pan was used as reference. 
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2.6. Lyophilization microscopy 
 
The Tc of each formulation was determined using a Linkam THMS350V 
lyophilization plate from Linkam Scientific Instruments (Tadworth, UK) assembled to an 
Olympus microscope (Osaka, Japan). Thus, samples were frozen at a rate of 10 ºC/min 
until -100 ºC, then held for 15 min and heated under vacuum at a rate of 5ºC/min. The Tc 
was obtained by the onset of product collapse during the drying of the frozen sample. 
 
2.7. Lyophilization of nanoparticles 
 
The insulin-loaded PLGA nanoparticles were placed into semi-stoppered glass 
vials, with slotted rubber closures at a maximal height of 10 mm. Three freezing 
conditions and temperatures were used, namely freezing samples at -80ºC in a freezer, 
freezing inside the lyophilizer chamber at -40ºC, and freezing in liquid nitrogen. The 
different freezing methods occurred during 4 hours, and all samples were dried following 
the same protocol in a VirTis Advantage Plus Benchtop lyophilizer from (SP Scientific 
(Warminster, PA, USA) at a condenser surface temperature of -60ºC. The primary drying 
occurred at -32ºC and 150 mtorr for 24 hours, followed by a secondary drying at 20ºC 
and 50 mtorr for 6 h (n = 3). 
 
2.8. Macroscopic evaluation and residual moisture content of the lyophilizates 
 
The lyophilizates were visually inspected to detect any shrinkage or collapse of 
the cake after lyophilization. The residual moisture content of the lyophilizates of insulin-
loaded PLGA nanoparticles was determined using an A&D MX-50 moisture analyzer 
from A&D Company Ltd. (Tokyo, Japan). An equal amount of lyophilizate of each 
formulation was analysed, and the residual moisture content was quantified as 
percentage of containing moisture. 
 
2.9. Reconstitution of lyophilizates 
 
After lyophilization, all the samples were reconstituted by adding Milli-Q water on 
the inside wall of the vials and kept for 10 min, in order to assure the wetting of the cake. 
Then, samples were hand swirled until complete homogenization. 
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2.10. Scanning electron microscopy analysis 
 
The morphology of insulin-loaded PLGA nanoparticles and the lyophilizates were 
observed by SEM using a FEI Quanta 400 FEG scanning electron microscope from FEI 
(Hillsboro, OR, USA). All the samples were mounted on metal stubs and coated under 
vacuum, with a layer of gold/palladium at a 15 mA current for 60 seconds prior to 
observation. 
 
2.11. X-Ray powder diffraction analysis 
 
The diffractograms of all formulations were obtained on a X-ray powder 
diffractometer PANanalytical X’pert PRO with a PIXcel detector (PANanalytical B. V., 
Almelo, Netherlands). The XRPD patterns were collected with a Cu Kα radiation (45 kV, 
40 mA, λ = 1.54187 Å), and with a 96-well plate stage in transmission mode from 2-40º 
at 2θ with a scan speed of 0.067º/s. 
 
2.12. Attenuated total reflectance-Fourier transform infrared spectroscopy 
analysis 
 
ATR-FTIR was used to assess the secondary structure of insulin loaded into 
PLGA nanoparticles. The formulations were run on an ABB MB3000 FTIR spectrometer 
from ABB (Zurich, Switzerland) equipped with a MIRacle triple reflection ATR accessory 
from PIKE Technologies (Madison, WI, USA).  The FTIR spectra were collected by 256 
scans at a 4 cm−1 resolution in the 4000−600 cm−1 region. The insulin spectra were 
obtained by a double subtraction method [243], followed by a Savitzky-Golay second 
derivative of 15 points, and a 3-4 point baseline correction in the amide I region 
(1710−1590 cm-1). Further, all the spectra were area-normalized for comparison. The 
spectral treatment was performed using the Horizon MB FTIR software from ABB. The 
similarity of the area normalized second-derivative amide I spectra, between native 
insulin and insulin loaded into PLGA nanoparticles was determined quantitatively, using 
the AO algorithm [244]. Therefore, it was used a 30 mg/mL insulin solution in HCl 0.1 M, 
to determine the percentage of spectral similarity. This solution was used as reference of 
native insulin, since it is considered that the stability of a solid protein formulation 
increases with the increase of the similarity to its spectra in solution [246]. 
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2.13. Circular dichroism analysis 
 
To assess the structure of insulin by CD, the protein was extracted from the 
PLGA nanoparticles by a treatment using a mixture of chloroform, to destroy the 
nanoparticles by dissolving the PLGA, and HCl 0.01 M to dissolve the extracted insulin. 
Then, all measurements were collected in a Jasco J-815 CD Spectrometer from Jasco 
Inc. (Easton, MD, USA) with the lamp housing continuously purged with nitrogen and at 
25ºC. The CD spectra were obtained from an average of 5 scans in the 190-250 nm 
region, using a 0.1 cm cell, and with a step size of 0.5 nm, a bandwith of 1.5 nm, and an 
averaging time of 5 s. The reference sample spectrum was subtracted from the test 
sample spectra. The molar ellipticity of insulin was calculated as CD signal x MRW of 
each insulin residue (116 Da) [insulin concentration (mg/mL) x cell pathlength (0.1 cm)]. 
The concentration of insulin was determined by UV absorption at 280 nm in a NanoDrop 
2000c UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE, USA), using a 
molar extinction coefficient of 6200 M-1cm-1 for 1.0 mg/mL. As control sample of native 
insulin it was used a 0.2 mg/mL insulin solution in HCl 0.01 M. 
 
2.14. Fluorescence spectroscopy analysis 
 
Insulin-loaded PLGA nanoparticles were treated with chloroform and insulin was 
extracted prior to fluorescence spectroscopy analysis. The fluorescence emission 
spectra were obtained in a range of 290 to 450 nm with a 1 nm step in a Jasco FP-6500 
Spectrofluorometer from Jasco Inc. (Easton, MD, USA) at 25ºC. The excitation occurred 
at 280 nm with excitation and emission slits set to 3 nm, an integration time per data 
point of 0.1 seconds and with 5 scans average. The reference sample spectrum was 
subtracted from the test sample spectra, and normalized based on insulin concentration. 
 
2.15. Thioflavin T assay 
 
The experiments were run in a Jasco FP-6500 Spectrofluorometer from Jasco 
Inc. (Easton, MD, USA) at 25ºC and the final concentration of insulin and thioflavin T 
were 11 µM and 25 µM, respectively.  The samples of insulin extracted from 
nanoparticles were excited at 450 nm, and the fluorescence intensity was measured at 
485 nm with slit widths of 5 nm. The reference sample spectrum was subtracted from the 
test sample spectra. Insulin fibrillated by incubation at 60ºC during 12 hours was used as 
a positive control. 
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2.16. In vivo activity analysis of insulin-loaded formulations 
 
2.16.1. Animals 
 
The animals were male Wistar Han rats (150-174 g) obtained from Harlan 
Laboratories (Sant Feliu de Codines, Spain), and were maintained for 7 days for 
nutritional, physiological and behavioral stabilization. They were kept accordingly to the 
recommendations of Federation of Laboratory Animal Science Associations (FELASA), 
and also to the European Parliament and Council Directive 2010/63/EU. A standard diet 
food from Mucedola srl (Settimo Milanese, Italy) and water ad libitum were given to 
animals. The floor of the cages were filled with Corn Cob ULTRA12 bedding from 
Ultragene (Santa Comba Dão, Portugal), and enriched with nesting materials. The room 
conditions were kept at 22ºC ± 2ºC, 55% ± 10% RH and 12/12 light exposition. Upon 
quarantine, the diabetes was induced to animals by intraperitoneal injection of 
streptozotocin with a concentration of 10 mg/mL in citrate buffer pH 4.5 at a dose of 60 
mg/kg. After a week, the animals that presented fasted blood glucose levels higher than 
250 mg/dL were grouped (n = 5) and used in the in vivo experiment. 
 
2.16.2. In vivo pharmacological activity of insulin 
 
The animals were fasted 12 hours before and during the experiment, but were 
allowed water ad libitum. The formulations were administered subcutaneously using a 25 
G needle at a dose of 50 IU/kg bodyweight.  An insulin solution in PBS at 2.5 IU/kg 
bodyweight administered subcutaneously was used as control. The blood samples were 
taken from the tail vein at 0.5, 1, 2, 4, 6, 8, 12 and 24 h and the plasma glucose levels 
were obtained using test strips from Abbot Laboratories (Amadora, Portugal) in a 
Precision Xtra blood glucose meter from the same supplier. In order to evaluate the 
cumulative hypoglycemic effect over time, the plasma glucose levels were plotted 
against time, as percentage of values at the beginning of the experiment. The PA of the 
formulations was determined using the equation: 
 
                (Eq. 7.1) 
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The area above the curve (AAC) test and control refers to the AAC of subcutaneous 
formulations and subcutaneous insulin solution in PBS (2.5 IU/kg bodyweight), 
respectively. Simultaneously, the dose test and control refers to the insulin dose at IU/kg 
bodyweight of subcutaneous formulations and subcutaneous insulin solution, 
respectively. 
 
2.17. Statistical analysis 
 
All the statistical analyses were performed using a one-way ANOVA Tukey post 
hoc test, with a significance level of p < 0.05 in the OriginPro 8 software from OriginLab 
Corporation (Northampton, MA, USA). 
 
3. Results and discussion 
 
The therapeutic protein model, insulin, was loaded into PLGA nanoparticles 
following a protocol previously developed [101]. The strategy of co-encapsulation of 
cryoprotectants together with insulin into PLGA nanoparticles showed to better protect 
the protein structure upon lyophilization, comparatively to the conventional 
cryoprotectant addition method immediately prior to lyophilization [227]. Therefore, this 
approach was used to study the effect of the freezing step of lyophilization in the 
structure of the loaded insulin. 
The freezing step is the one that most influences the properties of the final 
product [184], nevertheless its impact in the structure of the loaded protein was not 
investigated so far. In the present study, several cryoprotectants were used, namely, two 
nonreducing sugars, trehalose and sucrose, and one sugar alcohol, sorbitol. The 
concentration of cryoprotectants used in formulations was 10% (w/v) to obtain the 
highest acceptable cryoprotectant effect, since its level of formulation stabilization 
depends on its concentration [7]. To assess the effect of the freezing step, additionally to 
the characterization of insulin structure, it was also characterized the properties of 
nanoparticles, the obtained lyophilizates and, likewise, the in vivo therapeutic 
performance of formulations. 
 
3.1. Particle size, zeta potential, association efficiency and loading capacity 
 
It was produced insulin-loaded PLGA nanoparticles containing no cryoprotectant 
(insulin-PLGA nanoparticles) and also co-encapsulated with trehalose (insulin-trehalose 
10%-PLGA nanoparticles), sucrose (insulin-sucrose 10%-PLGA nanoparticles) and 
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sorbitol (insulin-sorbitol 10%-PLGA nanoparticles). The mean particle size, PdI and zeta 
potential characterizations of insulin-loaded PLGA nanoparticles are depicted in Figure 
7.1. Insulin-PLGA nanoparticles, without any cryoprotectant,  presented a particle size of 
339 ± 10 nm, in agreement with that obtained in a previous work [227]. The insulin-
loaded PLGA nanoparticles co-encapsulated with cryoprotectants ranged between 243 
nm and 394 nm. On its turn the PdI of such formulations ranged between 0.17 and 0.25, 
which shows the low heterogeneity of nanoparticles.  
 
 
Figure 7.1. Mean particle size (top bars), PdI, and zeta potential (bottom bars) characterization of 
insulin-loaded PLGA nanoparticles (n = 3, mean ± SD). 
 
All insulin-loaded PLGA nanoparticles had a negative surface charge, 
characteristic of the acidic PLGA polymer [147]. The insulin-loaded PLGA nanoparticles 
containing co-encapsulated cryoprotectants presented lower zeta potential, 
comparatively to the formulation without co-encapsulated cryoprotectant. These results 
were similar with those obtained previously [227], and may be explained by the presence 
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of cryoprotectants able to expand the location of the slipping plane during the 
electrophoretic movement, due to the formation of a viscous layer on the surface of 
nanoparticles [248]. Therefore, the co-encapsulation of cryoprotectants may increase the 
colloidal stability of the nanoparticles, since the more negative zeta potential results in 
greater particle-particle repulsion. 
The insulin-loaded PLGA nanoparticles were further characterized in terms of 
insulin AE and LC (Table 7.1). The insulin AE of formulations was higher than 90%, a 
very good achievement considering the hydrophilic nature of insulin and hydrophobic 
nature of the PLGA polymer. Regarding the insulin LC it was noticed a slight decrease 
for insulin-loaded PLGA nanoparticles co-encapsulated with cryoprotectants, due to the 
presence of cryoprotectants loaded into nanoparticles. Both AE and LC were in 
agreement with those obtained previously [227], demonstrating the robustness of the 
production protocol and its ability to load insulin together with cryoprotectants, without 
prejudice the encapsulation of the protein. 
 
Table 7.1. Characterization of insulin AE and LC of insulin-loaded PLGA nanoparticles (n = 3, 
mean ± SD). 
 
 
 
 
 
 
 
3.2. Design of the lyophilization cycle 
 
To obtain a lyophilized product with high quality, it is necessary to focus both in 
the formulation and in the lyophilization cycle. Most of the research works on the 
lyophilization of nanoparticles have been done following trial and error observations, 
without considering the scientific principles of such process. Thus, the lyophilization 
cycle needs to be developed following engineering and physical-chemical principles of 
nanoparticles, in order to preserve its characteristics and obtain a good lyophilizate [7, 
140, 153].  
The critical properties of formulations, necessary to design an adequate 
lyophilization process are the Tg’ and the Tc. Thus, nanoparticles need to be cooled 
below its Tg’ to assure the total solidification of the formulation [163], and the Tc is the 
maximum allowable temperature of product during the primary drying [193].  If product is 
Formulation AE (%) LC (%) 
 
Insulin-PLGA nanoparticles 
 
94.1 ± 0.3 
 
12.5 ± 0.5 
Insulin-trehalose 10%-PLGA nanoparticles 90.2 ± 0.4 11.4 ± 0.4 
Insulin-sucrose 10%-PLGA nanoparticles 90.7 ± 0.5 11.7 ± 0.3 
Insulin-sorbitol 10%-PLGA nanoparticles 93.7 ± 0.3 11.9 ± 0.4 
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heated above Tc, the lyophilized product may collapse losing its macroscopic structure 
[195]. The obtained Tg’ and Tc results of the produced formulations are depicted in 
Table 7.2, and it was noticed a decrease on those parameters when cryoprotectants 
were co-encapsulated. It has been reported that when cryoprotectants are added to 
nanoparticle formulations, the success of the lyophilization cycle depends just on the 
thermal properties of the cryoprotectants [153]. However, with the approach of co-
encapsulating the cryoprotectant the success of the lyophilization cycle relies on the 
thermal properties of the formulation as a whole. Focusing in the Tg’ and Tc results, it 
were designed three different lyophilization cycles. The used temperatures of the 
freezing and primary drying steps were defined considering the lower Tg’ and Tc values 
obtained, since the formulations were lyophilized together in the different lyophilization 
cycles. The variation in the freezing step was performed to assess the contribution of 
different freezing methods in lyophilization, to the maintenance of the structure of insulin 
loaded into PLGA nanoparticles with and without cryoprotectants co-encapsulated. 
Besides being simple, the freezing step is the one in which most of the water is 
removed, and being the first step, its effectiveness determines the success of the 
lyophilization cycle [184]. Therefore, the freezing step needs to be properly regarded, 
and it is important to distinguish between cooling rate and freezing rate, since they may 
not be necessarily related. The first is related with the rate that a formulation is cooled, 
whereas the freezing rate is the rate of postnucleation growth of ice crystals that is 
influenced by the supercooling amount prior to nucleation [270, 271]. Both cooling and 
freezing rates are influenced by the freezing method, such as the freezing at -80ºC, 
freezing inside the lyophilizer (ramped cooling) or freezing in liquid nitrogen. These 
different freezing methods, result in different ice crystals growth regarding its size, shape 
and number, and consequently result into different stresses to nanoparticles. 
Furthermore, the morphology of ice crystals is strictly related with the sublimation rate 
[185]. 
 
Table 7.2. Tg’ and Tc of insulin-loaded PLGA nanoparticles. 
 
 
 
 
 
 
 
 
Formulation Tg’ (°C) Tc (°C) 
Insulin-PLGA nanoparticles -25.0 -23.2 
Insulin-trehalose 10%-PLGA nanoparticles -27.3 -25.7 
Insulin-sucrose 10%-PLGA nanoparticles -29.1 -27.8 
Insulin-sorbitol 10%-PLGA nanoparticles -31.3 -29.3 
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3.3. Lyophilizate visual inspection, reconstitution and residual moisture content 
 
The freezing method decisively influences the characteristics of the lyophilized 
product such as its morphology, physical state, uniformity, reconstitution time, and 
residual moisture content. The lyophilizates obtained from the different lyophilization 
cycles were visually inspected, and all of them were white with cotton-like texture, and 
were occupying the same volume of the original frozen mass, without shrinkage or cake 
collapse, indicating that the used lyophilization cycles were properly optimized. The 
cakes of all the insulin-loaded PLGA nanoparticles were easy and fast to completely 
reconstitute obtaining good suspensions with no visual aggregates. The product collapse 
is a problem to avoid, since leads to high residual moisture content and large 
reconstitution times of nanoparticles, due to the absence of a porous structure [168, 173, 
194]. 
 
Table 7.3. Lyophilization ratio, insulin retention efficiency and residual moisture content of insulin-
loaded PLGA nanoparticles after lyophilization at different freezing conditions (n = 3, mean ± SD). 
 
Formulation 
Lyophilization 
ratio 
Insulin 
retention 
efficiency (%) 
Residual 
moisture 
content (%) 
 
-80 °C    
Insulin-PLGA nanoparticles 1.07 ± 0.10 97.7 ± 0.8 1.27 ± 0.28 
Insulin-trehalose 10%-PLGA nanoparticles 1.09 ± 0.19 98.2 ± 1.2 1.35 ± 0.32 
Insulin-sucrose 10%-PLGA nanoparticles 1.11 ± 0.35 97.1 ± 1.5 1.28 ± 0.44 
Insulin-sorbitol 10%-PLGA nanoparticles 0.98 ± 0.08 97.4 ± 0.8 1.40 ± 0.15 
 
Ramped cooling    
Insulin-PLGA nanoparticles 1.01 ± 0.16 97.8 ± 0.9 1.55 ± 0.68 
Insulin-trehalose 10%-PLGA nanoparticles 1.14 ± 0.08 97.7 ± 1.2 1.39 ± 0.59 
Insulin-sucrose 10%-PLGA nanoparticles 1.14 ± 0.14 98.1 ± 1.2 1.36 ± 0.44 
Insulin-sorbitol 10%-PLGA nanoparticles 1.12 ± 0.06 98.3 ± 1.5 1.48 ± 0.36 
 
Liquid nitrogen    
Insulin-PLGA nanoparticles 0.82 ± 0.09 95.9 ± 0.8 1.22 ± 0.25 
Insulin-trehalose 10%-PLGA nanoparticles 1.05 ± 0.04 96.9 ± 1.8 1.24 ± 0.12 
Insulin-sucrose 10%-PLGA nanoparticles 1.01 ± 0.34 97.1 ± 1.6 1.16 ± 0.32 
Insulin-sorbitol 10%-PLGA nanoparticles 0.72 ± 0.01 97.9 ± 1.9 1.25 ± 0.17 
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The secondary drying removes the adsorbed water that did not separated as ice 
upon freezing, and therefore did no sublimate during the primary drying. The residual 
moisture content obtained from the analysis of the lyophilizates is shown in Table 7.3, 
and the overall results were about 1%. This was a good achievement, since lyophilized 
products need to have very low residual moisture content, and it is considered that for 
pharmaceutical products, it should be around 1% [150]. A high residual moisture content 
is able to destabilize nanoparticles upon storage due to the crystallization of the 
containing cryoprotectant [140], and may also lead to a low Tg of the PLGA formulations, 
which can catalyze the PLGA hydrolysis, hampering the shelf-life stability of PLGA 
nanoparticles 
In addition, the obtained results also revealed that the different freezing methods 
were suitable on freezing the formulations and the lyophilization cycle, particularly the 
secondary drying, was effective on removing water in order to obtain such low residual 
moisture content. 
 
3.4. Particle size, zeta potential and drug retention efficiency upon lyophilization 
 
Before lyophilization, insulin-loaded PLGA nanoparticles were washed with Milli-
Q water to remove the surfactant PVA, to avoid its cryoprotectant action. A washing step 
was also important to remove the free drug, since its presence may increase the zeta 
potential up to neutrality, increasing the probability of nanoparticles aggregation [7]. 
Figure 7.2 shows the mean particle size, PdI and zeta potential characterization of 
insulin-loaded PLGA nanoparticles after lyophilization, using the different freezing 
methods. In addition, the Table 7.3 shows the lyophilization ratio of formulations, which 
was obtained by dividing the mean particle size of nanoparticles after with that before 
lyophilization. Therefore, a lyophilization ratio around 1 represents that the mean particle 
size of nanoparticles was kept after lyophilization. The overall results of mean particle 
size showed that insulin-loaded nanoparticles maintained its particle size upon 
lyophilization. There were just two exceptions for insulin-PLGA nanoparticles and insulin-
sorbitol 10%-PLGA nanoparticles frozen in liquid nitrogen, which presented a lower 
mean particle size (p < 0.05) after lyophilization, achieving a lyophilization ratio of 0.82 ± 
0.09 and 0.72 ± 0.01, respectively. The freezing stresses suffered by nanoparticles at 
this freezing condition may be responsible of such particle size change. On their turn, 
trehalose and sucrose helped to mitigate the stresses of freezing in liquid nitrogen. The 
lyophilization ratio of the remainder formulations were around 1 demonstrating the 
maintenance of nanoparticles size upon lyophilization. Besides being higher than prior 
lyophilization, the PdI also demonstrated the low heterogeneity of nanoparticles size in 
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all formulations. Additionally, with the exception of insulin-sucrose 10%-PLGA 
nanoparticles frozen at -80ºC and in liquid nitrogen, the zeta potential values of the 
different formulations were similar upon lyophilization, demonstrating the good colloidal 
stability of nanoparticles. 
 
 
Figure 7.2. Mean particle size (top bars), PdI and zeta potential (bottom bars) characterization of 
insulin-loaded PLGA nanoparticles, after lyophilization at different freezing conditions (n = 3, 
mean ± SD). Results are significantly different (p < 0.05) from the respective formulation prior 
lyophilization, when marked with *. 
 
During freezing, the crystallization of ice leads to a phase separation and 
nanoparticles cryoconcentration, leading to their possible aggregation or fusion. Higher 
supercooling as occurs during freezing in liquid nitrogen, may result in smaller ice 
crystals and  higher surface area of ice, which decreases the mechanical stresses 
suffered by nanoparticles, avoiding their aggregation [185]. Such ice crystals originated 
by freezing in liquid nitrogen, lead to lower primary drying rates comparatively to shelf-
ramped freezing. Furthermore, the intra-vial heterogeneity of ice crystals or solutes 
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contributes to unpredictable modifications in the sublimation rate, causing potentially 
unacceptable quality of products [188, 272] Thus, the multidirectional growth of ice 
crystals as occurs during freezing in a -80ºC freezer or in liquid nitrogen may be 
detrimental to nanoparticles stability. This could be the possible explanation for the 
differences found in particle size of nanoparticles after lyophilization using freezing in 
liquid nitrogen. Generally, the lower the equilibration temperature in the sample, the 
more heterogeneous the ice crystals are formed. With a slower freezing occurred in 
ramped cooling, there is more time for nanoparticles to concentrate ahead of the 
advancing freezing front.  
The insulin retention efficiency in the formulations is depicted in Table 7.3. The 
occurrence of drug leakage after lyophilization may indicate modifications in the integrity 
of nanoparticles. Besides the results showed a very slight leakage of insulin from 
nanoparticles upon lyophilization, the drug retention efficiency values in the formulations 
were superior to about 96% in all the freezing conditions, demonstrating that the 
lyophilization cycles were able to preserve the integrity of nanoparticles. 
 
3.5. Nanoparticle morphology 
 
3.5.1. Before lyophilization 
 
The morphology of insulin-loaded PLGA nanoparticles and the lyophilizates may 
be visualized by SEM, since this technique allows evaluating the size, shape and surface 
of nanoparticles. This information is crucial to infer the nanoparticles stability, and 
consequently the stability of the loaded protein. The purification of insulin-loaded PLGA 
nanoparticles prior to the microscopy analysis was necessary to remove the PVA, 
because it forms a continuous film that difficult the observation of polymeric 
nanoparticles by SEM [153]. 
The SEM microphotographs are shown in Figure 7.3, and it was noticed that the 
nanoparticles of all formulations were characteristically similar with a spherical shape 
and smooth surface, which is characteristic of the used encapsulation method.  The size 
range of nanoparticles is also in accordance with the mean particle size characterization 
mentioned in section 3.1. In addition, the microphotographs also showed that the 
encapsulation methodology was able to co-encapsulate the cryoprotectants allowing the 
formation of nanoparticles, as it was also previously reported [227]. 
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Figure 7.3. SEM microphotographs of insulin-loaded PLGA nanoparticles. Scale bar: 1 µm. 
 
3.5.2. After lyophilization 
 
The lyophilizates were observed by SEM, and the results are shown in Figure 
7.4. Generally, the porosity and texture of the dried cake are influenced by the ice crystal 
growth during freezing. Regarding the freezing methods, the shelf ramped freezing is 
recognized to originate a high freezing rate after slow cooling, resulting in a sponge-like 
matrix and a small spherulitic pores [272]. On its turn, the freezing in liquid nitrogen 
originates a directional solidification, combined with a high freezing rate forming small 
lamellar-shaped pores [273]. All the lyophilizates showed a porous structure, which is 
important to the nanoparticles resuspension. In the lyophilizates of insulin-PLGA 
nanoparticles (no cryoprotectant), it was easily observable the nanoparticles with their 
round shape in the three freezing methods. However, in the formulations containing 
cryoprotectants co-encapsulated, the visualization of nanoparticles was not so clear, and 
instead, more tight structures were observed. This difference is due to the presence of 
some amount of cryoprotectants in formulation that may leak from inside and surround 
nanoparticles forming a protective matrix upon lyophilization. In fact, the ability of 
cryoprotectants to form a protective matrix has previously been reported [163], and their 
ability to form such a tight structures able to protect nanoparticles was also described 
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[175]. Some leakage of insulin and the lower zeta potential values of insulin-loaded 
PLGA nanoparticles co-encapsulated with cryoprotectants mentioned above, may also 
confirm this possibility. 
 
 
Figure 7.4. SEM microphotographs of the lyophilizates of insulin-loaded PLGA nanoparticles. 
Scale bar: 10 µm. Np stands for nanoparticles. 
 
Regarding the lyophilizates of insulin-PLGA nanoparticles (no cryoprotectant) at 
the different freezing conditions, it was observed that those obtained using freezing at -
80ºC and freezing in liquid nitrogen were similar, whereas the lyophilizate obtained using 
a ramped cooling presented a more tight shape. This difference may be due to a faster 
cooling in the first two methods originating many small ice crystals, whereas the ramped 
cooling originates larger ice crystals, and during the separation of ice it is also originated 
a more concentrated phase of nanoparticles. The same explanation applies to insulin-
trehalose 10%-PLGA nanoparticles with a ramped cooling, in which the filamentary 
structures that were observed may be due to the presence of those nanoparticles in the 
interfaces of the ice formation phase and the cryoconcentrated phase containing 
nanoparticles. Both insulin-sucrose 10%-PLGA nanoparticles and insulin-sorbitol 10%-
PLGA nanoparticles obtained very similar lyophilizates among the different freezing 
methods, achieving porous lyophilizates. These results demonstrated the versatility of 
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sucrose and sorbitol to be used in different freezing methods, achieving very similar 
lyophilizates. 
The lyophilizates were resuspended and observed by SEM (Figure 7.5). The 
microphotographs showed that insulin-loaded PLGA nanoparticles maintained their 
spherical shape after lyophilization, and corroborated the mean particle size described in 
section 3.4 of this chapter. These results confirmed that the three optimized lyophilization 
cycles, and also the cryoprotectants used were able to preserve the features of 
nanoparticles upon lyophilization, which is the main purpose in nanoparticles 
lyophilization. 
 
 
Figure 7.5. SEM microphotographs of lyophilized insulin-loaded PLGA nanoparticles after 
resuspension. Scale bar: 1 µm. Np stands for nanoparticles.   
 
3.6. X-ray powder diffraction analysis 
 
XRPD is the best technique to assess the crystalline state, and characterize 
possible polymorphs of solid materials such as lyophilizates. It has been reported that 
the crystallization of cryoprotectants during freezing, drying or even storage may 
prejudice nanoparticles stability [140]. Thus, both nanoparticles and cryoprotectants in 
amorphous state allow a better hydrogen-bonding, which is a stabilizing ability of 
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cryoprotectants. Regarding insulin, it was reported that upon storage this protein in the 
amorphous state was more stable than in the crystalline state [274]. The lyophilizates of 
insulin-loaded PLGA nanoparticles were assessed by XRPD, and the results are 
depicted in Figure 7.6. The amorphous state of a sample is elucidated in XRPD 
diffractograms if no clear peaks are observed. In a previous work from our group, it was 
showed that the PLGA polymer and insulin bulk materials, as well as a lyophilized insulin 
and lyophilized insulin added with cryoprotectants were amorphous [227]. It was also 
demonstrated that the co-encapsulation of cryoprotectants together with insulin yielded 
amorphous lyophilizates.  
The XRPD diffractograms demonstrated that all lyophilizates were amorphous 
upon lyophilization, using the three different freezing methods. Just a small and not 
significant peak appeared in lyophilized insulin-PLGA nanoparticles frozen with liquid 
nitrogen. Therefore, the overall obtained results showed that the used lyophilization 
cycles were adequate to obtain good amorphous lyophilizates, which are necessary to 
have a good perspective on their storage stability. 
 
 
Figure 7.6. XRPD pattern of insulin-loaded PLGA nanoparticles lyophilized using freezing at -
80ºC (A), ramped cooling (B) and liquid nitrogen (C). Np stands for nanoparticles.…………………
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3.7. Insulin structural integrity 
 
3.7.1. Fourier transform infrared spectroscopy analysis 
 
FTIR spectroscopy is a widely used technique, that may be applied in the 
assessment of the secondary structure of proteins loaded into nanoparticles in a non-
invasive way [85]. Regarding a protein spectra, the amide I region (1710-1590 cm-1) is 
commonly used to establish the similarity between the second derivative spectra of 
native and loaded proteins. Thus, the higher the similarity between them, better the 
maintenance of the secondary structure of the protein. 
 
3.7.1.1. Area of overlap 
 
The AO is a quantitative measurement of the similarity degree between the area-
normalized second derivative spectra of native insulin, and insulin loaded into PLGA 
nanoparticles. In protein formulations, the detrimental effects on protein stability during 
freezing may be correlated to the used freezing method. The main aspects that can 
influence the stability of proteins during freezing are the cold denaturation, ice formation 
and freeze-concentration [270]. However, most of the significant changes in protein 
stability occur during ice crystallization, that originates a freeze-concentration and large 
liquid/ice interfaces in which proteins may adsorb and lose its native conformation due to 
a surface-induced denaturation [204]. Similarly, in protein-loaded nanoparticle 
formulations these phenomena also occur, but in the protein environment inside the 
nanoparticles. 
The native structure of insulin was obtained by the FTIR analysis of an insulin 
solution 30 mg/mL, and the AO values obtained for the lyophilized PLGA nanoparticles 
are depicted in Figure 7.7. The results showed that upon lyophilization using freezing at -
80ºC, the insulin-loaded PLGA nanoparticles co-encapsulated with cryoprotectants 
showed higher insulin stability (p < 0.05) comparatively to insulin-PLGA nanoparticles 
(no cryoprotectant). The AO of insulin co-encapsulated with cryoprotectants was in the 
range of 83-85%, comparatively to only about 74.5 ± 0.7 % of insulin-PLGA 
nanoparticles. Regarding the formulations lyophilized using the other two freezing 
methods, with just the exception of insulin-sucrose 10%-PLGA nanoparticles, the 
formulations containing co-encapsulated cryoprotectants did not show a clear 
improvement in insulin stability comparatively to insulin-PLGA nanoparticles. However, 
when comparing the AO values from the different freezing methods, it was noticed that 
Chapter 7 I Optimization of Lyophilization Cycle and Effect of Freezing on the Stability and 
Bioactivity of Protein-loaded PLGA Nanoparticles upon Lyophilization 
  
186 
 
the freezing method influenced the AO of insulin loaded into PLGA nanoparticles without 
cryoprotectant co-encapsulated. Indeed, the AO of insulin was higher for lyophilization 
with ramped cooling with 89.0 ± 1.4 %, followed by the one frozen in liquid nitrogen with 
79.6 ± 1.0 % and freezing at -80ºC with 74.5 ± 0.7%. These differences may be 
explained by the distinct formation of liquid/ice interfaces in the protein environment, 
originated by the different freezing methods. 
The freezing methods that originate higher freezing rates as occurred in freezing 
at -80 and in liquid nitrogen, result in smaller ice crystals and consequently larger ice-
water interfaces, leading to a higher extent of surface-induced denaturation of proteins 
[204]. It was described that the increase in the surface area of ice crystals originated 
modifications in protein structure, and also protein aggregation [275]. Thus, this may be 
the explanation why in those two freezing methods, the insulin stability was lower than in 
the ramped cooling. Similar behavior was found in a previous study in which a lower 
amount of insoluble aggregates of bovine IgG were found for shelf-ramped freezing, 
comparatively to the immersion in liquid nitrogen [276]. The same tendency was 
observed in a freeze-thawing study of a human growth hormone solution [277]. Different 
proteins also showed less turbidity in a slow freezing after freeze-thawing, comparatively 
to freezing in liquid nitrogen [278]. The difference of about 5% of AO between freezing at 
-80ºC and in liquid nitrogen may be explained by the faster freezing occurred in the latter 
freezing method. Indeed, it was reported that a faster freezing reduced the loss of LDH 
activity comparatively to slow freezing, since a faster freezing reduces the time that a 
protein remain in the freeze-concentrated phase in which degradation reactions occur 
[279].  
Considering the formulations containing cryoprotectants, a positive outcome was 
that the co-encapsulation of cryoprotectants helped to mitigate the differences in AO 
observed in the formulations without cryoprotectants. In fact, it was observed very similar 
insulin stabilization obtaining an AO of around 80% among the different freezing 
methods. These results demonstrated that the presence of cryoprotectants together with 
insulin inside the nanoparticles was important to mitigate the different freezing stresses 
caused by the freezing methods. It is known that cryoprotectants are able to stabilize 
proteins during freezing by a preferential exclusion [280]. In fact, cryoprotectants have 
tendency to be excluded from the protein surface leading to a preferential hydration of 
the protein, and increasing the thermodynamic stability of its native state. 
Simultaneously, cryoprotectants can also stabilize the protein by reducing its adsorption 
on the ice surface occurring during freezing and also by increasing the viscosity of the 
freeze-concentrate [269]. 
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It was previously reported that when using a controlled but not optimized 
lyophilization process, the co-encapsulation of cryoprotectants showed better protein 
stabilization comparatively to the conventional cryoprotectant addition method [227]. In 
the present work, this approach was taken further and it was observed that using 
optimized lyophilization cycles, the co-encapsulation of cryoprotectants may be 
determinant in insulin stability maintenance, when using specific freezing methods such 
as freezing at -80ºC. Furthermore and more importantly, the co-encapsulation of 
cryoprotectants allows very similar protein stabilization among the freezing methods, 
mitigating the different freezing stresses occurred. 
 
 
Figure 7.7. AO percentages of insulin loaded into PLGA nanoparticle formulations after 
lyophilization at different freezing conditions (n =  3, mean ± SD). Np stands for nanoparticles. 
Results are significantly different (p < 0.05) from formulation with no cryoprotectant co-
encapsulated, insulin-PLGA nanoparticles, when marked with *. 
 
3.7.1.2. Visual comparison of area-normalized second-derivative amide I spectra 
 
The AO values represent the quantitative maintenance of the native structure of 
insulin, whereas the qualitative changes of insulin structure are obtained by the analysis 
of the area-normalized second-derivative amide I spectra depicted in Figure 7.8. 
Commonly, upon lyophilization the protein structure suffers a decrease in α-helix, with a 
simultaneous increase in the β-sheet content, and it is generally accepted that the α-
helix content is a better indicator of the structural integrity of proteins [258]. The area-
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normalized second-derivative FTIR spectrum of native insulin (insulin solution 30 mg/mL, 
Figure 7.8) corresponds to the known secondary structure of insulin that is dominated by 
α-helix (1658 cm-1), containing also β-sheets (bands at 1640 and 1690 cm-1) [85, 259, 
281]. Thus, the changes of these bands occurred upon lyophilization corresponds to 
changes in insulin secondary structure, that may lead to protein denaturation or 
aggregation, affecting insulin bioactivity or even cause potential adverse effects upon 
administration. 
 Considering the freezing at -80°C, it was observed that insulin-PLGA 
nanoparticles (no cryoprotectant) showed a slight decrease and a shift in α-helix into 
1653 cm-1, presenting also a shift in its high wavenumber β-sheet content into 1684 cm-1, 
as well as a intermolecular β-sheet formation bands at 1616/1700 cm-1. These 
modifications showed a significant change in insulin secondary structure. On its turn, 
besides some differences among them, the insulin-loaded PLGA nanoparticles 
containing cryoprotectants co-encapsulated, demonstrated a similar structural behavior 
with no shift in α-helix content, a similar decrease and shift of the band of high 
wavenumber β-sheet content, and with no formation of intermolecular β-sheet at 1700 
cm-1. Regarding the α-helix content, it was found a maintenance, increase and decrease 
of the content of this structural feature for insulin-loaded PLGA nanoparticles co-
encapsulated with trehalose, sucrose and sorbitol, respectively. These results are in 
agreement with those obtained in the AO values, and clearly showed the superior 
stability offered by the insulin-loaded PLGA nanoparticles containing cryoprotectants co-
encapsulated, comparatively to the formulation containing no cryoprotectant upon 
lyophilization with freezing at -80ºC. 
 By analyzing the spectra of the formulations frozen by ramped cooling, it was 
possible to observe that, comparatively to the other freezing methods, the obtained 
spectra presented the most similarity among them. No significant shifts in α-helix were 
observed and just a more evident increase of this structural feature was observed for 
insulin-sucrose 10%-PLGA nanoparticles. The high frequency β-sheet content at 1690 
cm-1 was very similar, with just a significant decrease in this content for insulin-trehalose 
10%-PLGA nanoparticles. Regarding the insulin-PLGA nanoparticles (no cryoprotectant) 
it was evident a decrease in α-helix and an increase both in high and low wavenumber β-
sheet.  This latter increase in β-sheet content was also observed for insulin-sorbitol 10%-
PLGA nanoparticles; however the α-helix of insulin was better preserved than for the 
formulation containing no cryoprotectant. The overall results observed for formulations 
frozen in a ramped cooling, showed that besides insulin-PLGA nanoparticles presented a 
slight higher AO, the formulations containing cryoprotectants allowed a superior 
maintenance of insulin secondary structure. This gives rise to the importance of 
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analyzing together, the quantitative and qualitative maintenance of insulin secondary 
structure. 
 Regarding the samples frozen in liquid nitrogen, it was observed some variability 
in the insulin spectra upon lyophilization. It was verified a similar behavior of insulin 
structure for insulin-PLGA nanoparticles containing no cryoprotectant as observed in 
freezing at -80ºC. Thus, there was also a similar decrease and shift in the α-helix band 
into 1653 cm-1, and a shift in the high wavenumber β-sheet content into 1684 cm-1, as 
well as an intermolecular β-sheet band formation at 1616/1700 cm-1. The spectra of 
insulin loaded into PLGA nanoparticles containing cryoprotectants showed some 
variability. Insulin-trehalose 10%-PLGA nanoparticles showed an increase and shift in α-
helix into 1660 cm-1, together with a significant decrease in the low wavenumber β-sheet 
content. The insulin-sucrose 10%-PLGA nanoparticles presented no shift and no change 
in the intensity of the α-helix band, with just a shift and decrease in the high wavenumber 
β-sheet content. On its turn, the formulation containing sorbitol showed the worst 
performance among the cryoprotectant co-encapsulated formulations, with a significant 
decrease and a slight shift in the α-helix band into 1656 cm-1. Considering the overall 
results of formulations frozen at liquid nitrogen it was observed a superior performance 
on insulin stabilization in insulin-loaded PLGA nanoparticles with cryoprotectants co-
encapsulated, comparatively to the one containing no cryoprotectants. 
 Since the aggregation and denaturation of proteins are noticed by a decrease in 
α-helix with a simultaneous increase in β-sheet content, it was possible to infer that no 
clear significant denaturation or aggregation of insulin was observed. The ramped 
cooling was the method in which formulations presented the most similar insulin 
structure and maintenance. More importantly, in all the three freezing conditions the 
insulin-loaded PLGA nanoparticles containing cryoprotectants co-encapsulated offered 
better insulin stabilization upon lyophilization, comparatively to the formulation containing 
no cryoprotectant. In addition, and considering that α-helix is the best indicator of insulin 
stability, it was observed that in the three freezing methods the formulations containing 
trehalose and sucrose presented a better protein stabilization than those containing 
sorbitol.
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Figure 7.8. Area-normalized second-derivative amide I FTIR spectra of insulin loaded into PLGA nanoparticles lyophilized using freezing at -80ºC (A), ramped 
cooling (B) and liquid nitrogen (C). Np stands for nanoparticles. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9. Far-UV CD spectra of insulin extracted from insulin-loaded PLGA nanoparticles lyophilized using freezing at -80ºC (A), ramped cooling (B) and 
liquid nitrogen (C). Insulin 0.2 mg/mL in 0.01 HCl used as reference. Np stands for nanoparticles. 
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Figure 7.10. Fluorescence spectra of insulin extracted from insulin-loaded PLGA nanoparticles lyophilized using freezing at -80ºC (A), ramped cooling (B) and 
liquid nitrogen (C). Insulin 0.2 mg/mL in 0.01 HCl used as reference. Np stands for nanoparticles. 
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3.7.2. Circular dichroism experiments 
 
CD spectroscopy was also used to assess the secondary structure of insulin, and 
confirm the results obtained by FTIR. To obtain the CD spectra it was necessary to 
extract insulin from nanoparticles, to avoid spectral artifacts due to light scattering. The 
obtained far-UV CD spectra are shown in Figure 7.9. The spectrum of native insulin 
corresponds to the spectrum of 0.2 mg/mL insulin used as reference, and it was 
observed two minima at about 208 nm and 222 nm, which are characteristic of the 
predominant α-helix structure of the protein [266].  The obtained native insulin spectrum 
is in accordance with that described in other research works [85, 282].  
All CD spectra of insulin extracted from nanoparticles showed no relevant shifts in 
the two minima, demonstrating the predominant α-helical structure of insulin. The 
denaturation, aggregation or even fibrillation of insulin is characterized by the presence 
of considerable and predominant β-sheet content, represented by a minima of ellipticity 
at around 216 nm [143, 283]. Since this structural modification from α-helix into β-sheet 
was not observed, it is supposed that insulin from all formulations kept its bioactivity. 
Some variability in the decrease of the negative ellipticity signal of insulin was observed, 
which represents the modifications in the secondary structure of insulin. Since the CD 
characterization of insulin structure was performed in an invasive way, together with the 
structural modifications caused both by the encapsulation and the lyophilization 
processes, some variability in the CD spectra of insulin may be also explained by the 
extraction process of insulin from nanoparticles. Despite the concerns about the 
extraction process and its possible influence, the results were similar to those obtained in 
non-invasive way by FTIR data. For instance, the insulin-loaded PLGA nanoparticles 
lyophilized using a ramped cooling demonstrated the closest similarity among them, as it 
was observed by FTIR. Thus, it was again demonstrated that the lyophilization using this 
freezing method, helped to mitigate the structural modifications of insulin, comparatively 
to the other freezing methods. 
 
3.7.3. Fluorescence spectroscopy 
 
The fluorescence spectroscopy was used to assess the tertiary structure of 
insulin extracted from PLGA nanoparticles. Since insulin lacks tryptophan, its 
fluorescence depends on the four tyrosine residues [284]. Thus, the changes in the 
intensity of the emission spectra of intrinsic protein fluorescence are indicators of 
modifications in the conformation of insulin. The fluorescence spectra of insulin are 
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depicted in Figure 7.10. The spectrum of native insulin was obtained by the analysis of 
an insulin solution 0.2 mg/mL in HCl 0.01 M, and it was showed a maximum of 
fluorescence intensity at the wavelength of 304 nm. The insulin spectrum was in 
agreement with those obtained in previous works [285-287]. The overall insulin spectra 
showed no shift in the fluorescence intensity maxima, indicating that the overall structure 
of insulin was preserved.  However the decrease in the intensity of fluorescence 
occurred in insulin from the lyophilized PLGA nanoparticles, suggested some 
conformational changes [288].  
Regarding the spectra of insulin from formulations lyophilized using freezing at -
80ºC, it was observed that insulin-PLGA nanoparticles (no cryoprotectant) showed lower 
fluorescence intensity comparatively to the samples containing cryoprotectants co-
encapsulated. Additionally this formulation showed slight formation of a peak at around 
414 nm, which may be caused by a potential tyrosine oxidation [289]. These results were 
in agreement with those obtained by FTIR, and showed that cryoprotectants offered 
superior stability to insulin upon lyophilization using freezing at -80ºC. Similar better 
insulin stabilization was observed for formulations containing cryoprotectants upon 
lyophilization using freezing at liquid nitrogen. The formulations lyophilized using ramped 
cooling showed the most similar insulin conformation, since the fluorescence intensity 
was very similar in all formulations. The overall results are in agreement with those 
obtained for the characterization of the secondary structure of insulin by FTIR and CD. 
 
3.8. Thioflavin T assay 
 
The thioflavin T is a cationic benzothiazole dye able to bind to amyloid fibrils with 
crossed β-sheet structures, exhibiting an enhancement of fluorescence emission at 485 
nm and shift of its excitation maximum from 340 to 450 nm [290, 291]. Amyloid fibrils are 
a particular class of protein aggregates, so its presence in formulation means that the 
protein structure and consequent bioactivity is drastically compromised. Insulin may form 
amyloid-like fibrils caused by various stress factors, with different morphologies 
depending on the arrangement of its protofilaments [292, 293].The enhancement in 
thioflavin T fluorescence intensity shows the insulin aggregation, whereas no signal 
enhancement shows no aggregation of insulin [287]. 
All insulin samples from formulations showed no presence of thioflavin T-positive 
filaments, suggesting no formation of amyloid fibrils, since no enhancement on 
fluorescence emission at 485 nm was observed. Since all the normalized data were 
around zero, the data is not shown. On its turn, the positive control of fibrillated insulin 
showed enhanced fluorescence emission. The results showed that neither the method of 
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nanoparticles production nor the lyophilization processes acted as stress factors for 
insulin instability that could lead to its fibrillation. These results are also in agreement 
with the structural characterization mentioned above, since no fibrillation was evidenced 
by FTIR, CD and fluorescence spectroscopy. 
 
3.9. In vivo bioactivity analysis of insulin-loaded formulations 
 
The bioactivity of insulin loaded into PLGA nanoparticles was evaluated in vivo 
using a diabetic animal model. Since the formulations lyophilized using ramped cooling 
presented the closest structural similarity of insulin, their performance in vivo was 
evaluated. Thus, it were tested the insulin-PLGA nanoparticles (no cryoprotectant) and 
also one formulation with cryoprotectant co-encapsulated, insulin-trehalose 10%-PLGA 
nanoparticles. The latter was chosen as a representative of the formulations with 
cryoprotectants co-encapsulated, since it was demonstrated a close structural similarity 
of insulin. The insulin-loaded PLGA nanoparticles were subcutaneously administered to 
overnight fasted diabetic rats, and blood samples were collected at predetermined time 
points for glucose quantification. These formulations were administered at an insulin 
dose of 50 IU/kg, to have a high acceptable hypoglycemic effect. The obtained reduction 
of the initial glucose levels over time after subcutaneous administration of insulin-loaded 
PLGA nanoparticles, subcutaneous insulin and unloaded nanoparticles is shown in 
Figure 7.11. The baseline value of mean plasma glucose level was taken as 100%. In 
addition, the parameters for plasma glucose levels and relative PA are depicted in Table 
7.4. 
After subcutaneous administration of insulin solution (2.5 IU/kg), the glycemia 
decreased significantly to 30.9 ± 13.5 % after 1 hour, achieving a maximal decrease after 
4 h. The formulations of insulin-loaded PLGA nanoparticles showed the minima of 
glucose levels at around 4-6 hours followed by an increase in glucose, but this increase 
was quite lower than that obtained for subcutaneous insulin, demonstrating that PLGA 
nanoparticles were able to prolong the hypoglycemic effect of insulin. The pattern of 
plasma glucose percentage for these formulations was in agreement with their in vitro 
release pattern, characterized by an initial burst release, and followed by a controlled 
release of insulin [227]. The initial burst release seems to be related with the increase of 
nanoparticles porosity upon lyophilization [101], whereas the following controlled release 
occurs mainly due to the erosion of the polymer matrix. Regarding the insulin-trehalose 
10%-PLGA nanoparticles, it was observed that the plasma blood glucose percentage 
was significantly higher (p < 0.05) than that obtained by subcutaneous insulin in the first 
2 hours, which was naturally explained by the faster availability of insulin into the 
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bloodstream provided by the subcutaneous insulin. On contrary, from 6 to 24 hours the 
plasma glucose percentage was significantly lower (p < 0.05) than that obtained by 
subcutaneous insulin, which is clearly caused by the sustained release of insulin from 
PLGA nanoparticles, prolonging its hypoglycemic effect. 
 
 
Figure 7.11. Plasma glucose levels in diabetic rats over time as percentage of initial  levels, after 
subcutaneous administration of an insulin solution (2.5 IU/kg), unloaded nanoparticles, insulin-
PLGA nanoparticles (50 IU/kg), insulin-PLGA nanoparticles + trehalose 10% (50 IU/kg) and 
insulin-trehalose 10%-PLGA nanoparticles (50 IU/kg). Data represent the mean ± SD, n = 
5/group. Results are significantly different (p < 0.05) from subcutaneous insulin when marked with 
*. Sc stands for subcutaneous. 
 
As a control sample it was also administered to rats a formulation of insulin-PLGA 
nanoparticles added with trehalose at 10% (w/w) prior lyophilization using ramped 
cooling (insulin-PLGA nanoparticles + trehalose 10%). The formulation with co-
encapsulated trehalose showed an enhanced hypoglycemic effect comparatively to the 
other insulin-loaded PLGA nanoparticles, caused by both a higher release rate [227], 
and superior insulin stabilization and bioactivity. The PA results (Table 7.4) also 
corroborate the superior hypoglycemic effect provided by insulin-loaded PLGA 
nanoparticles co-encapsulated with cryoprotectant. 
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Table 7.4. Parameters for plasma glucose levels and relative pharmacological availability 
percentage. Data represent the mean ± SD, n = 5/group. 
 
Subcutaneous 
insulin 
Insulin-PLGA 
nanoparticles 
Insulin-PLGA 
nanoparticles + 
trehalose 10% 
Insulin-trehalose 
10%-PLGA 
nanoparticles 
Insulin dose (IU/kg) 2.5 50 50 50 
Cmin (%) 11.7 ± 4.7 14.3 ± 4.9 13.8 ± 8.9 12.4 ± 4.9 
Tmin (h) 4 4 4 6 
PA (%) - 6.1 ± 1.2 6.7 ± 0.8 7.0 ± 0.6 
 
4. Conclusion 
 
In this chapter, it was evaluated the influence of the freezing step of lyophilization 
in the structure of a therapeutic protein, insulin, loaded into PLGA nanoparticles. In 
addition, it was assessed the performance of different co-encapsulated cryoprotectants, 
in the protection of insulin-loaded PLGA nanoparticles upon lyophilization. 
The overall results regarding the mean particle size, zeta potential and insulin 
retention efficiency, besides some differences, demonstrated that the features of insulin-
loaded PLGA nanoparticles were preserved upon the optimized lyophilization cycles. 
The lyophilizates of insulin-loaded nanoparticles with cryoprotectants co-encapsulated, 
presented a more tight structure comparatively to nanoparticles containing no 
cryoprotectants, forming a protective matrix that could be important to protect both 
nanoparticles and the loaded protein. In addition, all lyophilization cycles produced 
amorphous lyophilizates, which resulted in a good perspective for the storage stability of 
nanoparticles. 
Regarding the structure of insulin loaded into PLGA nanoparticles, it was verified 
that in absence of cryoprotectants, the insulin structure presented some variability 
depending on the freezing method, and it was the ramped cooling that presented the 
higher structural maintenance of insulin. Such structural loss of native conformation was 
mitigated when cryoprotectants were co-encapsulated, demonstrating that their presence 
in formulation reduced the different freezing stresses and better preserved the structure 
of insulin upon lyophilization, comparatively to formulations containing no cryoprotectant. 
It was also in the ramped cooling at -40ºC that formulations both with and without 
cryoprotectants co-encapsulated, presented the most insulin structural similarity and 
maintenance. In addition, in the three freezing methods, the formulations containing 
trehalose and sucrose presented better protein stabilization than those containing 
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sorbitol. Furthermore, it was found that neither the encapsulation process nor the 
lyophilization cycles acted as stress factors for insulin-loaded PLGA nanoparticles that 
could lead to insulin fibrillation. 
The in vivo bioactivity experiments found that the insulin-loaded PLGA 
nanoparticles were able to prolong the hypoglycemic effect of insulin, comparatively to 
the subcutaneously administered insulin. Such hypoglycemic effect was even enhanced 
by the formulation with cryoprotectant co-encapsulated, in comparison with the other 
insulin-loaded PLGA nanoparticles, essentially caused by the superior insulin 
stabilization and bioactivity. 
Overall, this chapter gave rise to the importance of optimizing the lyophilization 
process in order to obtain a good lyophilized product. It was also clearly demonstrated 
that the freezing process used in lyophilization, may have a detrimental effect in the 
structure of the protein loaded into nanoparticles. This could be avoided by the use of 
cryoprotectants co-encapsulated that better preserve insulin structure and bioactivity 
upon lyophilization. 
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1. Introduction 
 
The freezing step is considered the most important one in lyophilization, since it 
influences the size of ice crystals and consequently the duration of the drying steps 
[188]. Generally, the optimization of the lyophilization cycle is mainly focused on 
decreasing the time needed for the primary drying, which is the longest step in 
lyophilization. The shelf temperature and chamber pressure are the main lyophilization 
parameters that may improve the sublimation rate. However, if they are not properly 
adjusted it may lead to undesired product overheating and collapse. 
The annealing is a processing step in lyophilization in which samples are kept at 
a determined subfreezing temperature above the Tg’, during a period of time [190]. This 
process influences the size distribution of ice crystals, leading to their growth. Their size 
distribution during annealing is ruled by Ostwald ripening, which states that crystals 
smaller than a critical size decrease, whereas the larger ones grow [190]. Therefore, the 
increase of the size of ice crystals during annealing may accelerate the sublimation rate 
by increasing the diameter of pores, in spaces that were previously occupied by ice 
crystals, and by a decrease of the mass transfer resistance by the dried layer [191]. The 
annealing may also decrease the heterogeneity of the drying rate between samples, in 
order to obtain a more inter-vial homogeneous cake structure [163, 294]. Overall, 
annealing may be a useful tool to obtain a dried cake with good quality in a shorter 
period of time.     
The annealing step has been applied in the lyophilization of protein formulations. 
In a rhIFN-Ɣ formulation, the application of an annealing step avoided the cracking of the 
cakes, originated more native-like secondary structure of protein in the solid product and 
prevented the aggregation of the protein upon reconstitution [273]. Regarding 
nanoparticle formulations, just a few works have been focusing on the influence of 
annealing in the stability of nanoparticles [153, 191, 192]. It was demonstrated that 
annealing accelerated the sublimation, with simultaneous maintenance of size of 
polymeric nanoparticles [153]. However, the influence of annealing in the structure and 
stability of loaded proteins has not been studied so far. The possible modification of the 
structure of loaded proteins during annealing needs to be properly regarded, since it has 
been demonstrated that the freezing step in lyophilization influences the structure of 
proteins loaded into nanoparticles [295]. 
The main aim of this study was to develop an optimized lyophilization cycle using 
annealing, in order to decrease the time needed to lyophilize protein-loaded polymeric 
nanoparticles, assuring simultaneously the stability of nanoparticles and the structural 
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maintenance of the loaded protein. Additionally, it was assessed the influence of the 
cryoprotectant effect during annealing, in the stability of nanoparticles and with upmost 
importance, in the stability of the encapsulated protein upon lyophilization.  
 
2. Materials and Methods 
 
2.1. Materials 
 
PLGA 50:50 Resomer® RG 503 H (Mw 24,000-38,000; Tg 44-48 ºC) from Evonik 
Industries AG (Essen, Germany) was used for nanoparticles production. PVA, 
dichloromethane, recombinant human insulin and trehalose were from Sigma-Aldrich 
(Steinheim, Germany). For the HPLC analysis, it was used acetonitrile HPLC Gradient 
Grade from Fischer Scientific (Loughborough, UK) and trifluoroacetic acid from Acros 
Organics (Morris Plains, NJ, USA). Chloroform from Sigma-Aldrich (Steinheim, 
Germany) was used for protein extraction from nanoparticles. The milli-Q water was 
produced in-house and other reagents were of analytical grade. 
 
2.2. Preparation of PLGA nanoparticles 
 
The PLGA nanoparticles were produced following a previously developed and 
optimized protocol to co-encapsulate insulin and trehalose into PLGA nanoparticles 
[227]. Thus, 200 mg of PLGA 50:50 were dissolved in 2 mL of dichloromethane, and 
then added with 0.2 mL of a 150 mg/mL insulin solution in HCl 0.1 M containing 
trehalose at a concentration of 10% (w/v). The primary emulsion was obtained by 
sonication at 70% of amplitude for 30 seconds, using a Bioblock vibracell 75186 
sonicator from Fischer Bioblock Scientific (Rungis Complexe, France). The emulsion was 
then poured into 25 mL of PVA 2% (w/v) at pH 7.4, and sonicated again using the same 
previous conditions. The organic solvent was removed by evaporation for 3 h under 
magnetic stirring. The production method was also used to formulate both nanoparticles 
without co-encapsulated cryoprotectant and unloaded nanoparticles. After production, 
nanoparticles were washed three times with milli-Q water, and collected after each 
washing step by centrifugation for 30 minutes at 23,000 x g using a Heraeus Megafuge 
1.0 R centrifuge (Thermo Scientific). Finally, nanoparticles were redispersed in water. 
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2.3. Insulin association efficiency, loading capacity and retention efficiency 
 
The AE was calculated using the equation 4.1 (see Chapter 4) and LC of insulin 
was calculated using equation 6.1 (see Chapter 6). The nanoparticles suspension was 
centrifuged at 40,000 x g at 4ºC for 30 min in a Beckman Optima TL ultracentrifuge from 
Beckman Coulter (Brea, CA, USA.), and it was collected the supernatant containing free 
insulin. Centrifuged nanoparticles were lyophilized to obtain the dry mass of 
nanoparticles. Upon reconstitution of lyophilized nanoparticles, the suspension was 
centrifuged and the supernatant was collected for insulin quantification and 
determination of insulin retention efficiency. The insulin free in supernatant was 
quantified by a HPLC-UV method previously validated [233], in a Merck-Hitachi LaChrom 
HPLC instrument equipped with a LiChrospher 100 RP-18 guard column, 5 μm particle 
size from Merck (Whitehouse Station, NJ, U.S.A.) and also a XTerra RP 18 column, 5 
μm particle size, 4.6 mm internal diameter x 250 mm length from Waters (Milford, MA, 
U.S.A.). All the samples were run in triplicate. 
 
2.4. Particle size and zeta potential analysis 
 
To perform the analysis of mean particle size, PdI and zeta potential, the 
nanoparticles in suspension and reconstituted after lyophilization were diluted with milli-
Q water to achieve a suitable concentration. These analyses were performed by dynamic 
light scattering using a 90Plus Particle Size Analyser, and by phase analysis light 
scattering using a ZetaPALS Zeta Potential Analyser, from Brookhaven Instruments 
Corporation (Holstville, NY, USA). The lyophilization ratio was calculated as the ratio 
between the mean particle size after lyophilization, and that before lyophilization. 
 
2.5. Lyophilization of nanoparticles 
 
The insulin-loaded PLGA nanoparticles suspensions were poured into semi-
stoppered glass vials at a maximal height of 10 nm, and lyophilized in a VirTis 
Advantage Plus Benchtop lyophilizer from SP Scientific (Warminster, PA, USA). Thus, 
samples were frozen by ramped cooling at -40ºC during 4 hours, and primary drying 
occurred at -32ºC and 150 mtorr for 24 h, followed by a secondary drying at 20ºC and 50 
mtorr for 6 h, at a condenser surface temperature of -60ºC (n = 3). When the thermal 
treatment of annealing was included in the lyophilization cycle, the nanoparticle 
formulations were frozen by ramped cooling at -40ºC and the temperature was raised to 
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the annealing temperature of -10ºC and held for 2 h. Then, samples were cooled to -
40ºC and held for another 2 h. The primary drying occurred at -32ºC and 150 mtorr for 
15 h, followed by a secondary drying at 20ºC and 50 mtorr for 6 h, at a condenser 
surface temperature of -60ºC (n = 3). 
 
2.6. Macroscopic evaluation, residual moisture content and reconstitution of the 
lyophilizates 
 
The lyophilizates were visually inspected to assess the aspect of the cake, and 
the residual moisture content was evaluated using an A&D MX-50 moisture analyzer 
from A&D Company Ltd. (Tokyo, Japan). Thus, an equal amount of lyophilizate of each 
formulation was analysed, and the residual moisture content was quantified as 
percentage of containing moisture. The lyophilizates were reconstituted by adding milli-Q 
water on the inside wall of the vials to guarantee the cake wetting. Finally, formulations 
were swirled until complete homogenization. 
 
2.7. Scanning electron microscopy analysis 
 
The insulin-loaded PLGA nanoparticles morphology was evaluated by SEM, 
using a FEI Quanta 400 FEG scanning electron microscope from FEI (Hillsboro, Oregon, 
USA). Both nanoparticle suspensions and lyophilizates were mounted on metal stubs, 
and coated under vacuum with a layer of gold/palladium with a 15 mA current for 60 
seconds prior to observation. 
 
2.8. Attenuated Total Reflectance-Fourier transform infrared spectroscopy 
analysis 
 
The secondary structure of insulin loaded into PLGA nanoparticles was assessed 
by ATR-FTIR. The samples were analysed in an ABB MB3000 FTIR spectrometer from 
ABB (Zurich, Switzerland) equipped with a MIRacle triple reflection ATR accessory from 
PIKE Technologies (Madison, WI, USA).  The FTIR spectra were collected in the 
4000−600 cm−1 region after 256 scans at a 4 cm−1 resolution. The insulin spectra were 
obtained by a double subtraction method [243], followed by a Savitzky-Golay second 
derivative of 15 points, and a 3-4 point baseline correction in the amide I region 
(1710−1590 cm-1). This spectral treatment was performed using the Horizon MB FTIR 
software from ABB, and all the spectra were area-normalized for further comparison. The 
AO algorithm was used to assess the quantitative similarity of the area normalized 
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second-derivative amide I spectra between native insulin and insulin loaded into PLGA 
nanoparticles [244]. A 30 mg/ml insulin solution in HCl 0.1 M was analysed and used as 
the native insulin spectrum to determine the percentage of spectral similarity, since it is 
considered that the stability of a solid protein formulation increases with the increase of 
the similarity to its spectra in solution [246]. 
 
2.9. Circular dichroism analysis 
 
Insulin was extracted from the PLGA nanoparticles using chloroform and HCl 
0.01 M to dissolve insulin, prior to the CD analysis. All samples were analysed at 25ºC 
with the lamp housing continuously purged with nitrogen, in a Jasco J-815 CD 
Spectrometer from Jasco Inc. (Easton, MD, USA). The CD spectra were obtained using 
a 0.1 cm cell in the range of 190 to 250 nm with an average of 5 scans, with a step size 
of 0.5 nm, a bandwith of 1.5 nm, and an averaging time of 5 s. The spectrum of 
reference sample was subtracted from the test sample spectra. The molar ellipticity of 
insulin was calculated as CD signal x MRW (mean residual weight of each insulin 
residue, 116 Da) [insulin concentration (mg/mL) x cell pathlength (0.1 cm)]. The insulin 
concentration was determined by UV absorption at 280 nm in a NanoDrop 2000c UV-Vis 
Spectrophotometer (Thermo Scientific, Wilmington, DE, USA), using a molar extinction 
coefficient of 6200 M-1cm-1 for 1.0 mg/mL. As control sample of native insulin, it was used 
a 0.2 mg/mL insulin solution in HCl 0.01 M. 
 
2.10. Fluorescence spectroscopy analysis 
 
Insulin was extracted from the PLGA nanoparticles using chloroform and HCl 
0.01 M to dissolve insulin, prior to the fluorescence spectroscopy analysis. The emission 
spectra were obtained at 25ºC in the range of 290 to 450 nm with 1 nm step in a Jasco 
FP-6500 Spectrofluorometer from Jasco Inc. (Easton, MD, USA). The excitation 
occurred at 280 nm with both emission and excitation slits set to 3 nm, with an 
integration time per data point of 0.1 seconds and an average of 5 scans. The spectrum 
of reference sample was subtracted from the sample spectra, and normalized based on 
insulin concentration. As control sample of native insulin, it was used a 0.2 mg/mL insulin 
solution in HCl 0.01 M. 
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2.11. Thioflavin T assay 
 
The samples of extracted insulin were incubated with Thioflavin T and analyzed 
in a Jasco FP-6500 Spectrofluorometer from Jasco Inc. (Easton, MD, USA) at 25ºC and 
the final concentration of insulin and thioflavin T were 11 µM and 25 µM, respectively. 
They were excited at 450 nm, and the fluorescence intensity was determined at 485 nm 
with slit widths of 5 nm. The reference sample spectrum was subtracted from the test 
sample spectra. As a positive control it was used insulin fibrillated by incubation at 60ºC 
during 12 hours. 
 
2.12. Statistical analysis 
 
The statistical analyses were performed in the OriginPro 8 software from 
OriginLab Corporation (Northampton, MA, USA), using a one-way ANOVA Tukey post 
hoc test, with a significance level of p < 0.05. 
 
3. Results and discussion 
 
It is generraly accepted that the annealing process influences the sublimation rate 
and the quality of the lyophilized protein drug product. However, its impact on the 
stability of the protein loaded into nanoparticles was not investigated so far. In addition, 
the influence of the cryoprotectant effect in the stabilization of the loaded protein upon 
lyophilization using annealing needs to be scrutinized. 
Insulin was used as a model of therapeutic protein, and was co-encapsulated into 
PLGA nanoparticles together with a cryoprotectant, since this approach demonstrated to 
better preserve the protein structure upon lyophilization, comparatively to the 
conventional cryoprotectant addition method [227]. In this study, trehalose was used as 
cryoprotectant, because it demonstrated to be a versatile cryoprotectant to stabilize 
protein-loaded nanoparticles upon lyophilization using different freezing methods [295]. 
Trehalose was used at a concentration of 10% (w/v) to obtain the highest acceptable 
cryoprotectant effect, since the level of stabilization provided depends on its 
concentration [7]. To characterize the influence of annealing in the lyophilized 
formulations, the properties of nanoparticles and the lyophilizates were assessed, and 
was evaluated the structural maintenance of the loaded protein. 
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3.1. Particle size, zeta potential, association efficiency and loading capacity 
analyses 
 
Insulin-loaded nanoparticles co-encapsulated with trehalose (insulin-trehalose 
10%-PLGA nanoparticles) and without cryoprotectant encapsulated (insulin-PLGA 
nanoparticles) were produced to allow the comparison and assessment of the 
stabilization effect provided by the cryoprotectant. 
The mean particle size, PdI and zeta potential characterization of insulin-loaded 
PLGA nanoparticles is shown in Table 8.1. Both formulations presented a close particle 
size in the range of about 250-300 nm and a low PdI, demonstrating the robustness of 
the encapsulation protocol [295]. Considering the zeta potential analysis, it was observed 
that nanoparticles had a negative surface charge, characteristic of the acidic PLGA 
polymer [147]. The zeta potential of insulin-trehalose 10%-PLGA nanoparticles was even 
slightly lower, which indicated a potential better colloidal stability of these nanoparticles, 
comparatively to insulin-PLGA nanoparticles. 
 
Table 8.1. Mean particle size, polydispersity index, zeta potential, and insulin AE and LC 
characterization of insulin-loaded PLGA nanoparticles (n = 3, mean ± SD). 
 
 The insulin AE and LC of formulations are also depicted in Table 8.1. Both 
formulations presented an AE higher than 90%, which was a good achievement 
considering the hydrophilic nature of insulin and the hydrophobic nature of nanoparticles 
polymer. The AE and LC results were similar with those obtained in previous works [227, 
295], which demonstrated once again the robustness of the encapsulation protocol, and 
its ability to co-encapsulate the cryoprotectant together with the protein. 
 
 
 
 
Formulation 
Mean 
particle 
size (nm) 
PdI 
Zeta 
potential 
(mV) 
AE (%) LC (%) 
Insulin-PLGA 
nanoparticles 
294 ± 15 0.26 ± 0.02 -20.4 ± 2.5 92.6 ± 0.7 12.1 ± 0.6 
Insulin-trehalose 10%-
PLGA nanoparticles 
249 ± 14 0.23 ± 0.08 -23.8 ± 2.5 90.5 ± 0.5 11.2 ± 0.4 
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3.2. Design of the lyophilization cycle 
 
The lyophilization cycle needs to be designed considering the engineering 
principles of the process and the physical-chemical properties of nanoparticles, to obtain 
a lyophilizate with high quality and to properly preserve the nanoparticles features [7, 
140, 153]. The knowledge of physical-chemical properties of formulations, such as the 
Tg’ and Tc, is necessary to design an optimal lyophilization cycle [163, 193]. In a 
previous chapter, these parameters of formulations were characterized in order to design 
an optimal lyophilization cycle that was also used in the present work [295]. This cycle 
was the basis to design another one including an annealing step. 
To assess the effect of annealing in the formulations and simultaneously 
decrease the time of primary drying, an annealing step of 2 h at -10ºC was included in 
the freezing stage that kept its duration time of 4 h, and the duration of primary drying 
was shorten from 24 h to 15 h. This modification represented a decrease of the primary 
drying duration of about 38%, and the reduction of the duration of the lyophilization cycle 
of about 26%. Previously, annealing was applied in the lyophilization of polymeric 
nanoparticles, and it was observed that the sublimation rate was increased when the 
annealing temperature was well above the Tg’ of the formulation [191]. It has been also 
reported that when annealing occurred below the Tg’, the sublimation rate was not 
increased [190]. Therefore, it was used the temperature of annealing of -10ºC for being 
well above the Tg’ of the formulations. When this occurs, the ice melts and the smaller 
ice crystals melt faster than the larger ones. The size distribution of ice crystals during 
annealing is ruled by the Ostwald ripening, in which the crystals smaller than a critical 
size decrease, whereas those larger than that critical size increase in size [185] 
Overall, it is recognized that the morphology of ice crystals is directly related with 
the sublimation rate [185]. Since annealing promotes the growth of ice crystals and 
increases the sublimation rate due to the increase of pore size of the product, it was 
used this approach to decrease the duration of primary drying, which is the longest step 
in lyophilization. This possibility it is only feasible, if both the nanoparticles features and 
the stability of loaded protein are preserved upon lyophilization. 
 
3.3. Visual inspection, reconstitution and residual moisture content of the 
lyophilizates 
 
The lyophilizates obtained from nanoparticles lyophilization with and without 
annealing were inspected, and they presented a cotton-like texture and white colour. The 
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lyophilizates occupied the same volume of the original frozen mass and no shrinkage or 
cake collapse were observed, which demonstrated that particularly the lyophilization with 
an annealing step allowed obtaining good lyophilizates. The cake collapse is a problem 
to avoid, because it originates prolonged reconstitution times and high residual moisture 
content [168, 173]. All the lyophilizates were easily reconstituted obtaining suspensions 
with no visual aggregates. The complete reconstitution of the lyophilizates of 
formulations lyophilized with annealing was even in average about 10 seconds faster, 
than those lyophilized with no annealing. This property may be explained by the larger 
pores of the lyophilizates that were previously occupied by larger ice crystals formed 
during annealing [191]. Such pores allowed a faster reconstitution of the lyophilizates 
obtained by lyophilization with annealing. 
The residual moisture content of the lyophilizates is depicted in Table 8.2. The 
nanoparticles lyophilized using annealing obtained a similar residual moisture content of 
those lyophilized without annealing, around 1%, which demonstrated that annealing 
allowed the decrease of the primary drying time in about 38%, without increasing the 
residual moisture content. These results showed that the lyophilization process was 
effective on removing the water from formulations, since they need to have very low 
residual moisture content, which for pharmaceutical products should be around 1% 
[150]. This result is also explained by the faster sublimation rate promoted by the porous 
structure of annealed formulations. Another possible explanation for a faster sublimation 
rate that allowed a decrease in the duration time of primary drying, without compromising 
the low residual moisture content of the lyophilizates, was the ability of annealing to 
eliminate the thin skin layer on the top surface of the cake [296]. Such thin layer occurs 
due to the migration of nanoparticles and cryoprotectant during ice crystallization, 
hampering the water removal from the product. 
 
3.4. Particle size, zeta potential and drug retention efficiency after lyophilization 
 
After resuspension of the lyophilizates, the nanoparticle suspensions were 
characterized in terms of mean particle size, PdI and zeta potential and the results are 
depicted in Table 8.2. The overall mean particle size of nanoparticles after lyophilization 
were similar with that after nanoparticles production, with just the exception for insulin-
PLGA nanoparticles lyophilized with annealing that presented a significant size 
modification (p < 0.05). This result showed the importance of the presence of co-
encapsulated trehalose, acting as cryoprotectant, when annealing was used. The 
potential residual leakage of trehalose from nanoparticles may protect them in a 
localized manner, by forming a protective matrix around nanoparticles [163, 295]. The 
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lyophilization ratio is also shown in Table 8.2. This ratio was obtained by dividing the 
mean particle size of nanoparticles after with that before lyophilization. Thus, a value 
around 1 demonstrates that the mean particle size of nanoparticles was maintained after 
lyophilization. The lyophilization ratio of nanoparticles were around 1 demonstrating that 
the lyophilization process used did not led to significant particle aggregation or fusion. 
When using annealing in the lyophilization of nanoparticle suspensions, the main 
problem is the mechanical stress of ice crystals that may lead to nanoparticles 
aggregation or fusion, since this effect on nanoparticles stability is more accentuated for 
larger ice crystals than for smaller ones [185, 191, 295]. Therefore, the mean particle 
size and lyophilization ratio results clearly showed that the nanoparticles stability was 
maintained upon lyophilization using annealing. The PdI of nanoparticles were similar 
after lyophilization, also demonstrating the low heterogeneity of nanoparticles size and 
the absence of significant particle aggregation. 
 
Table 8.2. Lyophilization ratio, insulin retention efficiency, residual moisture content, mean 
particle size, PdI and zeta potential characterization of insulin-loaded PLGA nanoparticles after 
lyophilization with and without annealing (n = 3, mean ± SD). Results are significantly different (p 
< 0.05) from the respective formulation prior lyophilization, when marked with *. 
Formulation 
Mean 
particle 
size (nm) 
PdI 
Zeta 
potential 
(mV) 
Lyophilization 
ratio 
Insulin 
retention 
efficiency 
(%) 
Residual 
moisture 
content 
(%) 
No annealing 
      
Insulin-PLGA 
nanoparticles 
280 ± 10 0.26 ± 0.01 -29.2 ± 3.5* 0.95 ± 0.07 99.1 ± 0.4 1.33 ± 0.41 
Insulin-trehalose 
10%-PLGA 
nanoparticles 
245 ± 18 0.25 ± 0.02 -31.6 ± 2.5* 0.98 ± 0.08 99.0 ± 0.5 1.45 ± 0.35 
Annealing 
      
Insulin-PLGA 
nanoparticles 
270 ± 4* 0.21 ± 0.01 -33.1 ± 1.8* 0.91 ± 0.04 98.5 ± 0.9 1.55 ± 0.27 
Insulin-trehalose 
10%-PLGA 
nanoparticles 
250 ± 23 0.26 ± 0.07 -30.8 ± 1.5* 1.00 ± 0.09 98.7 ± 0.4 1.48 ± 0.37 
 
Regarding the zeta potential, it was observed a significant decrease (p < 0.05) of 
the surface charge of nanoparticles upon lyophilization, leading to a better colloidal 
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stability of nanoparticles. The drug leakage during lyophilization may occur due to 
possible modifications of nanoparticles integrity. Therefore, it was evaluated the insulin 
retention efficiency in nanoparticles after lyophilization, which is shown in Table 8.2. The 
leakage of insulin from nanoparticles during lyophilization was negligent, demonstrating 
that the integrity of nanoparticles was preserved after lyophilization. These results also 
showed the annealing did not induced stresses to nanoparticles that could damage them 
and lead to insulin leakage. 
 
3.5. Morphology of nanoparticles 
3.5.1. Prior lyophilization 
 
The morphology of nanoparticles and lyophilizates were assessed by SEM to 
assess the shape, surface and size of nanoparticles. These features are important to 
infer the stability of nanoparticles and the loaded protein. Figure 8.1 shows the insulin-
loaded PLGA nanoparticles after production. The nanoparticles of both formulations 
were similar presenting a smooth surface and spherical shape, which are characteristic 
of the used encapsulation method and of the nanoparticles polymer. The size range of 
nanoparticles is also in accordance with the mean particle size described in section 3.1 
of this chapter. 
 
 
Figure 8.1. SEM microphotographs of insulin-loaded PLGA nanoparticles after production. Scale 
bar: 1 µm. 
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3.5.2. After lyophilization 
 
Figure 8.2 shows the SEM microphotographs of the lyophilizates obtained by 
lyophilization with and without annealing. The lyophilizates presented a porous structure, 
which were formed during water sublimation and are necessary to the adequate 
resuspension of nanoparticles. In the lyophilizates it was possible to visualize the 
arrangement of nanoparticles that maintained its spherical shape upon lyophilization. 
However, the lyophilizates obtained using annealing showed a more homogenous 
structure, comparatively to those obtained without annealing. This occurred mainly due 
to the decrease of the heterogeneity of the sublimation rate caused by annealing, 
obtaining a more homogeneous cake structure [163, 294]. 
 
 
Figure 8.2. SEM microphotographs of the lyophilizates of insulin-loaded PLGA nanoparticles. 
Scale bar: 10 µm. 
 
After resuspension of the lyophilizates, nanoparticles were observed by SEM 
(Figure 8.3). The nanoparticles of all formulations maintained their spherical shape and 
smooth surface after lyophilization and resuspension. The size range observed in the 
Chapter 8 I Optimization of Lyophilization Cycle Using Annealing and its Effect on the Stability of 
Protein-loaded PLGA Nanoparticles  
  
212 
 
microphotographs was also in accordance with the mean particle size described in 
section 3.4 of this chapter. The microphotographs clearly demonstrated that the 
lyophilization process with and without annealing was able to preserve the integrity of 
nanoparticles, which is the main aim in nanoparticles lyophilization. 
 
 
Figure 8.3. SEM microphotographs of lyophilized insulin-loaded PLGA nanoparticles after 
resuspension. Scale bar: 1 µm. 
 
3.6. Insulin structural integrity 
 
3.6.1. Fourier-transform infrared spectroscopy analysis 
 
FTIR spectroscopy is a powerful technique in the assessment of the secondary 
structure of proteins loaded into nanoparticles, in a non-invasive manner [85]. In a 
protein spectra, the amide I region at 1710-1590 cm-1 is used to evaluate the similarity of 
the second derivative spectra of the native protein with that of the loaded protein. 
Therefore, the highest the similarity between those spectra represents the highest 
maintenance of the secondary structure of the protein. This protein structure may be 
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assessed quantitatively and qualitatively, by analyzing the AO and the area-normalized 
second derivative amide I spectra, respectively. 
 
3.6.1.1. Area of overlap 
 
The AO measures the degree of similarity between the area-normalized second 
derivative spectra of native insulin, and the insulin loaded into PLGA nanoparticles. The 
spectrum of native insulin was obtained by the FTIR analysis of an insulin solution 30 
mg/ml in HCl 0.1 M. The AO results for the lyophilized insulin-loaded PLGA 
nanoparticles are depicted in Figure 8.4. 
 
 
Figure 8.4. AO percentages of insulin loaded into PLGA nanoparticle formulations after 
lyophilization with and without annealing (n = 3, mean ± SD). Np stands for nanoparticles. Results 
are significantly different (p < 0.05) from formulation with no cryoprotectant co-encapsulated, 
insulin-PLGA nanoparticles, when marked with *. 
 
It was observed that either for lyophilization with and without annealing, the 
nanoparticles co-encapsulated with trehalose had a significantly higher AO of insulin (p < 
0.05), comparatively to the formulation containing no cryoprotectant. The AO of insulin-
trehalose 10%-PLGA nanoparticles was 85.3 ± 0.7% and 86.0 ± 1.0% for annealing and 
no annealing conditions, respectively. These results demonstrated that the presence of 
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trehalose as cryoprotectant, better preserved the structure of insulin loaded into PLGA 
nanoparticles upon lyophilization both for annealing and no annealing conditions. This 
may be explained by the ability of cryoprotectants, to stabilize proteins by a preferential 
exclusion during freezing [280]. The cryoprotectant co-encapsulated with insulin into 
PLGA nanoparticles has tendency to be excluded from the protein surface, originating a 
preferential hydration of insulin and increasing the thermodynamic stability of its native 
state. Additionally, the cryoprotectant may also preserve the insulin structure by reducing 
its adsorption on the ice surface during freezing, and also by increasing the freeze-
concentrate viscosity [269]. 
Regarding the comparison of lyophilization with and without annealing, no 
differences were observed in the AO of both insulin-PLGA nanoparticles and insulin-
trehalose 10%-PLGA nanoparticles. The insulin AO of those formulations, for annealing 
and no annealing conditions was even almost identical. This was a particularly good 
result, since it was clearly demonstrated that annealing allowed the optimization of the 
lyophilization cycle by decreasing its duration time, and simultaneously ensuring the 
structural stability of the loaded protein. The possible explanation for this phenomenon is 
that the stability of proteins loaded into nanoparticles may be more related with the 
freezing method, rather than the annealing conditions during freezing [295]. 
 
3.6.1.2. Visual comparison of area-normalized second derivative amide I spectra 
 
The AO is a quantitative indicator of the preservation of insulin native structure, 
whereas the analysis of the area-normalized second-derivative amide I spectra allows 
the evaluation of the qualitative changes of insulin structure. This data is depicted in 
Figure 8.5.  
Generally, upon lyophilization, the protein structure suffers a decrease in α-helix, 
with a concomitant increase in the β-sheet content, and it is usually accepted that the α-
helix content is the best indicator of the integrity of protein structure [258]. The area-
normalized second-derivative FTIR spectrum of native insulin was obtained by the 
analysis of an insulin solution 30 mg/ml. The spectrum showed the insulin structure was 
dominated by α-helix band at 1657 cm-1, including also β-sheets with bands at 1640 cm-1 
and 1690 cm-1. These band features of insulin were in agreement with those reported in 
previous works [85, 281, 295]. The changes of such bands occurring during 
lyophilization, represent the changes in the secondary structure of insulin that may lead 
to its denaturation or aggregation, hampering insulin bioactivity or even causing possible 
adverse effects after administration [259].  
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Figure 8.5. Area-normalized second-derivative amide I FTIR spectra of insulin loaded into PLGA 
nanoparticles lyophilized using no annealing (A), and annealing (B). Np stands for nanoparticles. 
 
Overall, no denaturation or aggregation of insulin was noticed upon lyophilization 
of the formulations, since these phenomena are evidenced by a clear decrease in α-helix 
content and a concomitant increase in β-sheet. This result was a good indicator that 
insulin could maintain its bioactivity upon lyophilization with and without annealing. 
Previously, it was demonstrated the in vivo bioactivity of insulin loaded into the PLGA 
nanoparticles used in the present work, upon lyophilization without annealing [295]. The 
insulin contained in formulations presented distinct structural rearrangements upon 
lyophilization. Interestingly, the structural features of insulin in the different formulations 
lyophilized both with and without annealing were practically identical, demonstrating the 
robustness of the lyophilization cycles, and also that the distinct morphology of ice 
crystals and liquid/water interfaces formed during annealing, in which surface-induced 
denaturation of insulin may occur [204], had not a detrimental effect on the structural 
stability of insulin. 
The insulin-trehalose 10%-PLGA nanoparticles presented the closest similarity 
with native insulin, with just a slight decrease and shift of α-helix band into 1659 cm-1, 
and a decrease of the high-wavenumber β-sheet content. On its turn, the nanoparticles 
containing no cryoprotectant showed a more pronounced decrease of the α-helix band 
and its shift into 1653 cm-1, which modification was similar to that of the respective band 
position of lyophilized insulin. These structural features demonstrated that the co-
encapsulation of the cryoprotectant was crucial, to better preserve the structure of insulin 
loaded into PLGA nanoparticles upon lyophilization with and without annealing. 
 
 
 
Chapter 8 I Optimization of Lyophilization Cycle Using Annealing and its Effect on the Stability of 
Protein-loaded PLGA Nanoparticles  
  
216 
 
3.6.2. Circular dichroism analysis 
 
The CD spectroscopy was also used to evaluate the secondary structure of 
insulin. Prior to the analysis, insulin was extracted from PLGA nanoparticles to avoid 
spectral artifacts caused by light scattering. During the extraction process, it can occur 
some minor modifications of insulin structure, nevertheless CD is still a good tool to 
corroborate the results obtained by FTIR spectroscopy. The far-UV CD spectra of insulin 
are depicted in Figure 8.6. To obtain the spectrum of native insulin, it was analyzed a 
solution of insulin 0.2 mg/ml in HCl 0.01 M, obtaining a spectrum with two ellipticity 
minima characteristic of the predominant α-helical structure of the protein, at 208 nm and 
222 nm [266]. The spectrum of native insulin was similar to those described in previous 
works [85, 282]. 
 
 
Figure 8.6. Far-UV CD spectra of insulin extracted from insulin-loaded PLGA nanoparticles 
lyophilized using no annealing (A), and annealing (B). Np stands for nanoparticles. 
 
Overall, the spectra of insulin did not showed relevant shifts of the characteristic 
minima, demonstrating the prevalent α-helical structure of insulin. The structural 
modification that could lead to the denaturation, aggregation or fibrillation of insulin is 
evidenced by prevalent β-sheet content, with an ellipticity minimum around 216 nm [143, 
283]. Once this detrimental modification did not occur, the CD results were in agreement 
with those of FTIR on demonstrating the ability of the lyophilization cycles with and 
without annealing, to preserve insulin structure in such a way that it could maintain its 
bioactivity. 
The variability in the rearrangement of insulin structure upon lyophilization was 
demonstrated by the decrease of the negative ellipticity signal. Despite the possible 
influence of the extraction process of insulin, the CD results were similar to those 
obtained by FTIR. For instance, the CD spectra of insulin from formulations lyophilized 
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with no annealing were practically identical, to those obtained after lyophilization with 
annealing. Furthermore, the insulin from formulations with co-encapsulated trehalose 
showed a closer similarity with native insulin, comparatively to the insulin from PLGA 
nanoparticles containing no cryoprotectant co-encapsulated, since the latter evidenced a 
more pronounced decrease of the negative ellipticity signal. These results confirmed 
both that annealing had not a detrimental effect in insulin structure, and that PLGA 
nanoparticles co-encapsulated with trehalose presented a superior structural stability of 
insulin, comparatively to nanoparticles without cryoprotectant co-encapsulated. 
 
3.6.3. Fluorescence spectroscopy analysis 
 
The fluorescence spectroscopy is another technique used in the evaluation of 
proteins, particularly their tertiary structure [288]. Prior analysis, insulin was also 
extracted from PLGA nanoparticles to avoid potential spectral artifacts. Insulin lacks 
tryptophan, so the protein fluorescence is mostly dependent on the four tyrosine residues 
[284]. Therefore, the modification of the emission spectra of insulin fluorescence is an 
indicator of possible changes in the protein structure. Figure 8.7 shows the fluorescence 
spectra of insulin from nanoparticles, in which the spectrum of native insulin (insulin 
solution 0.2 mg/ml), evidenced a maximum fluorescence intensity at 304 nm. The 
spectrum of native insulin was in agreement with those previously reported [285-287, 
295]. 
 
 
Figure 8.7. Fluorescence spectra of insulin extracted from insulin-loaded PLGA nanoparticles 
lyophilized using no annealing (A), and annealing (B). Np stands for nanoparticles. 
 
The structural modifications configured with insulin denaturation, aggregation or 
fibrillation are characterized by a decrease in the intensity of fluorescence emission and 
the shift of its maxima [284].  Since all the insulin spectra were practically identical, it was 
possible to conclude that those structural modifications did not occur, and the 
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lyophilization cycles both with and without annealing were able to preserve the stability of 
insulin in order to assure its bioactivity. No differences were found between the insulin 
spectra from nanoparticles lyophilized using annealing, with those lyophilized with no 
annealing. 
 
3.7. Thioflavin T experiment 
 
The thioflavin T experiment is a useful tool to assess the fibrillation of insulin, 
which may occur during nanoparticles processing and lyophilization. The amyloid fibrils 
are proteins aggregates that indicate the protein structure and its bioactivity are 
decisively compromised. The thioflavin T is a dye able to bind to amyloid fibrils with 
crossed β-sheet structures, leading to a shift of the fluorescence excitation maximum 
from 340 nm to 450 nm, and an increase of fluorescence emission at 485 nm [290, 291]. 
Thus, the enhancement of the thioflavin T fluorescence intensity is indicative of insulin 
aggregation/fibrillation [287]. 
The insulin from PLGA nanoparticles did not evidenced the presence of amyloid 
fibrils, since it was not verified a fluorescence emission at 485 nm (data not shown). In 
turn, the positive control of fibrillated insulin showed a clear fluorescence emission. 
These results were in agreement with aforementioned structural characterization of 
insulin, and were elucidative on demonstrating that both the nanoparticles production 
and lyophilization cycles with and without annealing, did not acted as stress factors that 
could originate insulin fibrillation. 
 
4. Conclusion 
 
In this chapter, the main objective was to develop an optimized lyophilization 
cycle using annealing to decrease the duration time of the process, and simultaneously 
ensure the stability of nanoparticles and with upmost importance the maintenance of the 
loaded protein stability. Additionally, it was assessed the cryoprotectant effect in this 
stabilization process. Insulin and PLGA nanoparticles were used as models in this study. 
Annealing allowed obtaining good lyophilizates with no cake collapse, and its 
reconstitution was even faster than the lyophilizates obtained without annealing. The 
lyophilizates obtained using annealing had similar residual moisture content of those 
without annealing. The presence of cryoprotectant co-encapsulated was found important 
to better stabilize the nanoparticles size during lyophilization with annealing, mitigating 
the stresses caused by ice crystals growth. However, no nanoparticles aggregation or 
fusion, and a superior colloidal stability of nanoparticles were observed after 
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lyophilization. The lyophilizates obtained using annealing demonstrated a more 
homogenous structure, comparatively to those obtained without annealing, due to the 
decrease of heterogeneity of the sublimation rate caused by annealing.  
Regarding the maintenance of protein structure upon lyophilization, no insulin 
denaturation, aggregation or fibrillation was observed, being a good indicator that the 
lyophilization process was able to preserve the bioactivity of insulin. It was demonstrated 
that nanoparticle formulations with co-encapsulated cryoprotectant, better preserved the 
structure of insulin upon lyophilization, comparatively to nanoparticles without 
cryoprotectant co-encapsulated. Indeed, the structural features of insulin loaded into 
nanoparticles co-encapsulated with trehalose presented the closest similarity with those 
of native insulin. The level of insulin structural maintenance of nanoparticles lyophilized 
using annealing was similar to that obtained without annealing, demonstrating that 
annealing allowed the optimization of lyophilization cycle by decreasing its duration time 
with a simultaneous preservation of protein structure. 
Overall, this work gave rise to the importance of the optimization of lyophilization 
cycle of polymeric nanoparticles loaded with proteins, and particularly recognized 
annealing as a tool to decrease the duration of the process and simultaneously ensure 
the stability of nanoparticles and the structural preservation of the encapsulated protein. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 8 I Optimization of Lyophilization Cycle Using Annealing and its Effect on the Stability of 
Protein-loaded PLGA Nanoparticles  
  
220 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
General Conclusions and Future 
Perspectives 
 
 
 
Chapter 9 
Chapter 9 I General Conclusions and Future Perspectives 
  
222 
 
 
The therapeutic proteins are the most common biopharmaceuticals available in 
the market, usually in the lyophilized form. Benefiting from the development of the 
nanotechnology field in the last decades, proteins have been encapsulated into 
polymeric nanoparticles mainly due to its ability to load, protect, release in a sustained 
manner and deliver proteins to a specific target. A good example is the PLGA polymer, 
regularly used in the production of nanoparticles, mainly due to its biodegradability, 
biocompatibility and good sustained release properties. However, PLGA nanoparticles in 
aqueous suspension are unstable, due to the hydrolytically unstable polyester. The 
lyophilization is a dehydration process commonly used in the pharmaceutical industry to 
increase the long term stability, and allow easy handling and storage of products. 
Besides its stabilizing effects, the lyophilization steps may induce different stresses to 
formulations with detrimental and irreversible consequences both to nanoparticles and 
the loaded protein. To mitigate such stresses, several excipients such as cryo- and 
lyoprotectants have been used. Despite being an easy process, lyophilization is based in 
several engineering principles that must be properly regarded. These principles and the 
physical-chemical properties of formulations are usually neglected, and lyophilization is 
often used empirically or in a trial and error way, with obvious negative and unpredictable 
consequences to the formulation as a whole, namely to the lyophilizate, nanoparticles 
and loaded protein. 
In the present Thesis, it was developed an optimization of the lyophilization 
parameters of polymeric nanoparticles for delivery of therapeutic proteins, using PLGA 
nanoparticles and insulin as models. Those parameters focused on every component 
involved in the lyophilization of nanoparticles, as are the nanoparticle formulations and 
the lyophilization cycle. The general purpose followed in the optimization of lyophilization 
parameters was obtaining the best preservation of nanoparticle features and with upmost 
importance, assures the superior stability of the loaded protein. Therefore, the 
nanoparticles were first optimized in order to obtain acceptable features regarding its 
size, zeta potential and insulin association efficiency. It was also assessed the influence 
of cryoprotectants and a standard lyophilization process in the porosity of nanoparticles. 
Then, the nanoparticles added with cryoprotectants were used to evaluate their stability 
and the structural maintenance of insulin, upon storage during 6 months at different 
storage conditions. Using a more controlled lyophilization cycle, it was proposed an 
approach in the lyophilization of nanoparticles by co-encapsulating the lyoprotectants 
with insulin, as a way to better stabilize the structure and bioactivity of the loaded protein. 
The success of this strategy allows saving some lyoprotectant, since the amount needed 
is quite lower than that used in the conventional lyoprotectant addition method, and also 
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to avoid this latter processing step, which may be interesting from an up-scale and 
industrial point of view. After precisely assessing the physical-chemical properties of 
nanoparticles, it was developed an optimized lyophilization cycle and was evaluated the 
influence of different freezing methods in the stability of insulin-loaded nanoparticles, and 
the performance of cryoprotectants as excipients to avoid possible freezing stresses to 
nanoparticles. Finally, after choosing a cryoprotectant with good stabilizing performance, 
it was evaluated the effect of annealing in the stability of insulin-loaded nanoparticles and 
its ability to decrease the duration time of lyophilization.  
All the objectives proposed for this Thesis were met. The formulation containing 
PLGA 50:50 as polymer and PVA 2% as surfactant was the one that presented the best 
features regarding its size, zeta potential and association efficiency, and was chosen for 
further experiments. The porosity of nanoparticles was enhanced upon lyophilization, 
especially when cryoprotectants were added as excipients, namely trehalose, glucose, 
sucrose, fructose and sorbitol. The release profile of insulin from nanoparticles showed a 
burst release in the first 2 h, followed by a sustained release up to 48 hours. The release 
of insulin was increased after nanoparticles lyophilization, potentially due to the porosity 
enhancement. The insulin released from nanoparticles showed different performances 
dependent on the cryoprotectant used. It was hypothesized that nanoparticles porosity 
and cryoprotectants presence may have distinct influences in the stability of insulin-
loaded nanoparticles. 
In the 6 months storage stability study, it was observed that the use of a standard 
lyophilization cycle led to the collapse of several formulations with detrimental effects to 
lyophilizates resuspension and nanoparticles aggregation. Interestingly, collapsed 
formulations showed better protein stabilization upon storage, than non-collapsed ones. 
The cryoprotectants enhanced the nanoparticles stability, but they presented different 
performances on the stabilization of insulin structure. Sorbitol showed better 
performance over the other cryoprotectants, which was surprising since it is known the 
propensity of sorbitol to crystallize, which may interfere with the storage stability of 
formulations. These results showed the variability occurred when a standard 
lyophilization cycle was used.  
The co-encapsulation of lyoprotectants with the protein into nanoparticles 
revealed to be a promising strategy. Insulin-loaded PLGA nanoparticles co-encapsulated 
with lyoprotectants obtained a mean particle size of 386-466 nm, and a zeta potential 
ranging between -34 and -38 mV, dependent on the lyoprotectant used. The AE and LC 
of formulations were about 85-91% and 10-12%, respectively.  These formulations 
obtained no cake collapse and amorphous lyophilizates. This strategy offered superior 
insulin stability with an AO of about 82-87%, comparatively to the conventional 
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lyoprotectant addition method achieving an AO of 66-83%. The reducing sugars used as 
cryoprotectants did not show an adverse effect on insulin stability, when they were co-
encapsulated. Surprisingly, the concomitant co-encapsulation and addition of 
lyoprotectant prior lyophilization showed to be even detrimental to insulin stability. 
Regarding the in vitro release of insulin, the nanoparticles added with lyoprotectants prior 
lyophilization showed a lower release of insulin, comparatively to nanoparticles co-
encapsulated with the same lyoprotectant. This ability may be used to provide benefits to 
diabetes therapy. 
The lyophilization cycle was optimized considering the physical-chemical 
properties of nanoparticle formulations. Then, it was assessed the influence of the 
freezing step of lyophilization in the stability of insulin-loaded nanoparticles co-
encapsulated with cryoprotectants. In this work it were used the two nonreducing sugars 
and the sugar alcohol as cryoprotectants, used previously. The features of nanoparticles 
were preserved upon lyophilization using the different freezing methods. The 
lyophilization cycle of each freezing condition produced amorphous lyophilizates, which 
was a good perspective for their storage stability. Insulin-loaded nanoparticles lyophilized 
without cryoprotectant showed some variability in the structure of the protein depending 
on the freezing method, being the ramped cooling at -40ºC that obtained the highest 
structural maintenance of insulin with an AO of about 89%. Such structural variability 
was mitigated when cryoprotectants were co-encapsulated, showing that they reduced 
the freezing stresses and better preserved the insulin structure. The ramped cooling at -
40ºC was the freezing method in which the formulations both with and without 
cryoprotectants co-encapsulated, obtained the most similar structural maintenance of 
insulin. Trehalose and sucrose showed better cryoprotectant performance than sorbitol. 
Both the encapsulation and lyophilization processes, did not acted as stress factors to 
insulin that could lead to its fibrillation. More importantly, the formulation containing 
trehalose was used in the assessment of the in vivo bioactivity of insulin-loaded 
nanoparticles upon lyophilization and reconstitution, and was observed that the carriers 
were able to prolong the hypoglycemic effect of insulin, comparatively to subcutaneous 
insulin. The hypoglycemic effect was even enhanced by the nanoparticles co-
encapsulated with trehalose, comparatively to both nanoparticles without and with 
trehalose added prior lyophilization, essentially caused by the superior insulin 
stabilization and bioactivity. 
After optimization and choosing the most suitable freezing method, the 
lyophilization cycle was included with an annealing step in order to increase the 
sublimation rate and thus, decrease the duration time of lyophilization. In this process the 
stability of insulin-loaded nanoparticles with co-encapsulated trehalose had to be 
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assured. The lyophilization using annealing obtained good lyophilizates with no cake 
collapse, and their reconstitution was even faster than the lyophilizates produced without 
annealing. The residual moisture content of lyophilizates obtained with annealing was 
similar to those without annealing, demonstrating that the time reduction of lyophilization 
using annealing was possible and equally effective on water removal. The presence of 
trehalose co-encapsulated mitigated the freezing stresses of ice crystals growth caused 
by annealing, and was important to stabilize nanoparticles. As previously observed, 
nanoparticles co-encapsulated with trehalose preserved better the insulin structure, than 
nanoparticles without cryoprotectant. The structural maintenance of insulin obtained by 
annealing was similar to that without annealing, showing that the inclusion of an 
annealing step in the lyophilization cycle allowed to decrease its duration time in about 
26%, with no detrimental effects to protein structure. 
The work underlying this Thesis has to be seen as an ongoing work. In research, 
there is always another experiment to be done. At this point, the performed work may be 
a good contribution to the biopharmaceutics and nanomedicine fields. The importance of 
optimization of the parameters involved in protein-loaded nanoparticles lyophilization, 
from the formulations itself to the lyophilization cycle was highlighted here. Future works 
may extend these principles to improve the stability of different proteins loaded into other 
nanocarriers, polymeric or not. The strategy of co-encapsulating cryo- and lyoprotectants 
together with proteins with the purpose of better stabilizing it may open a new paradigm 
in the lyophilization of biopharmaceutic products. From an upscale and industrial point of 
view, it might be important since allows eliminating the cryo- and lyoprotectant addition 
step between nanoparticles production and lyophilization, and at the same time reduces 
drastically the amount of excipient needed. More importantly, since therapeutic proteins 
are usually expensive, the superior maintenance of insulin native structure and 
consequent enhanced bioactivity may be valuable from a cost-benefit perspective. In the 
following years, it will be also interesting to apply the technologies of monotorization and 
management of lyophilization that have been developed, in the lyophilization of 
nanoparticle-based products, in order to improve their quality and storage stability with a 
simultaneous decrease of the duration and cost of lyophilization. 
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